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Preface to ”Mass Spectrometric Proteomics”
The growing in complexity of biological samples observed over the last 20 years resulted in
the emersion of sophisticated liquid chromatographic-mass spectrometric techniques that widened
the application of proteomics to a variety of novel samples. These applications span from the
characterization of complex protein networks and the detection of their perturbations to large-scale
protein analysis and the identification of proteins which may clarify molecular mechanisms that
govern cellular processes. Despite the undoubted potential of proteomics, collection of data has
often proven difficult due to obstacles originated from the inherent complexity of protein profiles
under investigation. Considerable technological advancements have led to the birth of innovative
approaches helpful to surmount these hurdles. Attractive strategies toward the increase of the
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The term “Proteomics” refers to the characterization of the proteome, that is, all proteins present
in a biological system. Because the protein content of an organism changes in response to many
conditions, the proteome dynamism helps investigation on differences in protein states between
different conditions. Identifying all proteins present in biological systems is a difficult task and a crucial
role in enabling the analysis of proteomes is played by mass spectrometry (MS). Given the complexity of
biological systems, high performance liquid chromatography-based (HPLC) separations are currently
applied to separate the mixture of proteins before analysis. After these extensive procedures, confident
identifications may be obtained by MS and tandem MS (MS/MS) either on intact proteins (top-down)
or on peptides obtained after enzymatic digestion (bottom-up). Changes in protein abundances
between different biological states may be obtained by several approaches, with or without stable
isotopic labeling.
In this Special Issue of Molecules the reader will find a topical selection of both research and review
articles which bring together different sophisticated methodological strategies with applications in
protein profiling of organs, in the study of post translational tissue modifications or in the investigation
of the molecular mechanisms behind human disorders.
Mauri and co-workers [1] open the section of seven research articles with a study that describes
the application of multidimensional protein identification technology (MudPIT) to discover the
urinary proteomes of head and neck squamous cell carcinoma (HNSCC) and thyroid cancer patients.
They analyzed urine samples from these subjects to identify protein profiles prior and after infusion
with 10Boron and neutron capture therapy (BNCT) during surgery. The results of this study allowed
the identification of several inflammation- and cancer-related proteins, which could be potential
tumor biomarkers. In particular, a reduction of three proteins (Galectin-3 binding protein, CD44, and
osteopontin) that were involved in inflammation was observed after treatment. Analysis of the urinary
proteome during and after therapeutic interventions made it clear that this fluid reflects changes that
are induced by several diseases, including different types of cancer.
Another interesting study from the same research group aimed at exploring the potentiality
of shotgun proteomic platforms in the characterization of the status and the evolution of metabolic
pathways during ex vivo lung perfusion (EVLP), an emerging procedure that allows organ preservation
in lung transplantation. The application of a nanoLC–MS/MS system to the proteome analysis of
lung tissues from three experimental groups (native, pre- and post-EVLP) of an optimized rat model
allowed identification of potential EVLP-related biomarkers. Given the promising findings provided
by this work, future perspectives will attempt to confirm these data with the aim of translating the
experimental research to human specimens [2].
The huge potential of sophisticated technologies in the proteomic area is shown by two
original articles.
The report by Delphine and coworkers [3] demonstrates the utility of quadrupole time-of-flight
(Q–ToF) hybrid mass spectrometer equipped with electrospray ionisation source (ESI). Their study
aimed at optimising tandem MS analysis by testing the effect of some of the parameters concerning the
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in-source collision-induced dissociation (IS-CID) procedure in combination or not with conventional
CID. A total of 11 MS/MS methods were assessed on samples bearing increased complexity, including
individual milk protein standards, mixed protein standards and cow’s raw milk samples from
different breeds. Results of top-down sequencing from the nine most abundant proteoforms of
caseins, alpha-lactalbumin and beta-lactoglubulins were compared. Nine MS/MS methods achieved
more than 70% sequence coverage overall to distinguish between allelic proteoforms varying only by
one or two amino acids.
Zhang and colleagues [4] used ultra-performance liquid chromatography/Orbitrap Fusion
mass-spectrometry (UPLC/MS/MS) and chemometrics to study Ophiocordyceps sinensis, an important
fungal drug used in Chinese medicine. This approach allowed identification of a number of marker
tryptic peptides in the wild O. sinensis fruiting body and in various commercially available mycelium
fermented powders. This represented the first extensive study on the authentication of O. sinensis and
cultured Ophiocordyceps mycelia.
The isobaric tags for relative and absolute quantitation (iTRAQ) technique was used by Su and
coworkers [5] to investigate the oviduct of Rana chensinensis (another important traditional Chinese
medicine resource widely used in the treatment of asthenia after sickness or delivery, deficiency in
vigor, palpitation and insomnia), which, in contrast to the breeding period, significantly expands
during prehibernation. To explain this phenomenon at the molecular level, the protein expression
profiles of Rana chensinensis oviduct during these two conditions were analyzed. Among the 4479
proteins identified, 312 were up- or down-regulated between these two periods. The application of
gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses allowed them
to understand that this distinctive physiological phenomenon of Rana chensinensis oviduct was mainly
involved in extracellular matrix–receptor interaction, metabolic pathways, and focal adhesion.
The interest of Li and co-authors [6] was focused on the study of protein lysine acetylation (PKA),
a key post-translational modification involved in the regulation of various biological processes in rice.
They applied an MS-based label-free approach to perform a quantitative analysis of PKA proteins in
rice callus, root, leaf and panicle. The identification of 890 PKA proteins, which covered 1536 sites,
allowed construction of a tissue atlas of rice acetylome and provided an overall view of the acetylation
events in rice tissues.
The targeted proteome analysis performed by Tokumaru and co-workers [7] aimed at investigating
the SigE dependent-regulation of central metabolism in Synechocystis sp. PCC 6803, a model
cyanobacteria. In their study, they compared the protein abundance profiles among the wild type,
a SigE deletion mutant (DSigE), and a SigE over-expression (SigEox) strain. The protein profile
showed that SigE plays a pivotal role as a positive regulator of oxidative pentose phosphate pathway
(OxPPP) activity and NADPH reproduction. The results also suggested that SigE over-expression
increases GdhA abundance, which is involved in the nitrose assimilation pathway using NADPH and
downregulates the proteins involved in photosynthesis.
The Special Issue is concluded by a compilation of review articles on different topics.
Given the relevance of isobaric labeling reagents for quantitative isobaric derivatization strategies
in proteomics, Bachor and colleagues [8] review the trends in the design of new isobaric markers.
The development of selective methods for introducing into a peptide a tag that increases the
multiplexicity of markers and the sensitivity of measurement and lowers the cost of synthesis is
currently a topic of great interest in proteomics. Different types of isobaric reagents are used in
quantitative proteomics, and their chemistry and advantages offered by their application are clearly
presented in this article.
In recent years, platinum-based anticancer drugs (especially cisplatin) have played an important
role in the clinical chemotherapy of cancer. Due to the adverse effects and acquired resistance of these
drugs, efforts have been made to exploit novel anticancer metallodrugs and unveil the molecular
mechanism of anticancer activity and drug resistance. The article by Jia and co-workers [9] is focused
2
Molecules 2019, 24, 1133
on the identification, by MS-based quantitative strategies, of proteins which specifically respond or
bind to metal-based anticancer drugs and on the elucidation of their mechanisms of action.
Finally, Zdenek Perutka and Marek Šebela [10] review the cleavage properties of bovine
pseudotrypsin, a trypsin proteoform, in the digestion of protein samples with a different complexity.
While cleaving peptide bonds predominantly at the conventional trypsin cleavage sites, pseudotrypsin
shows non-specific cleavages (mostly after the aromatic residues of Tyr and Phe) which are not expected
to occur for the major trypsin forms. The valuable information provided by this peculiar activity could
be of great utility in common proteomics protocols.
I hope that the content of this Special Issue meets the expectations of readers and would like to
thank all authors for their excellent contributions.
Acknowledgments: The author would like to thank Maddalena Cagnone in Biochemistry at the Department of
Molecular Medicine, University of Pavia, Italy, for fruitful and stimulating discussions.
Conflicts of Interest: The authors declare no conflict of interest.
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Abstract: Boron neutron capture therapy (BNCT) is a binary cancer treatment modality where two
different agents (10B and thermal neutrons) have to be present to produce an effect. A dedicated
trial design is necessary for early clinical trials. The concentration of 10B in tissues is an accepted
surrogate to predict BNCT effects on tissues. Tissue, blood, and urines were sampled after infusion
of two different boron carriers, namely BSH and BPA in the frame of the European Organisation
for Research and Treatment of Cancer (EORTC) trial 11001. In this study, urine samples were used
to identify protein profiles prior and after drug infusion during surgery. Here, an approach that is
based on the mass spectrometry (MS)-based proteomic analysis of urine samples from head and neck
squamous cell carcinoma (HNSCC) and thyroid cancer patients is presented. This method allowed
the identification of several inflammation- and cancer-related proteins, which could serve as tumor
biomarkers. In addition, changes in the urinary proteome during and after therapeutic interventions
were detected. In particular, a reduction of three proteins that were involved in inflammation has
been observed: Galectin-3 Binding Protein, CD44, and osteopontin. The present work represents a
proof of principle to follow proteasome changes during complex treatments based on urine samples.
Keywords: urine; thyroid cancer; squamous cell cancer of head and neck; BNCT; boron; proteomics;
LC-MS; MudPIT
1. Introduction
Boron neutron capture therapy (BNCT) is based on the high cross section of the non-radioactive
isotope boron-10 for capturing thermal neutrons, leading to the nuclear reaction 10B(n,α)7Li [1].
The resulting high linear energy transfer (LET) particles have a very short range in tissues, limiting
the damages to cells containing 10B [2]. For a successful tumor treatment, 10B has to be selectively
delivered to tumor cells through specific boron-containing compounds. In the frame of the research
project “Therapeutic strategies for Boron Neutron Capture Therapy (BNCT): Boron imaging” (financed
by the European Commission QLK3-CT-1999-01067), several early clinical trials under the auspices
of the European Organisation for Research and Treatment of Cancer (EORTC) were performed [3].
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The investigation that is presented here is based on urine samples that were collected in the EORTC
trial 11001 and urine samples from heavily smoking (>25 cigarettes/day) volunteers.
BNCT has already proven to be a promising tool in the treatment of a number of cancer, including
head and neck squamous cell carcinoma (HNSCC) [4–7]. BNCT has been explored as an alternative
therapy to the currently employed surgery, chemotherapy, or radiotherapy, bearing the advantages
of less application (one or two doses) and the ability to maintain intact the oro-facial structures and
functions [8]. Although no clinical application has been performed, BNCT has been discussed for the
treatment of thyroid cancer in patients not responding to standard therapies [9,10].
To date, a very limited number of papers have investigated the molecular effects of boron
compounds and BNCT. Molecular studies were mainly based on the monitoring of Boron-containing
compounds in cell lines [11,12], tissue [13], plasma [14,15], and urine [16,17]. As far as we know,
no extensive genomic or transcriptomic studies have been performed to evaluate the changes in
the transcription that is induced by this treatment. A preliminary study focused on the DNA
damage induced by irradiation while using a rat tumor graft model [18]; this work followed
the levels of some proteins by means of western blotting and showed an upregulation of High
mobility group box 1 (HMGB1), a nuclear protein involved in necrosis and inflammation processes,
which was proposed as an early diagnostic marker. Surely, for the study of the effects of BNCT,
proteomics is a promising tool, which has already been applied in an in vitro study on the
effects of mercaptoundecahydrododecaborate (BSH) on phospholipid hydroperoxide glutathione
peroxidase [19]; in this case, a gel-based approach was used to separate the native protein from
the protein that was covalently bound to BSH, which were then characterized by means of liquid
chromatography coupled to mass spectrometry (LC-MS). A more comprehensive application of the
gel-based proteomics coupled to MALDI-TOF identification was reported in a study where a human
oral squamous carcinoma cell line was treated with boronophenylalanine (BPA) and then irradiated
with thermal neutrons [20]. Changes in the levels of 29 proteins were observed and they were mainly
related to vesicle regulation, mRNA processing, and transcription.
In the last years, proteomics technologies considerably improved and a gel-free approach, which
was mainly based on LC-MS (so called shotgun or MS-based proteomics), became the gold standard
methodology to investigate the proteome profiles, increasing both the number of identified proteins
and their quantitative analysis. In the present work, we took advantage of the availability of both
urine samples, which were previously used for pharmacokinetic investigations, and of a gel- and
label-free proteomics facility. We analyzed urine samples by means of multidimensional protein
identification technology (MudPIT) to describe the urinary proteomes of HNSCC and thyroid cancer
patients. Moreover, the effects on urinary proteome due to boron infusion (as BPA or BSH) in cancer
patients were also investigated.
2. Results
2.1. Proteome Profiles of Urine
The multidimensional separation of peptides and the MS-based proteomic approach that was
used in this work allowed for the characterization of proteome profiles of urine from healthy subjects
and tumor patients. Thus, it was possible to compare healthy subjects and tumor patients with a simple
and convenient shotgun protocol, which was based on liquid chromatography coupled to tandem mass
spectrometry (LC-MS/MS). Good repeatability between technical replicates was observed (Figure S1).
The complete list of proteins for each sample is reported in the supplementary materials (Table S1).
When considering all of samples, 365 proteins were identified and 62.2% of them have more than one
peptide. For the healthy group, 172 proteins were detected, while for HNSCC and thyroid cancer
patients, 253 and 228 proteins were found, respectively. The three groups share 110 proteins, while
the two groups of tumor patients share almost 60% of their proteins (Figure S2). An analysis of the
Uniprot Keywords showed that 219 out of 365 proteins have a signal peptide sequence, indicating that
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they are destined to the endoplasmic reticulum and possibly secreted. When considering the groups
separately, the analysis showed that about two-thirds of each group’s protein have a signal peptide.
The Uniprot keywords also showed that 84 out of 365 proteins have a transmembrane domain, with
no significant differences between healthy subjects and tumor patients.
The proteins identified for each group of patients were plotted on a two-dimensions map with
MAProMa software, using theoretical molecular weight (MW) and isoelectrical point (pI) (Figures
S3–S5). Figure 1 reports the two-dimensional map that was obtained by plotting all identified proteins.
These maps show the ability of the shotgun approach to identify proteins in a wide range of MW
and pI.
 
Figure 1. Two-dimensions map of the identified proteins from all analyzed urinary samples plotted
with MAProMa software, according to their theoretical pI and MW (in Log scale). Proteins identified
by 1 Peptide Spectrum Match (PSM) are reported as yellow triangles, those with PSMs between 2 and 4
as blue squares, and those with a number of PSMs over or equal to 5 as red circles.
An analysis of the enriched Gene Ontology (GO) biological process terms that was performed with
DAVID confirms a qualitative similarity in the protein composition of urine between the three groups
of subjects (Figure 2). In particular, the terms enriched in both tumor groups were the same, with little
difference in the number of proteins for each term. It has to be noted that three of these terms were
not found to be enriched in the urine of healthy subjects: phagocytosis, engulfment (GO:0006911), cell
adhesion (GO:0007155), and Fc-gamma receptor signaling pathway that is involved in phagocytosis
(GO:0038096).
6
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Figure 2. Enrichment in Gene Ontology (GO) biological process terms, using DAVID for each
considered group. * denotes GO Terms enriched only in tumor patients’ proteome but not in
healthy subjects.
2.2. Differentially Secreted Proteins in Urine from Tumor Patients
A quantitative approach was used, since there were no evident qualitative differences in the
proteic composition of urine for the three groups. In this study, a label-free quantification has been
applied, considering the total number of peptides (Peptide Spectrum Matches—PSMs, also called
Spectral Count—SpC) for each protein. Indeed, this quantitative analysis led to the identification of
significant alterations in the amount of single proteins that were secreted in the urine, when comparing
healthy subjects with tumor patients, using DAVE and DCI algorithms [21]. Proteins with highly
significant differences (i.e., |DAVE| > 0.2 and |DCI| > 10) are reported in Figure 3 and in Table S2,
together with fold changes and G test values.
By comparing the healthy subjects with those that were affected by HNSCC, 14 proteins were
found to be more abundant in urine from tumor patients, as indicated by the positive values of DAVE
and DCI (Figure 3), while the levels of six proteins were higher in control subjects. Analogously, the
analysis of urine from thyroid cancer patients led to the identification of 17 differentially secreted
proteins in comparison to healthy volunteers. Among these proteins, 13 were overrepresented in
affected subjects. It is interesting to note that the two types of tumors taken in account share similar
highly secreted proteins, and some of them show significant differences in both cases. Nine proteins
were higher in both tumors as compared to healthy patients, while three were lower: keratin, type
II cytoskeletal 1 (KRT1), serotransferrin (TF), and alpha-1-antitrypsin (SERPINA1). The urinary
proteins of the two tumor-affected groups were compared with the same method in order to identify
the differences between them. Indeed, 21 proteins were differentially secreted, eight proteins were
overrepresented in HNSCC patients, and 13 were overrepresented in thyroid cancer patients (Table S3).
7
Molecules 2019, 24, 794
 
Figure 3. DAVE values of the significantly different levels of proteins found in urinary proteome of
head and neck squamous cell carcinoma (HNSCC) patients (full bars) and thyroid cancer patients
(dashed bars) in comparison to the healthy subjects. Red/positive and blue/negative bars correspond
respectively to up- and down-secreted proteins in tumor patients compared to healthy subjects.
In addition, the enriched GO biological process terms were searched for the proteins that were
altered by the presence of tumor (Figure 4), and they showed similarity in the enriched terms between
the two tumor entities. Only two terms were found to be enriched in HNSCC and not in thyroid
cancer differentially secreted proteins: ERK1 and ERK2 cascade (GO:0070371) and B cell receptor
signaling pathway (GO:0050853). Three terms were enriched exclusively in differentially secreted
proteins of thyroid cancer patients: angiogenesis (GO:0001525), extracellular matrix disassembly
(GO:0022617), and extracellular matrix organization (GO:0030198). A comparison with the GO term
that was enriched in the whole urinary proteome profiles (Figure 2) showed that they share six GO
biological process terms with the ones enriched in the differentially secreted proteins; these terms are
reported in Figure 4 as slices with stripes pattern). The remaining terms were not enriched in urinary
proteome profiles, and they are reported in Figure 4 with a colored solid fill: angiogenesis (GO:0001525),
phagocytosis, recognition (GO:0006910), acute-phase response (GO:0006953), extracellular matrix
disassembly (GO:0022617), lipoprotein metabolic process (GO:0042157), positive regulation of B cell
activation (GO:0050871), ERK1 and ERK2 cascade (GO:0070371), and B cell receptor signaling pathway
(GO:0050853).
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Figure 4. Enrichment in GO biological process terms, as performed with DAVID on the significantly
different secreted proteins list reported in Table S2 and Figure 3 for HNSCC and thyroid cancer patients,
as compared to healthy subjects. Each slice is proportional to the number of proteins identified for each
GO biological process terms. The slices with the stripes pattern were already found to be enriched in
the analysis that was performed on the total urinary proteome of HNSCC and thyroid cancer patients
(see Figure 2).
2.3. Proteome Profiles in Urine to Monitor Effects of Interventions
2.3.1. Infusion of a HNSCC Patient with BPA
The first step in the BNCT therapy involves boron infusion before neutron irradiation; in this
context, we investigated the effect of boron on urinary proteome. Specifically, the effect of the two
boron-containing compounds BPA and BSH was investigated. One patient with a HNSCC was
infused with BPA. Using flow-injection electrospray ionization mass spectrometry (FI-ESI-MS), the
BPA-concentration in urine of the patient was measured before and after BPA-infusion (Figure 5) [16].
To evaluate the molecular effects of the compound on urine-secreted proteins, MudPIT proteomics
analysis was performed on a urine sample that was taken before BPA-infusion and on a sample taken
at the time point, when the urine concentration of BPA resulted in the highest. This time point equals
5 h after starting the BPA infusion, 6:45 h after starting anesthesia, and 6 h after starting the surgery
(Figure 5).
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Figure 5. Concentration of boronophenylalanine (BPA) in the urine of the HNSCC patient analyzed.
BPA infusion started at 0 min and ended at 1 h. * indicates the time point of urine sampling for
proteomic analysis.
This proteomic analysis allowed for a preliminary evaluation of the combined effects of BPA
infusion during surgery under anesthesia on the urinary proteome. Significant changes in the levels
of urinary proteins were identified using the MAProMa platform, which showed variations in the
urinary level of 29 proteins (Figure 6 and Table S4). The majority (22) of protein levels decreased
after BPA infusion (as indicated by negative values of DAVE and DCI). Among the proteins that
decreased after the intervention were some that showed higher levels in the urine of HNSCC patients as
compared to healthy subjects, namely Inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4), Pancreatic
alpha-amylase (AMY2A), osteopontin (abbreviated as OPN–gene name SPP1), uromodulin (UMOD),
aminopeptidase N (ANPEP), pro-epidermal growth factor (EGF), and vasorin (VASN). Two proteins
higher in the tumor patients, as compared to healthy volunteers, resulted in additional increase after
the infusion of BPA: Retinol-binding protein 4 (RBP4) and Protein AMBP (AMBP).
 
Figure 6. DAVE values of the significantly different secreted proteins that were found in urinary
proteome of a patient with HNSCC, before and 5 h after the infusion of BPA and during surgery
under anesthesia. The positive values indicate proteins increased after infusion, while negative values
indicate proteins decreased after infusion.
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The GO analysis of enriched biological process terms (Table S5) showed that there are some
terms that were affected by the infusion with BPA. Some of GO terms were found to be enriched
only after infusion: positive regulation of protein ubiquitination involved in ubiquitin-dependent
protein catabolic process (GO:2000060), leukocyte cell-cell adhesion (GO:0007159), retinol metabolic
process (GO:0042572), retinoid metabolic process (GO:0001523), and carbohydrate metabolic process
(GO:0005975).
2.3.2. Infusion of a Thyroid Cancer Patient with BSH
In a patient with thyroid cancer, we investigated the changes in the urinary proteome in urine
samples that were taken before BSH infusion and 10 h after starting the infusion. This time point
equals 30 min after starting anesthesia and just before starting surgery. Again, we identified the
differential levels of proteins (Figure 7 and Table S6). Twenty-one proteins changed their levels in
urine after BSH infusion. Only two proteins that were more abundant in the urine of tumor patients
in comparison to healthy volunteers decreased: uromodulin and OPN. Interestingly, there was an
increase of serotransferrin (TF) after BSH infusion, while levels of this protein were lower in tumor
patients as compared to healthy subjects.
 
Figure 7. DAVE values of the significantly different secreted proteins found in urinary proteome of
a patient affected by thyroid cancer, before and 10 h after the infusion with BSH and at the start of
surgery under anesthesia. The positive values indicate proteins increased after infusion, while negative
values indicate proteins decreased after infusion.
For this patient, a total number of 24 GO biological process terms were enriched, when
considering the differentially secreted proteins after BSH-infusion (Table S7). Eleven GO terms
were specifically enriched in relation to BSH infusion: Defense response to bacterium (GO:0042742),
inflammatory response (GO:0006954), phagocytosis, engulfment (GO:0006911), B cell receptor signaling
pathway (GO:0050853), cellular oxidant detoxification (GO:0098869), cellular iron ion homeostasis
(GO:0006879), vitamin transport (GO:0051180), oxygen transport (GO:0015671), establishment of skin
barrier (GO:0061436), hydrogen peroxide catabolic process (GO:0042744), and positive regulation of
cell death (GO:0010942).
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2.4. Reduction of Proteins Related to Inflammation after Infusion: galectin 3 Binding Protein, CD44, and OPN
In both treated patients, regardless of the boron compound infused, a reduction in three proteins
has been observed: galectin 3 Binding Protein (LGALS3BP), CD44, and OPN (SPP1) (Figure 8).
These glycoproteins are involved in inflammatory processes and possibly tumor progression [22–24].
All three proteins were reduced or even absent in urine that was sampled after boron compound
infusion and during anesthesia and surgery.
Figure 8. (a) Total amount of LGALS3BP (red fill), CD44 (blue fill), and osteopontin (OPN) (SPP1, green
fill) found in urine of the HNSCC patient infused with BPA before (solid fill) and 5 h after infusion
(diagonal lines fill). (b) Total amount of LGALS3BP (red fill), CD44 (blue fill), and OPN (SPP1, green
fill) found in urine of the thyroid cancer patient infused with BSH before (solid fill) and 10 h after
infusion (diagonal lines fill). Data are expressed as SpC ± SEM.
3. Discussion
In this work, we present the potential of LC-MS-based proteomics for monitoring treatment, using
an easily collectable biological fluid, such as urine. Protein profiles from urine samples allowed for the
discovery of potential tumor biomarkers by using a label-free quantitative comparison between healthy
subjects and HNSCC or thyroid cancer patients to find proteins that were differentially secreted in
urine from tumor patients. The urinary proteomes of cancer patients showed similarity in their overall
composition, as confirmed by the GO biological process enriched terms. In particular, “cell adhesion”
term was found to be enriched in patients but not in healthy volunteers, suggesting that this biological
process is disrupted by the presence of tumors and it is reflected in urine protein composition.
In both groups of patients with tumors, a great increase in uromodulin (UMOD) is interesting to
note, as this is known to be the most abundant in urine [25], as confirmed in our data for all subjects.
Although the total amount of uromodulin is related to the disease, it is hard to explain this increase
with respect to the healthy subjects, since the role of uromodulin is still not completely clear in both
physiological and pathological conditions. It is possible that uromodulin is related to an inflammatory
state that is observed in tumor patients, since its involvement in inflammatory processes in kidney
injury has been demonstrated [26].
Indeed, some of the proteins with higher levels in both groups are involved in inflammatory
processes. Among these, one of the most interesting is ITIH4, which is involved in inflammatory
responses to trauma [27]. Several groups have also demonstrated the potential of ITIH4 as a predictive
biomarker in a number of tumor entities [28–30]. In our investigation, the ITIH4 levels are elevated in
the urine of patients with HNSCC and in patients with thyroid cancer, but it is significantly higher in
the urine of HNSCC patients as compared to the urine of thyroid cancer patients.
Two immunoglobulins were found to be excreted in urine from tumor-affected subjects to a higher
extent, with no significant differences between the two tumor entities: Ig gamma-1 chain C region
(IGHG1), and Ig kappa chain C region (IGKC). In particular, IGKC show a very distinctive increase,
which was similar for both of the tumor entities examined. Proteins that are secreted in urine clearly
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reflect what happens in the organism and, in particular, the inflammation processes in progress. OPN
(SPP1) is an interesting protein that is involved in inflammatory processes and it resulted higher in
urine samples of tumor patients. Many cells, including the cells of the immune system but also tumor
cells, secrete it. Specifically, OPN increases in breast, colon, gastric, liver, lung, and prostate cancers [31].
It interacts with the CD44 receptor and it is considered to be one of the most promising prognostic
biomarkers for cancer [32].
The presence of inflammatory processes in tumor patient seems to be also confirmed by the GO
biological process enrichment analysis of differentially secreted proteins. Indeed, the enrichment of GO
terms, such as acute-phase response (GO:0006953), positive regulation of B cell activation (GO:0050871),
and B cell receptor signaling pathway (GO:0050853), indicate that the inflammatory processes are in
progress and they are reflected by changes in urine proteome composition.
Obviously, inflammation-related proteins are not sufficient for the diagnosis of cancer, since they
could be linked to additional conditions. Indeed, among the other proteins found to be excreted to an
enhanced extent, some have been already related to cancer and could therefore be considered to be
cancer biomarkers. As an example, aminopeptidase N (ANPEP) has been associated with the growth
of different human cancers and has been suggested as a suitable target for antineoplastic treatment
approaches [33]. In particular, an increase in aminopeptidase N activity in HNSCC has already been
observed [34]. Vasorin (VASN) is a type I transmembrane protein that plays an important role in tumor
development and vasculogenesis; it is a potential serum biomarker of hepatocellular carcinoma and
it may be a drug target for its treatment [35]. Pancreatic alpha-amylase (AMY2A) has been related
to cell adhesion, growth, and the invasion of cancer cells and it has been proposed as a candidate
urine biomarker for pancreatic cancer [36]. Zinc-alpha-2-glycoprotein (AZGP1) is a protein that is
known to have a role in different tumor entities. An overexpression of zinc-alpha-2-glycoprotein has
been observed in a proteomic analysis of saliva and serum from patients that are diagnosed with
HNSCC [37].
Some of the proteins that were identified as significantly higher in the urine of tumor patients
as compared to healthy subjects have been already proposed as possible biomarkers, although no
cancer-related functions have been identified so far. For example, the protein AMBP (AMBP), which
shows high levels in urine from patients with both HNSCC and thyroid cancer, has been found to also
be secreted in urine from the bladder [38] and prostate cancer patients [39] and in other biofluids (such
as cerebrospinal fluid and serum) of such patients [40,41].
The effect of tumor could also lead to a loss of function and therefore to a decrease in particular
proteins. As an example, the reduction in serotransferrin (TF) observed is possibly related to a
dysfunction in iron homeostasis. This could lead to further damage of the tissues following cancer
progression. Additionally, the reduction of cadherin 1 (CDH1), a growth and invasion suppressor,
is an interesting observation [42].
These data show that LC-MS proteomic analysis of urine could be a suitable and convenient
method for the characterization of different types of cancer. In particular, it is possible to simultaneously
follow several urine-secreted proteins that were altered by the presence of a tumor, thus creating a tool
more reliable than an approach based on the changes of exclusively one single protein. Furthermore,
specific proteins in urine could be followed for differentiating one cancer from another. As an example,
in this study, we showed that retinol-binding protein 4 (RBP4) was exclusively found in the urine of
patients with HNSCC but not thyroid cancer, indicating that this protein could be a specific HNSCC
biomarker. RBP4 is an adipokine that is mainly produced by adipose tissue and its serum levels
in medullary thyroid carcinoma patients are not significantly different from those that are found in
healthy individuals [43]. On the contrary, RBP4 was recently reported as a potential biomarker of
oral squamous cell carcinoma, in combination with clusterin, haptoglobin, complement C3c, and
proapolipoprotein A1 [44].
The method presented has been proven to also be useful for monitoring the effects at a molecular
level of two different boron compounds, used for BNCT: BPA and BSH. The infusion of patients with
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either one of the boron compounds induces changes in the proteins that were secreted in the urine. In
particular, we observed a reduction in proteins that were involved in inflammation, such as GALS3BP
and CD44. Additionally, OPN was decreased after boron infusion, both by BPA and BSH. OPN is a
secreted protein that is overexpressed in several human carcinomas. It has been implicated in different
mechanisms of tumor progression: cell proliferation, survival, drug resistance, invasion through its
role in intercellular communication, and tumor microenvironment formation [45]. Moreover, high
levels of OPN have been found in cerebrospinal fluid and serum of cancer patients [46] and it is
considered a possible target for cancer therapy [23]. It is to be noted that the role in inflammation of
OPN is possibly mediated by CD44 isoforms [47,48], suggesting that a specific inflammatory pathway
could be the target of BSH or BPA.
It has already been reported that other boron-containing compounds are able to reduce
inflammation both in animals and in humans [49], suggesting a beneficial effect of boron as a regulator
of the inflammatory reactions with a possible role in cancer and other diseases [50]. Our proteomics
data suggest that BPA and BSH could also reduce tumor-derived inflammation, thus possibly helping
the treatment. Certainly, further experiments are needed to confirm this hypothesis and to find
other inflammation-related proteins that are reduced by boron infusion. Of note, in the setting of
this feasibility investigation, the effects of drugs infused for anesthesia, and/or surgery itself might
influence the proteasome of the urine as well; thus, the observed effects cannot be solely attributed to
the boron compounds.
To date, very few studies investigated the effects of BNCT on the proteome. Although BNCT is a
binary therapy, up to now, the existing studies analyze the effects of both boron infusion and neutron
irradiation, but not the effect of either component of this treatment modality. In very few cases, the
effect of neutron irradiation with and without the infusion of a boron compound were evaluated, such
as the unique proteomics investigation after BNCT, as performed by Sato et al. [20]. Unfortunately,
their data cannot be compared with those that were obtained in the present work, because the authors
analyzed squamous cell carcinoma SAS cells in vitro irradiated with a thermal neutron beam with and
without BPA. The authors used a 2D gel approach and characterized approximately 20 proteins that
were mainly related to the endoplasmic reticulum-localized lymphoid-restricted protein.
The results of our study demonstrate the ability of shotgun proteomics based on the MudPIT
approach to identify a great number of potential protein biomarkers in urine. This is of growing
interest, since it is becoming clear that urinary proteome reflects changes that are induced by several
diseases, including different types of cancer. Furthermore, urine could be preferred to blood or
cerebrospinal fluid because of the easier and less invasive procedure of collection. The presented
data must be considered as a feasibility evaluation due to low patients’ numbers and urine samples
that are not systematically drawn for this purpose. Obviously, larger patient sets will also help to
discover the influence on the urinary proteome of other factors, such as age, gender, medication, or
diet. The proteomic analysis of urine is non-invasive and fast method, not only for tumor diagnosis,
but also for following the effects of treatment at the molecular level. Indeed, in the future, urine and
possibly other biofluids will be analyzed during and after the treatment in order to follow and possibly
verify the changes that are induced by therapy. In addition, urinary exosomes will be studied, since it
seems that biomarkers are enriched in secreted vesicles, facilitating the identification of disease-specific
proteins [51]. A forthcoming application of this approach could also be the identification of biomarkers
that are useful in monitoring the BNCT treatment and potentially predicting the response of patients
to treatment, allowing for the application of the best therapy for each person in the pursuit of
personalized medicine.
Finally, although, in BNCT trials, the molecular effects due to boron-containing compounds were
never systematically evaluated, our data indicate the proteome analysis of urine samples as a specific
and informative method, and it may be a potential mirror of disease. These results suggest that future
investigations with this method should evaluate the effects of boron compound infusion. The present
work represents a proof of principle to investigate the BNCT treatment effects; of course, presented
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data should be considered as a preliminary evaluation and they need to be confirmed by further
analyses on larger patient sets through a multicenter collaboration.
4. Materials and Methods
4.1. Patients Recruitment and Urine Collection
The samples were collected from patients who participated in the clinical trial EORTC 11001,
“10B-uptake in different tumors using the boron compounds BSH and BPA”. This study investigates the
delivery of 10B to certain tumor entities by the boron compounds BSH and BPA. The study procedures
included intravenous infusion of BSH and BPA prior to a planned surgical procedure that was necessary
for tumor treatment and sample collection, but no radiotherapy with BNCT. All of the participants
gave written informed consent prior to inclusion. The evaluation presented here became possible
because all of the participants agreed that the samples taken might also be investigated by innovative
procedures that were not yet available at the time of the sampling. The Protocol Review Committee
of the EORTC and the Ethics Committee of the Medical Faculty of the University Duisburg-Essen
approved the trial. The complete clinical characteristics of patients are reported in Table S8.
In addition to sample collection within the EORTC trial 11001, urine samples were collected
after written informed consent from heavily smoking (>25 cigarettes/day) healthy staff members of
University Hospital Essen, who volunteered to participate. Healthy volunteers did not receive any
medication or study the compounds. The age of the healthy volunteers were in the same range of the
tumor-affected subjects.
All of the analyzed samples from cancer patients are reported in Table 1.
Table 1. Analyzed cancer patients’ age at the time of urine collection and tumor diagnosis.
Subject Age Diagnosis
P12 45.3 Squamous cell carcinoma of the head and neck region
P21 50.6 Squamous cell carcinoma of the head and neck region
P20 68.5 Squamous cell carcinoma of the head and neck region
P22 53.1 Squamous cell carcinoma of the head and neck region
P11 79.6 Thyroid carcinoma
P14 34.6 Papillary thyroid carcinoma
P16 34.0 Papillary thyroid carcinoma
4.2. Boron Compounds and Urine Collection
BSH and BPA were purchased from KATCHEM Ltd. (Praha, Czech Republic). The quality of
the study medication was strictly controlled, including an examination of the identity of compounds
by infra-red spectroscopy, monitoring of purity by high pressure liquid chromatography, and test for
pyrogenicity. The enrichment of 10B was ≥99.6% in both compounds and it was tested with prompt
gamma ray spectroscopy (PGRA) and inductively coupled plasma-atomic emission spectroscopy
(ICP-AES). The injection-solutions were prepared according to standard operating procedures that
were established for the EORTC trials 11961, 11001, and 11011 [52,53].
To improve solubility, BPA (100 mg/kg) was infused as a BPA–fructose complex, within 1 h. Urine
samples were taken before and up to 34 h after the start of infusion. Urine samples were immediately
frozen at −20 ◦C until analysis.
BSH (50 mg/kg) was dissolved in saline and infused within 1 h. The urine samples were taken
before the start of infusion and at 9.5 h after the start of the BSH infusion. Samples were immediately
frozen at −20 ◦C until analysis.
In the past, urine samples from patients that were infused by boron-containing compounds were
investigated to determine compound pharmacokinetics [16]. We took advantages of the availability
of these samples and the shotgun proteomics approach to describe the related proteome profiles.
Specifically, urine samples from four patients with HNSCC and three patients with thyroid cancer,
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which were collected before infusion of the boron-containing compounds, were analyzed and compared
to the healthy volunteers. Urine samples from two patients (one patient with HNSCC and one patient
with thyroid cancer) were analyzed before compound infusion and after compound infusion in
order to evaluate the eventual changes in the urinary proteome that is caused by the infusion of the
boron-containing drugs BPA and BSH, as well as surgery and anesthesia.
4.3. Urine Preparation for Proteomics Analysis
For each sample, 600 μL of urine were centrifuged at 2000 g for 10 min. Supernatant was collected
and filtered twice with the Microcon YM10 system to eliminate salts. The protein concentration was
assayed using the SPNTM–Protein Assay kit (G-Biosciences, St. Louis, MO, USA).
4.4. Enzymatic Digestion of Protein Samples
Sequencing grade modified trypsin (Promega, Madison, WI, USA) was added to 50 μL of
conditioned medium containing 1 μg protein at a 1:50 enzyme:protein ratio (w:w) in 100 mM
ammonium bicarbonate, pH 8.0, and then incubated at 37 ◦C overnight. The reaction was stopped
by acidification with trifluoroacetic acid. A second aliquot of each sample was digested with pepsin
(Sigma-Aldrich, Milan, Italy) at 1:50 enzyme:protein ratio (w:w) in 100 mM ammonium acetate pH 3.0
at room temperature for 4 h and then immediately analyzed. Ten microliters of the peptide mixture
were directly injected into the 2DC-MS/MS.
4.5. Two-Dimensional Capillary Chromatography-Tandem Mass Spectrometry (2DC-MS/MS) Analysis
Ten microliters of the peptide mixtures, as obtained from the digestion of the protein samples,
were analyzed by means of two-dimensional microchromatography coupled with an ion trap mass
spectrometer, using the ProteomeX system (ThermoElectron, San Josè, CA, USA) that was equipped
with Bioworks 3.1 as graphical interface for data handling. Peptide mixtures were first separated
by means of strong cation-exchange chromatography (Biobasic-SCX column, 5 μm, 0.3 ID × 150
mm, ThermoHypersil, Bellofonte, PA, USA) using seven steps of increasing ammonium chloride
concentration (0, 50, 100, 150, 200, 300, and 600 mM). Each salt step was directly loaded onto the
reversed phase column (Biobasic-C18, 0.180 ID × 100 mm, ThermoHypersil, Bellofonte, PA) and then
separated with an acetonitrile gradient: eluent A, 0.1% formic acid in water; eluent B, 0.1% formic acid
in acetonitrile; the gradient profile was 5% B for 3 min, followed by 5 to 50% B within 40 min. Peptides
that were eluted from the C18 column were sent directly to an ion trap LCQXP mass spectrometer
through an ESI ion source interface that was equipped with a metal needle (10 μm ID). The heated
capillary was held at 160 ◦C, ion spray 3.2 kV, and capillary voltage 67 V. Spectra were acquired in
positive mode (in the range of 400–1600 m/z) using dynamic exclusion for MS/MS analysis (collision
energy 35%).
4.6. Data Processing of MS Results
All data generated were searched using the Sequest HT search engine contained in the Proteome
Discoverer software, version 2.1 (Thermo Scientific, Waltham, MA, USA). The experimental MS/MS
spectra were correlated to tryptic peptide sequences by comparison with the theoretical mass spectra
that were obtained by in silico digestion of the Uniprot human proteome database (70,726 entries),
downloaded in January 2017 (www.uniprot.org). The following criteria were used for the identification
of peptide sequences and related proteins: trypsin as enzyme, three missed cleavages per peptide,
mass tolerances of ±1 Da for precursor ions, and ±1 Da for fragment ions. Percolator node was
used with a target-decoy strategy to give final false discovery rates (FDR) at Peptide Spectrum Match
(PSM) level of 0.01 (strict) based on q-values, when considering a maximum deltaCN of 0.05 [54].
Only peptides with high confidence, minimum peptide length of six amino acids, and rank 1 were
considered. Protein grouping and strict parsimony principle were applied. The MS data have been
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deposited to the ProteomeXchange Consortium via the PRIDE partner repository [55] and they are
available upon request to the corresponding author.
The output data that were obtained from SEQUEST software were treated with the MAProMa
(Multidimensional Algorithm Protein Map) in-house algorithm for a comparison of the protein lists,
evaluation of relative abundances, and plotting virtual 2D maps [56]. A label-free approach has been
used, counting the peptide spectrum matches (PSMs) for each identified protein [21]. Fold changes
were calculated as natural logarithm of the SpC (SpC1/SpC2) [57]; the natural logarithm of the proteins
identified exclusively in one of the two compared groups was set to ±100. G test was performed for
the differentially expressed protein, as already reported for label-free quantification [58].
Venn diagrams were created with Venny (http://bioinfogp.cnb.csic.es/tools/venny/index.html).
4.7. GO Terms Enrichment
GO terms enrichment was performed with DAVID 6.8 (https://david.ncifcrf.gov/), using Uniprot
accessions [59]. Biological process terms were considered to be enriched when the p-value and
Bonferroni test results were below 0.0001 and at least 10 gene were found for the term.
Supplementary Materials: The following are available online. Figure S1: Comparison between two different
replicates of patient 20, Figure S2: Two dimensions map of healthy subjects urine proteome profiles, Figure S3:
Two dimensions map of HNSCC patients urine proteome profiles, Figure S4: Two dimensions map of thyroid
cancer patients urine proteome profiles, Figure S5: Venn diagram of proteins distribution among the three groups,
Table S1: List of all proteins identified in the samples analyzed, Table S2: DAVE and DCI values, fold changes, and
G test values of the proteins differentially secreted in urine from healthy subjects versus those from cancer patients,
Table S3: DAVE and DCI values, fold changes, and G test values of the proteins differentially secreted in urine
from thyroid cancer patients versus those from HNSCC patients, Table S4: DAVE and DCI values of the proteins
differentially secreted in urine from a patient affected by HNSCC, before and 5 h after the infusion with BPA,
Table S5: GO biological process terms enriched in differentially expressed proteins for HNSCC patient treated
with BPA, Table S6: DAVE and DCI values of the proteins differentially secreted in urine from a patient affected
by thyroid cancer, before and 4 h after the infusion with BSH, Table S7: GO biological process terms enriched in
differentially expressed proteins for thyroid cancer patient treated with BSH, Table S8: Subjects analyzed with
complete clinical characteristics.
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Abstract: Ex vivo lung perfusion (EVLP) is an emerging procedure that allows organ preservation,
assessment and reconditioning, increasing the number of marginal donor lungs for transplantation.
However, physiological and airflow measurements are unable to unveil the molecular mechanisms
responsible of EVLP beneficial effects on lung graft and monitor the proper course of the treatment.
Thus, it is urgent to find specific biomarkers that possess these requirements but also accurate
and reliable techniques that identify them. The purpose of this study is to give an overview on the
potentiality of shotgun proteomic platforms in characterizing the status and the evolution of metabolic
pathways during EVLP in order to find new potential EVLP-related biomarkers. A nanoLC-MS/MS
system was applied to the proteome analysis of lung tissues from an optimized rat model in
three experimental groups: native, pre- and post-EVLP. Technical and biological repeatability were
evaluated and, together with clustering analysis, underlined the good quality of data produced.
In-house software and bioinformatics tools allowed the label-free extraction of differentially expressed
proteins among the three examined conditions and the network visualization of the pathways mainly
involved. These promising findings encourage further proteomic investigations of the molecular
mechanisms behind EVLP procedure.
Keywords: proteomics; Ex Vivo Lung Perfusion (EVLP); nanoLC-MS/MS; transplantation
1. Introduction
Ex vivo lung perfusion (EVLP) is an emerging procedure proposed for organ preservation
and reconditioning which can increase the number of lungs available for transplantation without
compromising its success [1]. In fact, it permits the evaluation and the treatment of lungs of doubtful
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function, such as ones from donors after cardiac death or from high risk donors, not only expanding
the pool of possible transplants but also improving patient outcomes [2,3].
This derives from the fact that organs, previously considered unsuitable for transplantation,
thanks to EVLP are now safely used and show similar or even better performances than those of lungs
transplanted immediately after procurement. In these circumstances, EVLP application could represent
a benefit for all donor lungs prior to implantation (so that it could be inserted in routine transplant
protocols), but the evidence-based medical data collected so far are still insufficient [4] and there are
different EVLP systems and application procedures adopted worldwide [5–7]. These weaknesses
emerged on the basis of lung function measurements, but further research and tools are needed to
obtain a deeper comprehension of the biological actions exerted by EVLP not only at the functional
but also at the molecular level.
Accordingly, there is the need to find clinical and molecular targets that could provide evidence
to recommend a specific protocol, to monitor the proper course of treatment and predict donor lung
performance during EVLP procedure and after transplantation. Despite the emergence of EVLP
technology, currently available methods employed for the evaluation of this procedure, are limited
to airway and pulmonary measurements and therefore inadequate in assessing EVLP procedure
monitoring and its molecular effects on lung graft [8]. In addition, the same respiratory diseases,
for which lung transplantation is the only possible therapy, are a class of highly heterogeneous and
multifactorial disorders that often make early screening, diagnosis, prognosis, disease progression, and
treatment effect challenging with the diagnostic techniques applied so far. In fact, traditional methods
based on reactive medicine (physiological examinations, medical history and airflow measurements)
are not sufficient to fully satisfy these requirements.
All these factors contributed to the urgency in finding new specific molecular and clinical
biomarkers that could be considered as objective diagnostic parameters by clinicians. In the new
era of medicine [8,9], biomarkers play an essential role, because they summarize a precise biological
state and provide quantifiable and comparable features that represent indicator of normal state,
pathogenic processes or therapeutic response [10]. Certainly, thanks also to rapid development of next
generation sequencing techniques (NGS) genomics approach is the first to be widely applied for the
identification of genes as molecular biomarkers of diseases and for the selection of personalized patient
therapies [11,12]. However, the genome only provides theoretical information of the protein levels
while the proteome describes its actual content, which ultimately determines the phenotype. For this
reason, genomic/transcriptomic investigations are recently giving way to proteomic approaches for
a deepened and a more precise characterization of biological processes related to different clinical
phenotypes and for the molecular monitoring of markers involved in respiratory diseases, such as
COPD [13,14], cystic fibrosis [15], rhinitis [16], and the effect of anti-IgE therapy [17].
Solid organ transplantation represents an interesting challenge to test the potential of the
proteomics approach and the first attempts to find new potential EVLP-related biomarkers were made
by analyzing the perfusate protein expression during EVLP with multiplex immunoassays [18–20].
In these studies, the attention was exclusively focused on a specific class of proteins involved in
inflammatory processes related to the transplant procedure.
Indeed, it is important to evaluate if these processes and other lung biological responses are
effectively due to EVLP-induced changes and not to reconditioning mechanisms that could occur
during the ex vivo perfusion procedure. To this end, our coauthors of Fondazione IRCCS Cà Granda
Ospedale Maggiore Policlinico of Milan developed a rat model [21] that reproduces a prolonged ex vivo
perfusion on uninjured lungs without the use of anti-inflammatory drugs. With gene expression studies
on lung tissues and the assessment of mediators and metabolites on perfusate, they demonstrated that
EVLP broadly affects the transcriptional profile and signaling pathways under monitoring [22].
In this context, the present work represents another step forward in our understanding of lung
biological response under ex vivo perfusion, employing the same rat model and taking advantage
of innovative proteomic technologies. In fact, advances in proteomic approaches, especially those
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which are mass spectrometry (MS)-based [23–27], could provide new tools to overcome the lack of
sensitivity and specificity of traditional diagnostic techniques, and to detect more than few proteins
simultaneously in a great dynamic range of concentration and in a wide variety of bio specimens [17,28].
Our main focus is to develop a shotgun label-free platform based on a nano-chip LC system
combined to an Orbitrap mass spectrometer benchtop as proof of principle to characterize the complete
proteome of frozen lung tissues derived from optimized EVLP rat models [21] stratified in three
experimental conditions: lung biopsies collected from animals in resting conditions (native group),
lung biopsies taken after death induction, in situ cold perfusion and lung procurement (pre-EVLP
group), and at the end of ex vivo perfusion (post-EVLP group). An added value to this approach is
given by the application of in-house software and powerful bioinformatics tools that facilitate large
scale analyses, allowing the detection and validation of differentially expressed proteins as potential
biomarkers of biological EVLP-induced states and the identification of metabolic pathways in which
they are involved [29–33]. Finally, the comparison of data obtained from frozen and formalin-fixed
paraffin-embedded (FFPE) tissues is also performed with the aim to point out all the potential of the
platform proposed, considering the wide availability of those tissues in clinical biobanks [34].
2. Results
The application of a shotgun label-free platform, based on a nanochip LC system combined
to a hybrid quadrupole Orbitrap mass spectrometer, allowed the direct analysis of lung samples
obtained from a reproducible EVLP animal model and in three distinct conditions: native,
pre-EVLP and post-EVLP. Specifically, each experimental condition was evaluated using five animals
(biological replicates) and separately analyzed in duplicate (technical replicates), for a total of
thirty nanoLC-MS/MS runs from which it was possible to identify proteins and perform label-free
semiquantitative evaluation, cluster and network analyses (Figure 1).
Figure 1. Experimental pipeline. Applied workflow for proteomic investigation of frozen and
formalin-fixed paraffin-embedded (FFPE) lung tissues derived from an optimized ex vivo lung
perfusion (EVLP) rat model. (A) Three distinct conditions (n = 5 for each group), native (lungs
procured from animals in resting conditions), pre-EVLP (lungs subjected to in situ cold flushing and
then procured), and post-EVLP (lungs subjected to in situ cold flushing, procurement and then to ex
vivo perfusion/ventilation), were analyzed. (B) After protein extraction and digestion, the obtained
peptide mixture was analyzed by a nanoLC-MS/MS system in order to allow protein identification and
label-free semiquantitative data handling, such as repeatability, extraction of differentially expressed
and discriminant proteins and systems biology analysis.
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2.1. Surgical Procedures and Physiological Assessments
As shown in Supplementary Table S1, mean time intervals of warm and cold ischemia were
similar among animals of the post-EVLP group. Conversely, agonal phase timespan was significantly
longer in the rat IE9 compared to other animals of the same experimental group (Grubb’s test, p < 0.05).
Lung functionality was evaluated through assessment of hemodynamic and respiratory
parameters and measurement of the perfusate composition throughout the EVLP procedure.
Pulmonary artery pressure (PAP) significantly increased (p < 0.003), whereas peak inspiratory pressure
(Ppeak) decreased following recruitment maneuvers (p < 0.001). In addition, gas analysis showed
that, together with a decrease in glucose concentration (p = 0.003), there was a rise of lactate up to
0.7 mmol/L (p < 0.001) (Figure 2).
Finally, the lung edema index of the Post-EVLP group was not significantly different compared to
the pre-EVLP and the native groups (p = 0.094).
Figure 2. Evaluation of lung function during EVLP procedure. (a) PAP, significantly increased
(p < 0.003), and (b) Ppeak, decreased following recruitment maneuvers (p < 0.001). (c) Concentration of
glucose (from 187 ± 6 mg/dL at 0 min to 174 ± 10 at 180 min, p = 0.003) and (d) lactate (0.6–0.7 mmol/L
at 180 min, p < 0.001) significantly changed during reperfusion. PAP, pulmonary artery pressure; Ppeak,
peak inspiratory pressure. One-way repeated measures ANOVA; Tukey’s multiple comparison test.
p < 0.05: a = vs. 0 min; b = vs. 30 min; c = vs. 90 min; d = vs. 120 min; e = vs. 150 min.
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2.2. Protein Profiles of Frozen Tissue Lung Lobes
All of the thirty protein lists of biological and technical replicate analyses were aligned through
an in-house Multidimensional Algorithm Protein Map (MAProMa) tool [29,30] and grouped by
calculating, for each distinct protein, the identification frequency and the average Spectral Counts
(SpC*) and Score (Score*), which are useful parameters for relative abundance protein assessment in
label-free quantitative approaches. In fact, SpC represents the total number of MS/MS spectra assigned
to each protein and, consequently, it reflects protein relative abundance in each analyzed condition,
while Score value is another semi quantitative parameter calculated by the integration of several search
engine variables. Overall, 1895 distinct proteins were identified: 1588, 1616 and 1330 for native, pre-
and post-EVLP, respectively. A complete list of the identified proteins is reported in Supplementary
Table S2. Figure S1a) shows the proportional Venn diagram of specific proteins for each condition.
In particular, 1160 proteins were identified in all conditions, while 205 proteins were identified in
both native and pre-EVLP, 75 proteins were common to pre- and post-EVLP, and 39 proteins were
identified in both native and post-EVLP conditions. Finally, a total of 184, 176 and 56 distinct proteins
were exclusively detected in native, pre- and post-EVLP, respectively. Using the MAProMa software
it was also possible to plot each experimental condition list on a 2D virtual map, according to the
theoretical Molecular Weight (MW) and Isoelectric point (pI) of identified proteins. An example is
shown in Figure S1b), where the protein list of a post-EVLP sample was mapped. For each protein,
a color/shape code was used according to the confidence of identification.
2.3. Data Handling
2.3.1. Repeatability
Technical and biological repeatability of the method was tested by plotting SpC values of lists
previously aligned with MAProMa; specifically, each technical replicate showed linear correlation (R2)
and slope close to the theoretical value of 1 (Figure 3 and Supplementary Table S3). Figure 4a reports
the technical repeatability of a sample from the native group. Similarly, the biological repeatability was
verified (Supplementary Table S3 and Figure 3). As shown in Figure 4b, the average SpC of sample
IIIM21 (X axis) was compared with that of IIIN23 (Y axis), both belonging to the post-EVLP condition:
R2 = 0.946 and y = 0.962. These findings demonstrated the good repeatability of the proteomic approach
adopted, because the reduced oscillations of SpC values are a robust starting point for subsequently
label-free investigations on protein profiles. Furthermore, similar results were also reported for all
the analyzed samples (data not shown), except for sample IE9 (belonging to the post-EVLP condition)
which shows a lower biological repeatability compared to the other samples in the same condition.
An example of low biological repeatability with sample ID7 was reported in Figure 4c. For this reason
sample, IE9 was further investigated and only 30 proteins (out of 1187) resulted significantly scattered
in IE9 (compared to the other post-EVLP samples); in particular, these nonlinear proteins were mainly
related to plasma proteins. Of note, deleting the plasma related proteins identified in the IE9 sample the
correlation with the other post-EVLP samples improved (Figure 4d). For these reasons, the IE9 sample
was taken into account for label-free quantitation and network analysis. The proteomics finding in the
IE9 sample were in agreement with its different agonal phase as reported in Section 2.1. The different
behaviors of the IE9 sample (both biological and molecular) could be correlated to possible lesions
due to the supplemental manipulation (double cannulation required) that occurred to IE9 during the
surgical procedure.
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Figure 3. Technical and biological repeatability of proteomic analysis. Diagrams of correlation
coefficient (R2) values of technical and biological replicates. Each R2 value of technical and biological
replicates was assigned a color code, and the corresponding ranges associated to a chromatic scale
were reported. The technical R2 value (ˆ) was obtained comparing the spectral count (SpC) values from
two runs of the same sample. Similarly, plotting the average SpC* values of two samples belonging to
the same condition the biological R2 value was calculated. The numerical linear regression values (R2)
for each comparison are reported in Supplementary Table S3.
Figure 4. Examples of technical and biological repeatability of proteomic analysis. (a) Typical technical
repeatability (IIIQ29 sample, native group). (b) Biological repeatability between two native samples
(IIIM21 and IIIN23). (c) Biological repeatability of IE9 sample compared to ID7 (post-EVLP samples).
(d) Biological repeatability of IE9 sample compared to ID7 without the scattered proteins (mainly
plasma proteins). SpC*: Average spectral count value.
2.3.2. Clustering and Linear Discriminant Analyses
Protein lists obtained by the proteomics analyses of the three experimental conditions analyzed
were processed by Linear Discriminant Analysis (LDA) [35] and 451 proteins with F ratio > 3.4 and
p-value < 0.05 were selected as descriptors of features able to correctly discriminate the three groups
(Supplementary Table S4). An oriented dendogram was obtained using all the average SpC protein
values of the fifteen animals analyzed. As shown in Figure 5, all post-EVLP samples resulted segregated
into a group and separated from native and pre-EVLP samples. Of note, observing the post-EVLP
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grouping more in detail, the IE9 sample, while remaining within the same cluster, shows a slightly
different trend than the other animals in the group and is localized on a separate branch, much closer
to the pre-EVLP and native ones.
 
Figure 5. Hierarchical clustering obtained by Linear Discriminant Analysis (LDA). Using the average
SpC values from all conditions, the post-EVLP samples were correctly segregated and 451 descriptor
proteins by LDA were identified. Of note, IE9 sample, although remaining within the correct subgroup,
is localized on a separate branch. The complete list of descriptor proteins extracted by LDA is reported
in Supplementary Table S4. filtering criteria.
2.3.3. Differential Analysis
Independently from cluster analysis, a label-free evaluation of differentially expressed proteins
was also performed using two parameters available in MAProMa software and comparing the average
SpC values obtained for each identified protein in the three examined conditions. These parameters
are DAve (Differential Average) and DCI (Differential Coefficient Index) representing the ratio and the
confidence in differential expression, respectively, of a protein between two samples. They allowed
the identification of 239 distinct differentially expressed proteins (DEP), using the filters described in
Material and Methods section (Section 4.4.3). In particular, 31 and 77 proteins resulted respectively
down- and upregulated in pre-EVLP compared to native. On the other hand, 180 resulted more
abundant in pre-EVLP compared to post-EVLP, and only three proteins were upregulated in post-EVLP.
Finally, 135 and 11 were down- and upregulated, respectively, in post-EVLP compared to native.
Noteworthy, the combination of the data obtained by the differential evaluation with LDA and DEP
analysis allowed the identification of 499 proteins, among which, 190 distinct proteins resulted common
to the two methods applied. In fact, about 80% of DEP were confirmed by LDA. The complete list of
differentially expressed proteins is reported in Supplementary Table S4, where proteins derived from
the same gene were grouped.
2.4. Network Analysis
Proteins selected by LDA and DEP analyses were used to reconstruct a Protein–Protein Interaction
(PPI) network of Rattus norvegicus involving 487 nodes and 7806 interactions for the investigation
of the functional relationships among groups of proteins identified in our proteomic approach.
Considered nodes were grouped into 25 distinct subnetworks based on their function and/or
subcellular localization. These subnetworks were grouped into five distinct main groups: extracellular
matrix, translation, cytoskeleton, cell cycle, and metabolism. The proteins displayed on the network
are represented by a chromatic scale that reflects the relative abundance (SpC) of their expression.
By means of Cytoscape [36] it is also possible to upload to the same metabolic network the results
derived from the label-free differential analysis of pairwise comparison: native vs. pre-EVLP
(Supplementary Figure S2a), pre-EVLP vs. post-EVLP (Supplementary Figure S2b), and native vs.
post-EVLP (Supplementary Figure S2c). The majority of subnetworks resulted mainly up- and
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downregulated in pre- and post-EVLP, respectively, compared to the native condition. Of note,
some subnetworks, such as redox, PDIA (Protein Folding Drives Disulfide Formation), actin- and
myosin-related proteins and vesicle-mediated transport seem unchanged in native vs. post-EVLP
comparison; on the contrary, these subnetworks resulted up regulated in pre-EVLP.
To further investigate more the modifications of proteome in response to the EVLP treatment,
it was calculated for each protein its variations (modules) due to perturbation (native vs. pre-EVLP)
and treatment (pre-EVLP vs. post-EVLP). Theoretically, if the two modules present similar
values but they have opposite sign, the protein recovers its level to the reference (in our case
native condition). The extraction of so-called “recovered proteins” was simplified by calculating
the Proteome Remodeling index (PRi) for each protein using an unbiased procedure. In this
way, we extracted 104 proteins, and 32 had a statistically significant result (ANOVA ≤ 0.05,
Supplementary Table S5). Proteome Activated index (PAi) was calculated using baseline and treatment
modules to extract proteins which unchanged between native and pre-EVLP conditions (perturbation
module), but resulted to be activated or inhibited (up- or downregulated, respectively) with treatment
(post-EVLP condition). In this case 168 proteins were found, of which 67 resulted statistically significant
by ANOVA (≤0.05) (Supplementary Table S6). Of note, only two proteins resulted increased with the
EVLP treatment. These extracted proteins were uploaded in the PPI network previously prepared
and four subnetworks resulted to be enriched (Figure 6 and Figure S3): myosin-related proteins,
actin-related proteins, and vesicle-mediated transport (belonging to cytoskeleton), and redox-processes
(metabolism). Similar results were obtained by means of ln[FoldChange] (Supplementary Tables S5
and S6).
Figure 6. Main pathways involved in the proteome remodeling induced by the EVLP procedure.
Enriched subnetworks based on recovered and activated proteins after ANOVA (<0.05) and Tukey’s
test (<0.05; * <0.08). These statistically significant proteins were previously extracted using an unbiased
procedure that evaluated simultaneously the changes in the proteome in the three conditions: native,
pre-EVLP, and post-EVLP. Recovered proteins, marked as a green/circle, were extracted using the
Proteome Remodeling index (PRi); while activated proteins marked as red/triangle and blue/arrow
for up- and downregulated in post-EVLP, respectively, were extracted using Proteome Activated index
(PAi). The application of PRi and PAi filters highlights an enrichment in (a) vesicle-mediated transport,
myosin-, and actin-related proteins, belonging to cytoskeleton and (b) redox regulation, belonging to
metabolism. The blank nodes identify the protein descriptors resulted outside the applied PRi and PAi
filters. (c) Summary of considered trends of remodeled proteins. The complete lists of PRi and PAi
extracted proteins are reported in Supplementary Tables S5 and S6.
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2.5. Comparison between Frozen and FFPE Tissue Lung Lobes
Shotgun proteomics approach was also employed to compare frozen and FFPE lung tissues.
In particular, three FFPE samples from the pre-EVLP condition were analyzed. Using MAProMa
software the three FFPE resulting proteomes were aligned with the corresponding frozen ones.
The resulting twelve nanoLC-MS/MS runs allowed the identification of 1764 distinct proteins: 1458 and
1351 for frozen and FFPE, respectively (Table S7). As reported in Figure 7a more than 77% (1044) of FFPE
proteins were confirmed in frozen specimens. Plotting the normalized average SpC values between the
two datasets both R2 and slope were close to the theoretical value of 1 (Figure 7b). Finally, through the
Protein ANalysis THrough Evolutionary Relationships (PANTHER) classification system [33] it was
possible to classify proteins based on their molecular function. As shown in Figure 7c the distribution
of proteins between the FFPE and frozen tissues was nearly identical, suggesting that the differences
in proteins observed in the two datasets were not biased toward a specific molecular function.
Figure 7. Comparison between frozen and FFPE pre-EVLP lung lobes. (a) Protein overlapping between
frozen and FFPE in three pre-EVLP analyzed samples (IIL11, IIG13 and IIH15). (b) Plot of frozen vs.
FFPE samples using normalized average spectral count (SpC*) values. (c) Distribution of proteins
between the frozen and FFPE according to their molecular function using Protein ANalysis THrough
Evolutionary Relationships (PANTHER) classification system. For each molecular function, reported as
percentage of proteins for the two tissues (blue/solid colour for frozen and blank for FFPE datasets),
the difference frozen vs. FFPE was <0.9%.
3. Discussion
Here, we employed a rat model and recent advances in MS-based proteomics to generate a
proteomic system biology view of the EVLP procedure. The EVLP procedure cannot be solely
evaluated on the basis of physiological measurements. In fact, analyses at the molecular level are
mandatory to find potential protein markers for a better understanding of mechanisms by which EVLP
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is ruled [18–20]. In light of this our approach represents a first attempt in this direction, with the intent
to develop a shotgun label-free platform which could be helpful in extracting informative features from
complex biospecimens in large scale analyses useful to correlate molecular expressions to biological
processes. In particular, a nanoLC system based on chip technology was combined to a next-generation
mass spectrometer with improved resolution and accurate mass detection in order to investigate
protein extracts obtained from frozen lung tissues in three experimental groups (native, pre-EVLP and
post-EVLP). This high throughput system was completely automatized and allowed the simultaneous
identification of thousands of proteins with a wide range of concentrations and without limits of pI
and MW [17,28] (see Figure 1).
Moreover, the large amount of data produced were properly processed with dedicated,
commercial or in-house, bioinformatic tools using parameters provided by the employed search
engines [29–33]. In our case, data handling was greatly simplified by means of MAProMa
software [29,30] since it allowed the automatic alignment of different protein lists, presenting the
results in a user-friendly format and highlighting differentially expressed proteins. In addition,
data dimensional reduction with support vector machines was also applied to extract informative
features useful for the correct classification and sample grouping using only information correlated to
them and their relationships [35]. In this respect, the hierarchical clustering analysis performed by LDA
and conducted on the fifteen average protein lists obtained by the three examined conditions, permitted
to discern the differences among them and to correctly group samples in the three distinct categories
(Figure 5). These findings indicate the high reproducibility and statistical reliability of the proposed
approach. An additional confirmation derived from the technical and biological repeatability results
obtained comparing SpC values of protein lists of the same sample injected in replicate and of different
animals belonging to the same experimental group (Figure 3). In this case, our platform was able to
point out differences in the IE9 sample with respect to the other biological replicates of the post-EVLP
group. Specifically, the IE9 sample showed a very low biological repeatability in all the comparisons
with animals of the same experimental group (Figure 3c). With the aim of further understanding the IE9
molecular variability, the protein profiles of this animal and its biological replicates were investigated.
The results of differential analysis showed a similar pattern of IE9 with the other post-EVLP animals
except for only a few proteins that resulted up regulated and essentially related to blood components.
These findings were in agreement with the longer agonal phase of this animal herein reported and
could be correlated to possible lesions due to the double cannulation incurred during the surgical
procedure. However, this did not compromise the final functional outcome of the animal, which was
not excluded from the study, but with its unique profile revealed the potentiality of our platform as
confirmed by clustering analysis (Figure 5). In contrast to the inability of functional measurements
to detect even small differences, clustering correctly maintained IE9 within the post-EVLP group but
underlined its incomplete alignment with the other components of the same group, providing in this
way a deeper and more accurate data evaluation strategy.
Another interesting feature that could be supported by our approach is the possibility to conduct a
label-free quantitative investigation for the identification of potential biomarkers. Given the increasing
popularity of EVLP treatment, the search for new molecular targets which could be employed in the
future as objective parameters to recommend a protocol over others, to monitor the entire procedure
and to predict lung performance is urgent. With this in mind, our study represents a first effort in this
direction, as far as we know. In particular, LDA analysis showed the post-EVLP group completely
segregated from the pre-EVLP and native conditions and provided the selection of 451 proteins whose
trends were able to discriminate the three groups (Figure 5). Using an independent methodology,
supplied by the application of DAve and DCI parameters included in MAProMa software [29,30],
246 distinct differentially expressed proteins were found with an overlap of 80% with those previously
extracted by LDA.
At this point, the differentially expressed proteins resulting from both these computational
tools were uploaded in a network built using Cytoscape [32] and with which it was possible to
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visualize protein–protein interactions and metabolic pathways mainly involved. As reported in
the Results section, the differentially expressed proteins were network visualizable with a color
code that represented the DAve values resulting by the pairwise comparison of the three conditions
(Supplementary Figure S2a–c). What emerged from a first observation was that EVLP treatment
involved a downregulation of a great number of proteins reported in the metabolic pathways. If,
from a functional point of view, both EVLP and native lungs seemed to achieve the same results in
term of graft acceptability criteria, the study of molecular profiles suggests that this take place in
different ways with the intervention of different pathways. Certainly, the experimental data permitted
to exclude that this phenomenon was attributable to sample degradation due to a different processing
time that the EVLP treatment required. In fact, the total number of identified proteins in the three
conditions presented similar orders of magnitude and only 13% of the distinct identified proteins
showed a differential expression (Supplementary Table S1).
Moreover, by means of proteome remodeling indexes, PRi and PAi, proteomic changes were
simultaneously evaluated in pre-EVLP and in post-EVLP, where proteome expression in the latter
seems to return to the reference condition (native group). After EVLP treatment, approximately
32 proteins resulted statistically significant in rebalancing the proteome to the reference condition
of native lungs. Based on these findings it was possible to speculate that restored proteins might
be correlated to the reconditioning effect exerted by EVLP. Of note, these proteins were always
down regulated in post-EVLP compared to pre-EVLP; specifically, they resulted mainly involved
in cytoskeleton (vesicle-mediated transport and myosin- and actin-related proteins) and in redox
regulation (metabolism) (Figure 6). Another interesting class of proteins extracted by calculating the
Proteome Activated index (PAi) did not show differential expression between native and pre-EVLP
conditions, but increased or decreased their abundance after EVLP treatment. In particular only Mal2
and SOD1 increased their level, while 65 proteins decreased their level in post-EVLP compared to both
native and pre-EVLP groups. Similarly to PRi-extracted proteins, those PAi-extracted resulted being
mainly involved in cytoskeleton (vesicle-mediated transport and myosin- and actin-related proteins)
and in redox regulation (metabolism).
To better understand these data and hypothesize possible mechanisms that govern the activation
or suppression of metabolic pathways, we need to keep in mind what happens at a biochemical
level during ex vivo lung perfusion. During the entire EVLP procedure, the lungs are subjected
to a first phase of oxygen breakdown, for cold flushing and recruitment of organ (cold ischemia),
and to a subsequent reperfusion by ex vivo perfusion/ventilation. The reduction of O2 causes
alterations in cellular metabolism and the switch from aerobic to anaerobic metabolism [37] with
the subsequent reduction of intracellular ATP. Alteration of cell pH and generation of reactive oxygen
species (ROS) [38,39] due to increase of Na+ [40,41] and Ca2+ ions [42,43] are significant events that
also occur. In addition, changes in cytoskeleton composition are signaled in endothelial cells with
the activation of adhesion proteins [44] and others one involved in the maintenance of flexibility and
adaptability of cytoskeleton during hypoxia [45].
As stated before, all these effects attributable to EVLP on different biomolecular pathways are
easily observable in networks built with proteins highlighted for their differential expression and
extracted by MAProMa, LDA and remodeling indexes. In particular, it is interesting to note that,
among upregulated proteins in the post-EVLP condition, there are some belonging to the extracellular
matrix (ECM), constituents of the basement membrane, and involved in inflammatory process and its
regulation. Their secretion is stimulated by IL-1β and TNF-α [46,47] in order to repair the basement
membrane, regenerating ECM around pulmonary fibroblasts and reconstituting epithelial tissue
integrity after lung injury [47]. Of note, our coauthors of the Fondazione IRCCS Cà Granda Ospedale
Maggiore Policlinico of Milan, in a work just published [22] and based on studies of gene expression
on the same animal model samples, observed that IL-1β and TNF-α resulted upregulated in EVLP,
due to lung injury resulting in the induction of ischemia by the surgical procedure, and activated
the NF-kB complex. The occurrence of an inflammatory response together with other alterations at
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the proteomic level in lungs, in a rat model designed without the use of anti-inflammatory drugs
that could falsify results, is to be considered another small step towards the discovery of molecular
mechanisms modulated by EVLP.
If on the one hand during riperfusion the activation of inflammatory processes leads to the
expression of pro-inflammatory mediators (like IL-1β and TNF-α) [48,49] on the other hand stimulates
the release of reactive oxygen species (ROS) [50–52]. Together with the involvement of redox regulation
and heat shock response in our networks, the observed SOD1 increase during the EVLP treatment
has just the purpose to decrease ROS levels and to neutralize ROS-dependent damage. This seems
to perform a protective action to contrast the inflammatory effect triggered by the procedure itself
and raises the possibility that EVLP donor lungs could be less immunogenic than standard ones.
The regulation of described proteins can be considered in all respects an integral part of the mechanism
of action of the EVLP treatment and it may explain at least in part its efficacy in restoring lung function,
or, as suggested by Lonati et al. [22], the resistance to damage caused by ischemia/reperfusion
occurrence after transplantation. Thus, these findings add new key information to the mechanism
behind potential EVLP beneficial effects and encourage additional research to implement EVLP
therapeutic interventions. If this is the case, unveiling the modes of action of EVLP on lung phenotype
and its monitoring at the molecular level, may be crucial not only for improving the transplant
procedure but also in providing a powerful tool in translational medicine and in the advancement of
pulmonary physiology. In addition, the present study can provide useful information to implement ex
vivo perfusion procedure of other solid organs.
In order to give a more complete view of our workflow potential, we performed a preliminary
proteomic characterization of FFPE tissues. In particular, we analyzed three FFPE samples belonging
to the pre-EVLP condition in order to compare their protein profiles with corresponding frozen tissues.
Despite the low overlap between FFPE and frozen datasets (around 60%), R2 and slope values plotting
the normalized average SpC values of the two tissues resulted being close to 1 (Figure 7). This suggests
that the differences in the two pools were only apparent and probably related to the effects of fixation.
In fact, as proof of this, the molecular function distribution of the identified proteins between frozen
and FFPE tissues was nearly identical and not biased toward a specific molecular function. The last
finding opens up the possibility to work with FFPE tissues and to connect proteomic outputs with
information on clinical outcomes.
Obviously, these results are still to be considered as preliminary and must be thoroughly
investigated; however, these results offer the possibility to generate with a proteomic platform an
overview of what happens at the molecular level during the entire transplant procedure with the ability
to track the pattern of target proteins. In this regard, our approach facilitates the extraction of signature
proteins from large datasets and their distribution in multiple pathways and quantitative traceability
without the need of labeling, make these proteins ideal targets in the biomarker validation phase. In fact,
the ongoing developments of MS-based proteomic technologies combined to increasingly powerful
bioinformatics tools are accelerating their employment as a valid alternative to traditional assay
methods for a number of features including: increased sensitivity, cost containment and simultaneous
recording of multiple biomarkers.
Of course, our study represents a proof of principle with which we want to prove the potential
of a shotgun proteomic platform in these investigations. However, animal model and sample size
limit drawing any further conclusions on proteins and pathways discussed above. In the near future,
it will be necessary to increase the cohort of study and translate to human specimens the experimental
research in order to confirm the findings derived from animal models and to overcome possible
drawbacks due to the incomplete overlap of data.
Another interesting aspect will be represented by the possibility of using other biospecimens,
in addition to lung tissues, for minimizing invasiveness without compromising diagnostic accuracy.
In this respect, exosomes and extracellular vesicles (EVs) are attracting great interest. As reported by
Vallabhajosyula et al. [53] in a study on the perfusate from EVLP lungs, understanding EVs biology
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may have important diagnostic and therapeutic implications in pulmonary medicine, expanding even
more the potentiality of the EVLP model.
4. Materials and Methods
4.1. Experimental Proteomic Pipeline
Figure 1 shows a schematic overview of the protocol adopted to prepare frozen and FFPE tissue
lung lobs prior to the nanoLC-MS/MS analysis. The protocol consists of different parts that will be
described in detail below.
4.2. Surgical Procedure and Frozen and FFPE Tissue Collection
4.2.1. Animals and Experimental Groups
The experiments were performed in strict accordance with the recommendations in the Guide
for the Care and Use of Laboratory Animals of the National Institutes of Health, at the Center for
Preclinical Investigation, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy.
The experimental protocol was approved by the Italian Institute of Health (permit number: 1082-15).
Adult Sprague–Dawley male rats (Charles River, Calco, Lecco, Italy) weighing 270 to 330 g were
housed in a ventilated cage system (Tecniplast S.p.A., Varese, Italy) at 22 ± 1 ◦C, 55 ± 5% humidity,
on a 12 h dark/light cycle, and were allowed free access to rat chow feed and water ad libitum.
Rat were randomly assigned to one of the following experimental groups (n = 5 in each group).
Following sacrifice of rats under general anesthesia, lungs were subjected to in situ cold flushing and
were then retrieved (pre-EVLP group). In separate experiments, after in situ cold flushing, isolated
lungs underwent ex vivo perfusion/ventilation for 180 min (post-EVLP group). Finally, in a third
group lung biopsies were taken from animals in resting conditions (native group). Samples of perfusion
fluid were collected at time intervals throughout EVLP procedure for gas analysis. Tissue biopsies
were harvested to investigate lung edema and proteome. Specifically, right superior lobes were used
for lung edema evaluation, right inferior lobes were snap-frozen and stored at −80 ◦C for proteomic
analysis, and median lobes were added to 4% formalin at room temperature.
4.2.2. Ex Vivo Lung Perfusion (EVLP)
Anesthesia, in situ flushing and lung procurement were performed according to our previous
work. Briefly, after sacrifice, lungs were flushed with ice-cold Perfadex® (XVIVO Perfusion AB,
Gotebörg, Sweden). Thereafter, the heart-lungs block was procured and connected to an isolated lung
perfusion system (Hugo Sachs Elektronik, Harvard Apparatus, GmbH, March-Hugsstetten, Germany)
primed with in-house acellular solution with extracellular electrolyte composition [21]. No treatment
with corticosteroids or other anti-inflammatory drugs was performed.
The protocol for rat ex vivo lung perfusion included a reperfusion phase (from 0 to 40 min) during
which the lungs were gradually re-warmed, ventilated and perfused in order to avoid hemodynamic
stress, and a steady-state phase (from 40 to 180 min). Specifically, initial pulmonary artery flow was
set at 20% of target value and was then augmented over 40 min. Lung temperature was enhanced up
to 37 ◦C in a 25 min time-span. Volume-controlled ventilation was started when the lungs reached a
normothermic state, with respiratory rate of 35 bpm and pulmonary end expiratory pressure (PEEP) at
3 cmH2O. Initial tidal volume was set at 5 ml/kg and was increased up to 7 ml/kg in 10 min.
4.2.3. Lung Function
• Pulmonary artery and airway pressure assessment.
PAP and Ppeak were continuously recorded, and digitally stored via an amplifier (data acquisition
software Colligo Elekton, Milan, Italy).
34
Molecules 2018, 23, 3061
• Gas analysis and determination of glucose and lactate concentration.
Gas analysis, glucose, and lactate concentration evaluation were performed on perfusate samples
using a gas analyzer (ABL 800 FLEX, A. De Mori Strumenti, Milan, Italy).
• Lung edema index.
At the end of the procedure, the right superior lobe was weighed (KERN & SOHN GmbH,
Balingen, Germany), before (wet) and after (dry) storage at 50 ◦C for 24 h (LTE Scientific, Oldham,
UK). Wet-to-dry ratio (W/D) was then calculated and used as index for pulmonary edema.
4.3. Protein Extraction
4.3.1. Frozen Lobes
For proteomic analysis of frozen samples, each lobe was suspended in 300 μL 0.1 M H4HCO3
pH 7.9 buffer with 10% acetonitrile (Sigma-Aldrich Inc., St Louis, MO, USA) and homogenized in
ice. The protein concentration was assayed using dotMETRICTM (G-Biosciences, St. Louis, MO, USA)
and the membrane proteins were solubilized by adding RapigestTM SF reagent (Waters Co, Milford,
MA, USA) at the final concentration of 0.33% (w/v). The resulting suspensions were incubated under
stirring at 100 ◦C for 5 min. The digestion was carried out on 50 ± 0.5 μg proteins of each sample by
adding Sequencing Grade Modified Trypsin (Promega Inc., Madison, WI, USA) at an enzyme/substrate
ratio of 1:50 (w/w) overnight at 37 ◦C. An additional aliquot of 2 μg of trypsin (1:25 w/w) was added
in the morning, and the digestion continued for 4 h. Moreover, the addition of 0.5% Trifluoroacetic
acid (TFA) (Sigma-Aldrich Inc., St Louis, MO, USA) stopped the enzymatic reaction, and a subsequent
incubation at 37 ◦C for 45 min completed the RapiGest acid hydrolysis [54]. The water immiscible
degradation products were removed by centrifugation at 13,000 rpm for 10 min. Finally, the tryptic
digest mixture was desalted using PepCleanTM C-18 spin column (Pierce, Rockford, Il, USA) and
was resuspended in 0.1% formic acid (Sigma-Aldrich Inc., St. Louis, MO, USA) in water. Water was
deionized by passing through a Direct Q (Millipore, Bedford, MA, USA).
4.3.2. Formalin-Fixed Paraffin Embedded (FFPE) tissues
Paraffin-embedded tissue sections were dewaxed by means of xylene deparaffinization. Briefly,
each lung biopsy was cut up to obtain five 10 μm-sections from the same block. Slices were
placed in a 1.5 mL collection tube and added to xylene (Sigma-Aldrich Inc., St Louis, MO, USA).
Following 10 min-incubation at room temperature, samples were centrifuged at 13,000 rpm for 2 min.
Supernatants were discarded and pellets underwent two additional xylene washes. Next, samples
were rehydrated using increasing ethanol dilutions (100%, 96%, and 70% ethanol, Sigma-Aldrich Inc.,
St Louis, MO, USA). Dry pellets were stored at −80 ◦C.
The dewaxed tissues from 3 pre-EVLP samples (IIF11, IIG13 and IIH15), were solubilized in
RapigestTM SF reagent at the final concentration of 0.25% (w/v) and incubated under stirring, first at
100 ◦C for 20 min and then sequentially at 80 ◦C for 2 h. Then the protein concentration was assayed
using dotMETRICTM, and 24 ± 2.1 μg of proteins from each sample was digested by Sequencing
Grade Modified Trypsin at an enzyme/substrate ratio of 1:25 (w/w) overnight at 37 ◦C. An additional
aliquot of 0.5 μg of trypsin (1:12,5 w/w) was added in the morning, and the digestion continued for
4 h. The enzymatic digestion was stopped with the addition of 0.5% TFA, and a subsequent incubation
at 37 ◦C for 45 min completed the RapiGest acid hydrolysis [54]. The water immiscible degradation
products were removed by centrifugation at 13,000 rpm for 10 min. Finally, the tryptic digest mixture
was desalted using PepCleanTM C-18 spin column and was resuspended in 0.1% formic acid in water.
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4.4. Proteomic Analysis
4.4.1. Liquid Chromatography
Trypsin digested mixture were analyzed using Eksigent nanoLC-Ultra® 2D System (Eksigent,
part of AB SCIEX, Dublin, CA, USA) combined with cHiPLC®-nanoflex system (Eksigent) in trap-elute
mode. Briefly, samples were first loaded on the cHiPLC trap (200 μm × 500 μm ChromXP C18-CL,
3 μm, 120 Å) and washed with the loading pump running in isocratic mode with 0.1% formic acid in
water for 10 min at a flow rate of 3 μL/min. The automatic switching of cHiPLC ten-port valve then
eluted the trapped mixture on a nano cHiPLC column (75 μm × 15 cm ChromXP C18-CL, 3 μm, 120 Å)
through a 65 minute gradient of 5 to 40% of eluent B (eluent A, 0.1% formic acid in water; eluent B,
0.1% formic acid in acetonitrile) at a flow rate of 300 nL/min. Trap and column were maintained at
35 ◦C for retention time stability.
4.4.2. Mass Spectrometry
MS spectra were acquired using a QExactive mass spectrometer (Thermo Fisher Scientific, San Jose,
CA, USA), equipped with an EASY-Spray ion source (Thermo Fisher Scientific). Easy spray was
achieved using an EASY-Spray Emitter (Dionex Benelux BV, Amsterdam, The Netherlands) (nanoflow
7 μm ID Transfer Line 20 μm × 50 cm) held to 2.1 kV, while the ion transfer capillary was held at
220 ◦C. Full mass spectra were recorded in positive ion mode over a 400 to 1600 m/z range with a
resolution setting of 70,000 FWHM (Full Width at Half Maximum) (@ m/z 200) with 1 microscan per
second. Each full scan was followed by 7 MS/MS events, acquired at a resolution of 17,500 FWHM,
sequentially generated in a data dependent manner on the top seven most abundant isotope patterns
with charge ≥2, selected with an isolation window of 2 m/z from the survey scan, fragmented by
higher energy collisional dissociation (HCD) with normalized collision energies of 30 and dynamically
excluded for 30 sec. The maximum ion injection times for the survey scan and the MS/MS scans were
50 and 200 ms and the ion target values were set to 106 and 105, respectively.
The MS data have been deposited to the ProteomeXchange Consortium via the PRIDE [55] partner
repository with the dataset identifier PXD006692.
4.4.3. Data Handling
All data generated were processed using the SEQUEST search engine [56] of BioWorks platform
(version 3.3.1, University of Washington, licensed to ThermoFinnigan Corp., San Jose, CA, USA).
The experimental MS/MS spectra were correlated to tryptic peptide sequences by comparison
with theoretical MS/MS spectra obtained by in silico digestion of the Rattus norvegicus protein
database (about 79609 entries), downloaded (January 2014) from the National Centre for Biotechnology
Information (NCBI) website (www.ncbi.nlm.nih.gov). This allowed the identification of peptide
sequences and related proteins. The confidence of protein identification, particularly when using data
from a single peptide, was assured by applying stringent filtering criteria: the MS/MS tolerance was set
to 1.00 Da; the precursor ion tolerance was set to 50 ppm (part-per million); and the intensity threshold
was set to 100. Moreover, searches were performed with no enzyme. Finally, to assign a final score to
the proteins, the SEQUEST output data were filtered by setting the peptide probability to 1 × 10−3,
the chosen minimum correlation score values (Xcorr) were 1.5, 2.0, 2.5, and 3.0 for single-, double-,
triple-, and quadruple-charged ions, respectively, and the consensus score higher than 10 (FDR < 0.01).
The output data obtained from the SEQUEST software were aligned, compared and grouped by
calculating the average Spectral Count (SpC*) and Score values for each distinct protein using an
in-house algorithm, namely, the Multidimensional Algorithm Protein Map (MAProMa) [29,30].
4.4.4. Label-Free Differential Analysis
Differential analysis was performed by comparing the average Spectral count (SpC*) values of
each protein, obtained from native, pre-EVLP and post-EVLP lungs, using Dave and DCI algorithm
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inserted in the MAProMa software. DAve is an index of the relative ratio between the two compared
protein lists and DCI is an index to evaluate the confidence of DAve. Most confident uprepresented
proteins in lung tissues showed a DAve ≥ +0.2 and a DCI ≥ +10; most confident downrepresented
proteins showed a DAve ≤ −0.2 and DCI ≤ −10.
4.4.5. Hierarchical Clustering and Linear Discriminant Analysis
Biological replicates were evaluated using an unsupervised learning method, such as hierarchical
clustering (HC) [57] using in-house R-scripts, which was based on the XlsReadWrite, clue, and clValid
libraries (http://cran.r-project.org). In particular, the Euclidean distance metric was applied, and
an Agglomerative Coefficient was calculated (Agglomerative Nesting—AGNES). AGNES, which as
additional information, yields the AC that measures the amount of clustering structures found. AC is
a dimensionless quantity, which could vary between 0 (bad structure) and 1 (very clear structuring).
In order to perform multivariate analysis, all protein lists were processed using Linear Discriminant
Analysis (LDA) [35]. This analysis was applied by using a common covariance matrix for all the
groups and the Mahalanobis distance [58] from each point to each group’s multivariate mean (proteins
derived from the same gene were grouped). The identifying features (proteins) that discriminated the
analyzed samples were considered to be those with the largest F ratio (>3.4) and the smallest p-value
(<0.05). Specifically, the F ratio represented the model mean square divided by the error mean square,
whereas the p-value indicated the probability of obtaining an F value greater than that calculated if,
in reality, there was no difference between the population group means.
4.4.6. Network Analysis
Starting from the list of experimentally identified proteins, the corresponding Rattus norvegicus
Protein-Protein Interaction (PPI) network was extracted. By means of a Cytoscape plug-in, STRING
8 database (http://string.embl.de/) [36], known interactions were retrieved from several databases
such as Prolink, DIP, KEGG, BIND and others. All types of interactions were retrieved from each
repository without applying a p-value threshold. Protein–DNA, protein–RNA, protein–metabolite,
and protein–drug interactions, if present in the data sets, were removed, as were duplicates and
self-interactions. PPI were examined using Cytoscape 3.2.1 (http://www.Cytoscape.org) [32] by
applying a score >0.15. Protein–DNA, protein–RNA, protein–metabolite, and protein–drug interactions,
if present in the data sets, were removed, as were duplicates and self-interactions. PPI were processed
using Cytoscape 3.2.1 (http://www.cytoscape.org/) [32]. Proteins that were not mapped or were
mapped as isolated components were not considered in the analysis. Bingo 2.44 [59], a Cytoscape
plug-in, was used to emphasize subnetworks based on functionally organized GO terms, and the
MCODE plug-in [60] was used to cluster subnetworks based on their topology and, specifically,
by considering densely connected regions. Further selection of nodes was made by means of evaluation
of baseline, perturbation and treatment modules, using Dave or ln[FoldChange] values to calculate
PRi and PAi parameters.
4.4.7. Proteome Recovery and Proteome Activation Index
For each protein it was evaluated its variations (modules) due to perturbation (native vs.
pre-EVLP) and/or treatment (pre-EVLP vs. post-EVLP); if the two modules present similar values but
opposite sign, the protein recovers its level to the reference (in our case native condition). The extraction
of so-called “recovered proteins” was simplified by calculating the Proteome Remodeling index (PRi)
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where J: each identified protein. M(b-p)J: Perturbation Module = Difference native vs. pre-EVLP
(b: baseline; p: perturbed); differential abundance of specific protein J comparing baseline vs. perturbed
(pre-EVLP) conditions. M(p-t)J: Treatment Module = Difference pre-EVLP vs. post-EVLP (t:treated);
differential abundance of specific protein J comparing perturbed (pre-EVLP) vs. treated (post-EVLP)
conditions.
Theoretically, if protein level after treatment remodeled to reference (native) the two modules
(perturbation and treatment) should have similar value and opposite sign; then the PRi will be negative
and close to unit (−1). In our case, we considered proteins with a PRi in the range −0.5 to −2.
Also, using a variant of PR index, called Proteome Activated index (PAi), it was extracted
unchanged proteins between native and pre-EVLP conditions (perturbation module), but activated
or inhibited (up- or downregulated, respectively) with treatment (post-EVLP condition). The related





M(t − b)J: Baseline Module = Difference post-EVLP vs. native (t: treated condition, post-EVLP);
differential abundance of specific protein J comparing treated (post-EVLP) vs. baseline conditions.
Differential abundance of each module may be expressed as DAVE value, from MAProMa
algorithm or ln[fold change]). However, because in some case the fold-change calculation returns
non-sense values (such as n/0 or 0/n), we preferred to use DAVE value to calculate modules. Moreover,
MAProMa platform permits the filtration by absolute variation, using DCI algorithm, excluding very
low expressed protein (very low spectral count, multiple DCI < |5|) confusingly with noise.
4.5. Statistics
Sample size was determined considering a statistical test power of 0.80 and an alpha value of 0.05.
Results indicated that a sample size of 15 animals (n = 5 per group) would enable to detect a minimum
difference in protein expression of 0.35 with an expected standard deviation of 0.15.
To detect outliers, Grubb’s test was applied for each parameter. A probability value <0.05 was
considered significant. Baseline characteristics and trends of PAP, Ppeak, glucose, and lactate during ex
vivo perfusion were analyzed by means of one-way analysis of variance (ANOVA) followed by Tukey’s
multiple comparison test. All analyses were performed using Sigma Stat 11.0 dedicated software
(Systat Software Inc., San Jose, CA, USA).
Identified protein were evaluated by LDA (F ratio > 3.4 and a p-value < 0.05) [61] and MAProMa
(confidence thresholds were set as DAve ≥ |0.2| and a DCI ≥ |10|) platforms.
Finally, proteins extracted by PRi and PAi algorithms were statistically evaluated by ANOVA and
Tukey’s test.
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Abstract: PKA (protein lysine acetylation) is a key post-translational modification involved in
the regulation of various biological processes in rice. So far, rice acetylome data is very limited
due to the highly-dynamic pattern of protein expression and PKA modification. In this study,
we performed a comprehensive quantitative acetylome profile on four typical rice tissues, i.e.,
the callus, root, leaf, and panicle, by using a mass spectrometry (MS)-based, label-free approach.
The identification of 1536 acetylsites on 1454 acetylpeptides from 890 acetylproteins represented
one of the largest acetylome datasets on rice. A total of 1445 peptides on 887 proteins were
differentially acetylated, and are extensively involved in protein translation, chloroplast development,
and photosynthesis, flowering and pollen fertility, and root meristem activity, indicating the important
roles of PKA in rice tissue development and functions. The current study provides an overall view
of the acetylation events in rice tissues, as well as clues to reveal the function of PKA proteins in
physiologically-relevant tissues.
Keywords: Rice (Oryza sativa L.); protein lysine acetylation; proteome; tissue atlas; post-translational
modification
1. Introduction
PKA (Protein lysine acetylation) refers to the substitution of an acetyl group for an active hydrogen
atom on the lysine residues of a protein. Three types of proteins are required to catalyze the reversible
PKA reaction. As acetylation “writers”, lysine acetyltransferases (KATs) catalyze the addition of acetyl
groups from acetyl-coenzyme A (acetyl-CoA) to proteins, whereas the reversible deacetylation process
is conducted by the “erasers” enzyme lysine deacetylases (KDACs). Proteins containing conserved
bromodomain (BRD) or YEATS domain were found to play the roles of PKA “readers” (acetyllysine
binders), as they can selectively interact with acetylated proteins [1]. Since its first discovery on
histones in over 50 years ago, PKA has been implicated for the functionality of their target proteins
in various cellular processes [2]. Histone acetylation has been associated with chromatin remodeling
and transcription activation, because a negatively-charged acetyl group could neutralize the positive
charges of lysine residues, which weakens the interaction of the histone with negatively charged
DNA, and consequently leads to a more relaxed chromatin structure for transcription. Conversely, the
reversible histone deacetylation usually results in a tighter interaction with DNA, leading to chromatin
condensation and transcription repression [3]. Recently, knowledge regarding PKA has been extended
to non-histone proteins, particularly key metabolic enzymes related to glycolysis, tricarboxylic acid
Molecules 2018, 23, 2843; doi:10.3390/molecules23112843 www.mdpi.com/journal/molecules42
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(TCA) cycle in different organisms, as well as photosynthesis in plants [4–7]. The status and intensities
of PKA may impose profound effects on the function of non-histone proteins by altering their enzyme
activity, cellular compartment localization, protein-nucleotide/protein-protein interaction, and protein
stability [3,8]. For example, the inhibition of PKA on tumor protein p53 is believed to be a cause of
cervical cancer in human [9]. In Arabidopsis, Lee et al. (2015) revealed that the P. syringae type-III
effector HopZ3, which is a YopJ type acetyltransferase, suppresses plant immune system by acetylating
multiple members of the RPM1 immune complex and its triggering effectors [10].
As the first step toward understanding PKA, identification of PKA sites and dynamics is crucial.
Aided by the technologies of acetylpeptides immune affinity purification and nano-HPLC/MS/MS,
Kim et al. (2006) reported the first proteome-wide profiling of PKA in HeLa cells and mouse liver
mitochondria. This screening identified 388 PKA sites on 195 proteins, which dramatically extended
the known inventory of in vivo acetylation sites and substrates [11]. So far, the information of 111253
PKA sites on 33025 PKA proteins from various species have been deposited into the PLMD (Protein
Lysine Modifications Database, http://plmd.biocuckoo.org/download.php) [12]. In comparison with
the tremendous progress achieved in human, mouse, fungi, and bacterium, PKA identification in
plants is lagging behind. Until 2011, Finkemeier et al. reported the first plant acetylomic analysis in
the dicot model species Arabidopsis. They revealed the extensive involvement of PKA in regulating
the activity of central metabolic enzymes such as Rubisco, phosphoglycerate kinase, glyceraldehyde
3-phosphate dehydrogenase, and malate dehydrogenase [13]. Nevertheless, only two reports are
presently available on Arabidopsis, which profiled a total of 398 PKA sites on 251 proteins from
suspension cells and young seedlings [13,14]. Similar works have also been done on grape fruits, pea
seedlings, soybean developing seeds, wheat leaf, strawberry leaf, grass leaf, potato tuber, and spruce
somatic embryo, but only yielded the identification of less than 7000 PKA sites in total [6,15–21].
Rice (Oryza sativa L.) is one of the most important food crops, as it serves as a staple food for
over half of the global population. On the other hand, rice is also a model species for biological
research due to its relatively small genome size, released genome sequence, ample genetic resources,
as well as the co-linearity with other grasses [22]. PKA has been recognized as a key mechanism
in regulating photosynthesis and metabolism in plants. For example, acetylation of the Lhcb1 and
Lhcb2 proteins appear to be involved in determining the LHC attachment to PSII complexes. Higher
PKA level on Lhcbs impaired their binding ablity to PSII to form the PSII-LHCII supercomplexes [23].
This also intrigued researchers to explore PKAs in rice. So far, at least 8 independent cases have been
reported regarding the profiling of PKA sites, peptides, and proteins in rice seedlings, reproductive
organs, and leaves under oxidative stress, which yielded the identification of over 8599 PKA sites
and 4990 proteins [7,24–30]. Despite efforts being made on rice, the previous studies only explored
the tip of the iceberg of rice acetylome, given that rice genome contains over 56,000 protein coding
genes [31]. Due to the spatial- and temporal-pattern of protein expression, investigating PKA in various
tissues has been considered as an effective way to expand the coverage of rice acetylome. In this
study, we performed a quantitative, MS-based identification of PKA proteins in four rice tissues, i.e.,
the callus, root, leaf, and panicle, and obtained 890 PKA proteins covering 1536 sites, which allowed
us to construct a tissue atlas of rice acetylome. The results obtained from this work aimed to provide
an overall view of the acetylation events in rice tissues, as well as clues to reveal the function of PKA
proteins in physiologically-relevant tissues.
2. Results
2.1. Profiling the Acetylsites and Acetylproteins on Various Rice Tissues
PKA is a highly transient and reversible post-translational modification. To achieve an overview
of PKAs in rice, we conducted a comprehensive, quantitative acetylomic profiling in 4 tissues of
Nipponbare (Oryza sativa L. ssp japonica), i.e., callus, leaves, panicles, and roots (Figure 1A–C),
by employing a label-free, MS-based approach. Prior to the MS identification, we performed western
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blot analysis on the tissue proteins using a pan anti-acetylation antibody. The protein acetylation levels
and patterns varied divergently from tissues, and the majority of the acetylated proteins are non-histone
proteins with a molecular weight over 25 KD (Figure 1D,E). MS identification yielded the data of 1164,
1105, 921, and 428 acetylsites on 1089, 1034, 848, and 385 acetylpeptides, which represented 682, 664,
547, and 263 acetylproteins from the callus, leaves, panicles and roots, respectively (Figure 2A, Tables 1
and S1). One hundred and seventy acetylproteins were commonly profiled in all the four tissues, while
97, 93, 27, and 44 acetylproteins were specifically detected in the callus, leaves, panicles, and roots,
respectively (Figure 2B). By integrating the data from four tissues and removing redundancies, a total
of 1454 acetylpeptides from 890 acetylproteins, covering 1536 acetylsites, were obtained. The mass
errors for those acetylpeptides were near 0, with the majority less than 5 ppm, implying a high level
of accuracy of the data (Figure S1). The length of most of the identified acetylpeptides ranged from
7–22 amino acids with a few longer exceptions that even reached up to 32 amino acids (AAs) (Figure 2C).
Over 60% of the acetylpeptides carried only 1 acetylsite, around 20% of the acetylpeptides covered 2 or
3 acetylsites, while the remaining 10% acetylpeptides had more than 3 acetylsites (Figure 2D).
Figure 1. Tissue morphologies of different rice tissues tested in this study. (A) leaf and root; (B) callus;
(C) mature panicle. Scale bar = 1 cm; (D) Total proteins of different tissues were resolved by SDS-PAGE
and stained by Coomassie brilliant blue (CBB) and (E) Western blot analysis of the acetylation dynamics
in different rice tissues by using anti-acetyl lysine antibodies. Equal amount of proteins (20 μg) were
used. Anti-actin was used as an internal control for normalization [32].
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2.2. Motif Analysis of the Acetylsite Flanking Sequences
Employing the motif-X algorithm (http://motif-x.med.harvard.edu/) [33], we searched the
potential conserved motifs in the context of 21 AA-long sequences centered by the acetylsites. Nine of
the most enriched motifs are depicted in Figure 3A (Fold increase > 2.5, P < 0.01). Positively-charged
residues like K and H are greatly favored by PKA, as we found the top three enriched consensus motifs
were [DxKacK,KacH] and [KacK]. There were 132, 118, and 73 acetylsites located in [KacxR,KacS] and
[KacT] motifs respectively. Meanwhile, motifs [YKac] [FxKac] [KxxxxxxKac] also showed over 2.5 fold
enrichment when compared with the rice proteome background. In addition to the conserved motifs,
we calculated the frequency of each AA type in the positions flanking the acetylsites. As revealed in
Figure 3B, the distribution of AAs displayed strong bias in certain positions. For example, there was
significantly higher chance of finding a H, K, R, or Y in the +1 position to acetylsites, while residues
like M, I, G, and E were barely detected in the same position.
Figure 3. (A) Acetylation sequence motifs and conservation of acetylation sites in identified callus,
leaf, panicle acetylproteins; and (B) Heat map of the amino acid composition of the acetylation sites,
showing the frequency of different amino acids surrounding the acetylated lysine (K).
2.3. Functional Features of Rice Acetylproteins
GO functional classification of all the acetylproteins were investigated in the terms of “biological
process”, “cellular component”, and “molecular function”. For the “biological process” category, the
largest two types of acetylprotein was associated with “metabolic process” and “cellular process”,
which accounted for over half of the identified acetylproteins, suggesting a predominant role of PKA
in metabolism. The remaining acetylproteins were related to processes such as “response to stimulus”,
“single-organism process”, and “cellular component organization or biogenesis” (Figure 4A). Within
the category of “cellular component”, 30%, 24%, and 14% of the acetylproteins were annotated as “cell”,
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“organelle”, and “membrane”, respectively. Meanwhile, we found that a small portion of the proteins
were relevant to “macromolecular complex”, “cell junction”, and so on (Figure 4B). Consistent with the
highly-presented “metabolic process”, the “molecular function” of the majority of the acetylproteins
was on “binding” (47%) and “catalytic activity” (40%), while the remaining were likely to be involved
in “structural molecule activity” and “transporter activity” (Figure 4C).
Figure 4. GO analysis of differentially-acetylated proteins in terms of: biological process (A); molecular
function (B); cellular component (C); subcellular location (D); and acetylation intensity, respectively.
The abbreviations in (D) represent the following. E.R.: endoplasmic reticulum; extr: extracellular
matrix; cyto: cytoplasm; mito: mitochondrial; chlo: chloroplast; vacu: vacuole; cysk: cytoplasmic
skeleton; cyto nucl: cytoplasm nuclear.
Eukaryotic cells are comprised of several membrane-bound subcellular compartments, such
as the nucleus, cytoplasm, and mitochondria, where functional proteins play distinct roles [34].
The prediction of the subcellular localization helps to understand the function of the acetylproteins.
We revealed that most of the acetylproteins were located to the cytosol (36%) and chloroplast (34%)
(Figure 4D). Nuclear proteins such as histones and transcription factors are regarded as potential
regulators of gene transcriptions. Sixteen percent of our identified acetylproteins were localized to
nuclear, indicating that PKA is extensively involved in gene regulation. Some of the acetylproteins
were predicted to be in mitochondria (7%), plasma membrane (3%), cytoskeleton (2%), and vacuole
(1%) (Figure 4D).
Functional domains on a protein usually indicated its function in biological processes. In this
study, we performed a PFAM functional domain enrichment assay to address the functional domain
features of rice acetylproteins (Figure 5A). As a result, the most enriched proteins are core histones
and histone-fold proteins, indicating PKA occurrs extensively on histones. Other enriched functional
domains include NAD(P)-binding domain, single hybrid motif, aldolase-type TIM barrel, enhancer of
polycomb-like and groEL-like equatorial domains, which are extensively involved in metabolism, and
transcriptional and translational regulations.
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We further conducted KEGG pathway enrichment analysis of the acetylproteins. The top 5
over-presented pathways are carbon metabolism, glycolysis, TCA cycle, biosynthesis of amino acides,
and carbon fixation in photosynthetic organisms, which is in line with the functional domain analysis
result that PKA occurs extensively on metabolism-related proteins (Figure 5B).
Figure 5. Protein domain enrichment analysis (A) and KEGG pathway enrichment analysis (B) proteins
identified acetylproteins in this study.
2.4. Differentially Acetylated (DA) Peptides among Rice Tissues
Employing a label-free approach, we quantified the acetylation intensity in each peptide, and
identified 1445 DA peptides on 887 proteins (Table S2). These included 125, 113, 35, and 53 peptides
which were specifically acetylated in the callus, leaf, panicle, and root, respectively. In addition,
we found 27 peptides were commonly acetylated in all the four tested tissues, with no significant
variations in the acetylation intensity level, indicating the potential use as an internal control for
PKA quantification experiments among rice tissues. There were also 82 acetylpeptides that were
constitutively acetylated with significantly different intensities in the four tissues. The acetylation
intensities of each DA proteins in various tissues were further visualized in a heatmap (Figure 6).
The 1445 DA peptides were primarily divided into 12 clusters; each represented a divergent acetylation
pattern from the others. For example, DA peptides in cluster 5 are predominantly acetylated in
leaf, while cluster 9 contains peptides that are predominantly acetylated in the callus. In cluster 8,
the peptides are highly acetylated in both the callus and leaf, suggesting the PKA on these peptides
may regulate pathways that are common to the two tissues.
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Figure 6. Hierarchical clustering analysis of the DA proteins in the callus, leaf, panicle, and root; Color
bar at the bottom represents the log 2 acetylation site quantitation values. Green, black, and red indicate
the low, medium, and high acetylation intensity, respectively.
2.5. Protein-Protein Interaction (PPI) Analysis of Acetylproteins
Using STRING (Search Tool for the Retrieval of Interacting Genes/Proteins version 10.0; http:
//string-db.org/) and Cytoscape software (Cytoscape 3.7.0, Bethesda, Rockville, MD, USA), we
constructed protein-protein interaction (PPI) networks of the specifically-acetylated proteins in the four
tissues for a better understanding of the possible relationships among them. The callus acetylproteins
form a profound PPI network containing 98 nodes (proteins) and 532 edges (interaction-ships)
(Figure 7A; Table S3). In this network, we identified 10 ribosomal proteins, including 40S ribosomal
protein S24, S9-2, 60S ribosomal protein L27, L36, as well as some ribosome recycling factors, which may
form a ribosomal complex and take charge of the protein translation in callus. For the leaf acetylproteins,
we acquired a network with 85 nodes and 465 edges (Figure 7B). Photosynthesis-related proteins
were involved in this network. For examples, three chlorophyll A–B binding proteins, which serve
as light receptors in the light-harvesting complex (LHC), may interact with each other. The network
also contains carbohydrates assimilation proteins such as sucrose synthases and exo-beta-glucanase.
In addition, we revealed an interaction module of gra(t)-OsAld-OsPORB, in which all members
are functionally related to chloroplast development. In the network of panicle-acetylated proteins,
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an actin protein was associated with rice flowering date regulator OsMADS50 and pollen fertility
regulator OsAIP1, suggesting that PKA on these proteins plays important roles in flower development
(Figure 7C). The network identified from root-acetylated proteins is majorly implicated in pentose
metabolism, as a couple of 6-phosphogluconate dehydrogenases, dihydroxy-acid dehydratases, and
glutamate dehydrogenases were involved in it (Figure 7D).
 
Figure 7. Protein–protein interaction (PPI) network of DA proteins identified in this study. (A) callus;
(B) leaf; (C) mature panicle, and (D) root.
3. Discussion
3.1. PKA Profiling in Rice
Given the essential regulatory roles of PKA in plant growth and development, acetylomic profiling
has become a hot topic in plant research. To date, at least 8 PKA identification cases have been reported
in rice, as well as many in other plant species (Table 2). Due to its easy availability, vegetative tissues
like leaf or whole seedlings have been repeatedly used for acetylomic identification. Xiong et al.
(2016) profiled a total of 716 rice seedling PKA proteins, which were implicated in glyoxylate and
dicarboxylate metabolism, carbon metabolism, and photosynthesis pathways [7]. Later, Xue et al.
(2017) further identified 866 acetylproteins by using the same seedling tissue. However, only 21.3%
51
Molecules 2018, 23, 2843
of the acetylproteins were overlapped with the previous study [29]. The authors deduced that the
difference in identification is due to the physiological status or growth stages of the samples used.
Zhou et al. (2018) also mapped 1024 acetylproteins from rice leaves under oxidative stress [30]. In rice
germinating embryo, 699 PKA sites on 389 proteins were found to be acetylated, including 144 sites that
were simultaneously modified by succinylation [26]. In an effort to discover the PKA in rice anthers in
the stage of meiosis, Li et al. (2018) identified a total of 1354 PKA sites in 676 proteins, which are mostly
related to chromatin silencing, protein folding, and fatty acid biosynthetic processes [27]. There were
also 44 and 692 lysine acetylated proteins that were identified from suspension cells and grain-filling
stage seeds [24,28]. With a special focus on the seed development, Wang et al. (2017) carried out a
quantitative acetylproteomic study on pistil and early developing seeds. A total of 972 acetylproteins
harboring 1817 acetylsites were identified, and 268 acetylproteins were differentially acetylated in the
three developing stages, providing novel insight into PKA in rice seed development [25]. Nevertheless,
rice acetylome is extremely complicated, largely due to the dynamic expression pattern of proteins in
various tissues and physiological conditions. To gain a more complete coverage of the rice acetylome,
the current study quantitatively profiled a total of 1454 acetylpeptides from 890 acetylproteins, covering
1536 acetylsites from callus, leaf, panicle, and root, which represented 4 major tissue types in rice.
In comparison with the previous data, around 85% of our identified acetylprotiens were overlapped
with other studies. A few examples are MADS50 (Q9XJ60), SUS1 (P31924), and USP (Q5Z8Y4).
Meanwhile, we also found that 139 acetylproteins are novel, which were majorly identified from
previously untested tissues such as the callus and panicle (Table S1). Our dataset greatly expanded
the rice acetylome inventory, considering that callus and panicle are two unexplored tissues in terms
of acetylome profiling. In contrast to previous studies that used the whole seedling for profiling,
our dataset separated the tissues into leaf and root, thus presenting more detailed information of
the spatial-distribution of the acetylproteins. Moreover, the quantified protein acetylation intensities
also provided cues for functional characterization of the acetylproteins in the development of the
corresponding tissues.
Table 2. Summary of the reported acetylome identification cases in rice and other plant species.
Species Tissue Treatment Acetylsites Acetylproteins Reference
Oryza sativa Callus, root, leaf and panicle 1536 890 This study
Oryza sativa Seed 1003 692 [28]
Oryza sativa Pistil and developing seeds 1817 972 [25]
Oryza sativa Suspension cells 60 44 [24]
Oryza sativa Young seedling 1337 716 [7]
Oryza sativa Leaf Oxidativestress 1669 1024 [30]
Oryza sativa Seedling 1353 866 [29]
Oryza sativa Anther 1354 676 [27]
Oryza sativa Seed Imbibition 699 389 [26]
Zea may Seedling Fungus 2791 912 [35]
Triticum
aestivum Leaf 416 277 [6]
Glycine max Seed 400 245 [17]
Arabidopsis Mitochondria of leaf 243 120 [14]
Arabidopsis Chloroplast of leaf 91 74 [13]
Arabidopsis Leaf Deacetylaseinhibitor 2057 1022 [36]
Arabidopsis Root, leaf, shoot, flowerand silique 64 57 [23]
3.2. Acetylproteins in Rice Callus
Rice callus is a mass of unorganized parenchyma cells which is capable of being regenerated in
an individual plant. Callus cells have robust metabolisms and protein expressions to maintain their
capability for differentiation. Ribosome is a complex molecular machine known as the translational
apparatus for protein synthesis. Ribosome consists of two major components: small ribosomal subunits
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for RNA recognition, and large ribosomal subunits for the synthesis of polypeptide chain using amino
acid substrates. Early in the 1970s, PKA was found to occur on rabbit ribosomal proteins, and
was implicated in the formation of the initiation complex during translation [37]. In yeast, protein
N-terminal acetylation of ribosomal proteins by N-acetyltransferase is necessary to maintain protein
synthesis [38]. It seems that PKA on ribosomal proteins might be a conserved mechanism, as we found
that 41 ribosomal proteins were acetylated in rice callus. Interestingly, twelve of these proteins were
predominantly acetylated in callus but not in the other tested tissues, including 40S ribosomal proteins
S4 (Q0E4Q0), S9 (Q2R1J8), S20 (Q10P27), and S24 (Q0DBK8), as well as 60S ribosomal proteins L2
(P92812), L21 (Q10RZ3), L27 (Q7XC31), and L36 (Q6L510), suggesting their essential roles in protein
expression regulation in callus (Table S1). In addition to the ribosomal proteins, OASA1 (Q94GF1),
which is a key enzyme for the synthesis of indole-3-acetic acid, and OsGH3.8 (Q0D4Z6), which is
involved in the auxin homeostasis, were both more acetylated in callus than in other tissues [39,40].
Thus, the auxin level may subject to PKA regulation in callus.
3.3. PKA on Chloroplast Development and Photosynthesis Proteins in Leaf
Photosynthesis majorly occurs in the chloroplast of leaf, where the photosynthetic pigment
chlorophyll captures and converts the light energy into the energy storage molecules ATP and
NAPDH, which could be further converted into chemical energy in the form of carbohydrates, via the
famous Calvin cycle. A number of key regulators of chloroplast development have been identified
as acetylproteins in the current study. Fd-GOGAT1 (Q69RJ0) is a ferredoxin-dependent glutamate
synthase which is known as a key enzyme in the process of inorganic nitrogen assimilation. Mutants
of Fd-GOGAT1 exhibited defective chlorophyll synthesis and low photosynthesis rates, and finally
led to early leaf senescence [41]. PORB (Q8W3D9) is defined as a NADPH:protochlorophyllide
oxidoreductase catalyzing the photoreduction of protochlorophyllide to chlorophyllide in synthesis.
Under high light conditions, PORB is essential for maintaining light-dependent chlorophyll synthesis,
while disruption of the gene could turn the new leaves yellow and cause lesions [42]. WSL12 (Q0IMS5)
is a chloroplast-localized, nucleoside diphosphate kinase knock-down of WLS12, which results in
abnormal chloroplast and white stripes on leaves [43]. Interestingly, these three proteins were all
predominantly acetylated in leaves, implying that PKA is a key switch for chloroplast development
in rice.
In terms of photosynthesis, we found that numerous key enzymes were predominantly acetylated
in leaf. For examples, glycine decarboxylase complex (GDC) recovers carbon following the oxygenation
reaction of ribulose-1,5-bisphosphate carboxylase/oxygenase in the photorespiratory C2 cycle of C3
species [44]. LFNR (Leaf-type ferredoxin-NADP (+) oxidoreductase), an essential chloroplast enzyme,
functions in the last step of photosynthetic linear electron transfer [45]. The current study revealed
that rice GDCH (A3C6G9) was acetylated at the 156th lysine site, while LFNR1 (Q0DF89) harbored
acetylation modifications on 79th and 188th lysine, and their acetylation intensities in leaf were
significantly higher than those in other tissues. In addition, Chlorophyll A-B binding proteins (Q5ZA98,
Q6Z411 and Q53N82), which are responsible for the capturing and delivering of excitation energy to
photosystems [46], as well as sucrose synthases participating in starch metabolism (P31924, P30298
and Q43009), also showed similar acetylated patterns in leaf, suggesting the extensive regulatory roles
of PKA on photosynthesis in leaf.
3.4. PKA May Regulate Flowering and Pollen Fertility in Rice Panicle
Initiation of panicle represents the transition of rice from vegetative growth to reproductive
growth. Transcription factor OsMADS50 is a known key regulator in rice flowering [47]. Suppression
of OsMADS50 significantly delayed rice flowering and increased the number of elongated internodes.
Meanwhile, ectopical expression of this gene could even induce the initiation of inflorescence on the
callus. OsMADS50 may be functionally antagonistic with another flowering repressor, OsMADS56,
and operates upstream of the rice florigen gene Hd3a to control rice flowering [47,48]. We found an
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acetylation modification of OsMADS50 on the 107th lysine site, which is located in the conserved DNA
binding domain MADS box (17–135 in protein sequence). It would be interesting to explore the effects
of acetylation on the binding ability of OsMADS50 to its target site in future study.
Programmed cell death (PCD) of tapetum cells in anthers is critical for the proper development of
male gametophytes in rice. Apoptosis inhibitor 5 (API5, Q5JK84) encoding a putative antiapoptosis
protein promotes the degeneration of the tapetum by interacting with two DEAD-box ATP-dependent
RNA helicases, AIP1 and AIP2. api5 mutants were fully sterile due to the inhibited tapetal PCD process,
suggesting their key roles in the development of male gametophytes [49]. Our MS identification results
showed that lysine 59, 144, and 161 were acetylated on API5. However, the three acetylsites displayed
various acetylation patterns in tissues. The acetylation intensities on lysine 59 and 144 are significantly
higher than in other tissues, whereas lysine 161 has the highest acetylation level in leaves, although it
is also moderately acetylated in the panicles. Therefore, the indication is that PKA on lysine 59 and
144, other than on lysine 161, is more likely to be involved in pollen development.
3.5. Acetylation on Root Proteins
In vascular plants, the root is an important, specified organ, providing mechanic anchoring
strength as well as controlling the water and nutrient uptake from soil. Root meristem activity is the
key to root growth and architecture. An enzyme 3-hydroxyacyl-CoA dehydrogenase named as AIM1
(Q8W1L6) was found to be a vital regulator of root meristem activity in rice. aim1 mutant displayed
shortened roots with reduced salicylic acid and ROS level. It is proposed that AIM1 mediates the
salicylic acid biosynthesis to promote ROS accumulation, thereby maintaining the root meristem in an
active status [50]. It is interesting to note that PKA only occurred on lysines 361 and 663 of AIM1 in
the callus, leaf, and panicle, but AIM1 acetylation was not found in roots, where it is expected to be
functional. The observation suggested that PKA on AIM1 may have negative effects on its function.
4. Materials and Methods
4.1. Collection and Preparation of Plant Materials
The Nipponbare (Oryza sativa L. ssp jing) plants used in this study were hydroponically-cultured
or grown in the field of the China National Rice Research Institute (CNRRI). Roots were harvested
from 14 days after germination of the hydroponic seedlings, leaves and panicles were collected from
plants in the field at 3–5 days before heading, when the husk of spikelets were in pale color, and
calluses were induced as described [51]. Three biological replicates of the callus, root, leaf, and panicle
were harvested and immediately stored in liquid nitrogen before use.
4.2. Protein Extraction
Samples was ground into fine powders in liquid nitrogen, transferred to a 5 mL centrifuge tube
containing lysis buffer (8 M urea, 150 mM Tris-HCl pH 8.0, 1 mM phenylmethylsulfonyl fluoride and
1× phosphoprotein protease inhibitor complex), and shaken for 30 min on ice. The extracted proteins
were sheared by sonication (Biosafer 650-92 model, Scientz, Ningbo, China) on ice before centrifugation;
then, the protein in the supernatant was precipitated in cold acetone for 30 min. The protein pellets
were washed in 75% ethanol, and finally dissolved in PBS (Phosphate Buffer Saline) buffer (137 mM
NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4). Qubit 2.0 fluorometer (Invitrogen, Carlsbad,
CA, USA) was used for the quantification of the extracted total proteins.
4.3. Western Blotting
In brief, around 20 μg of each extracted total proteins was separated by 10% SDS–polyacrylamide
gels, and subsequently transferred to a polyvinylidine fluoride fluoropolymer (PVDF) membrane
(0.45 μm, Millipore, Darmstadt, Germany) using a Trans-Blot Turbo transfer system (Bio-Rad, Hercules,
CA, USA). The TBST (10 mM Tris-HCl, 150 mM NaCl, and 0.05% Tween 20, pH 8.0) containing
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5% BSA was used to block the transferred membrane for overnight at 4 ◦C. Acetyl lysine primary
antibodies (1:1000 dilution in TBST) (ImmuneChem, Burnaby, BC, Canada) and secondary antibodies
HRP (horseradish peroxidase–conjugated) (1:1000 dilution in TBST) (Beyotime Company, Shanghai,
China) were used to detect the target protein bands, and lastly, visualized using the enhanced
chemiluminescence (Pierce, Waltham, WA, USA).
4.4. Protein Digestion and Acetylpeptide Enrichment
Protein was treated by a sequential of 10 mM DTT (DL-Dithiothreitol) reduction for 1 h at
37 ◦C, 20 mM IAA (indole-3-acetic acid) alkylation for 45 min at room temperature in darkness,
100 mM NH4CO3 dilution and trypsin at pH 8.0 (enzyme:protein = 1:50) digestion for overnight.
For acetylpeptide enrichment, the digested peptides were dissolved with NETN buffer (100 mM
NaCl, 1 mM EDTA, 50 mM Tris-HCl, 0.5% NP-40, pH 8.0). The tryptic peptides were incubated with
pre-washed antibody beads (PTM Biolabs, Hangzhou, China) by gently shaking at 4 ◦C overnight to
enrich PKA peptides. Afterwards, the beads were gently washed four times with NETN buffer, and
twice with ddH2O. Finally, the bound acetylproteins were eluted with 0.1% TFA, subsequently vacuum
dried using a SpeedVac (Thermo, Waltham, MA, USA), and cleaned with C18 ZipTips (Millipore,
Darmstadt, Germany) before LC–MS/MS analysis.
4.5. LC–MS/MS Analyses
The procedures were done as described by Wang et al. [25]. In brief, peptides were dissolved
in 0.1% formic acid, and directly loaded onto a reversed-phase pre-column (Thermo, Waltham, MA,
USA.). Peptide separation was performed using a reversed-phase analytical column (Thermo, Waltham,
MA, USA.). The gradient for MS analysis was described as follows: starting from 6 to 22% solvent
B (0.1% FA in 98% ACN) for 24 min, then 22 to 40% for 8 min, 80% over 2 min, and lastly at 80% for
5 min at a constant flow rate of 300 μL/min on an EASY-nLC 1000 UPLC system coupled with a Q
ExactiveTM mass spectrometer (Thermo, Waltham, MA, USA) over a mass range of 350–1800 m/z
with a resolution of 7000. Subsequently, raw data were processed for acetylpeptide identification and
acetylsite quantification with MaxQuant search engine against the uniprot_Oryza sativa database.
In the MaxQuant searches for carbamidomethylation on Cys, oxidation on Met, Acetylation on Lys
protein-N term was set as variable modification, and 4 missed cleavages on trypsin/P were allowed.
Peptide mass error was set at 10 ppm for precursor ions and 0.02 Da for fragment ions; the minimum
peptide length was set at 7. The false discovery rates (FDR) were set to <1%, and the minimum score
for modified peptides was set >40 for peptide identification for all searches.
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Abstract: Top-down sequencing in proteomics has come of age owing to continuous progress in
LC-MS. With their high resolution and broad mass range, Quadrupole Time-of-Flight (Q-ToF) hybrid
mass spectrometers equipped with electrospray ionisation source and tandem MS capability by
collision-induced dissociation (CID) can be employed to analyse intact proteins and retrieve primary
sequence information. To our knowledge, top-down proteomics methods with Q-ToF have only
been evaluated using samples of relatively low complexity. Furthermore, the in-source CID (IS-CID)
capability of Q-ToF instruments has been under-utilised. This study aimed at optimising top-down
sequencing of intact milk proteins to achieve the greatest sequence coverage possible from samples of
increasing complexity, assessed using nine known proteins. Eleven MS/MS methods varying in their
IS-CID and conventional CID parameters were tested on individual and mixed protein standards as
well as raw milk samples. Top-down sequencing results from the nine most abundant proteoforms of
caseins, alpha-lactalbumin and beta-lactoglubulins were compared. Nine MS/MS methods achieved
more than 70% sequence coverage overall to distinguish between allelic proteoforms, varying only
by one or two amino acids. The optimal methods utilised IS-CID at low energy. This experiment
demonstrates the utility of Q-ToF systems for top-down proteomics and that IS-CID could be more
frequently employed.
Keywords: top-down proteomics; HPLC-ESI-Q-TOF MS; cow’s milk; whey proteins and caseins;
tandem MS
1. Introduction
Top-down proteomics, a term invented by Kelleher and colleagues 20 years ago [1], describes
the analysis of intact proteins, either in their native form or more often in a denatured state, which
allows for a characterisation of proteoforms as comprehensively as possible. Coined in 2014, the
term proteoform “designates all of the different molecular forms in which the protein product of a
single gene can be found, encompassing all forms of genetic variation, alternative splicing of RNA
transcripts, and post-translational modifications (PTMs)” [2]. The analysis of intact proteins is now
always performed using mass spectrometry (MS) and technical progresses in top-down proteomics are
tightly linked to improvements made on mass analysers. The most important technological advance
was the coupling of the soft ionisation technique, electrospray ionisation (ESI), to a mass spectrometer
and the production of gas phase ions from large molecules [3], which led to its first application to
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intact proteins [4,5]. ESI generates multiply-charged protein ions of low m/z, thereby allowing the
analysis of very large molecules, even on an MS platform with a limited mass range. By applying
a deconvolution algorithm [6], the resulting complex multi-peak spectrum can be converted into a
single peak corresponding to the true molecular weight of the molecule. Further developments in
intact protein analysis quickly followed with the introduction of complex multistage mass analysers of
high resolution such as linear ion trap (LIT), quadrupole time-of-flight (Q-ToF), Fourier transform (FT)
ion cyclotron resonance, and orbitrap instruments.
Today, various methods of ion fragmentation are available, such as collision-induced dissociation
(CID, also called collisionally activated dissociation CAD), in-source CID (IS-CID, also known
as up-front CID, cone-voltage CID, and nozzle-skimmer dissociation), higher-energy collisional
dissociation (HCD), electron capture dissociation (ECD), and electron transfer dissociation (ETD)
(for review [7]). Different types of fragmentation modes yield different information about the structure
and composition of the analyte. Tandem mass spectrometers that carry out CID to generate product
ions from precursor ions have proven extremely useful for the identification and characterisation of
proteins from a complex mixture. CID was first described by McLafferty and Bryce in 1967 [8] and
Jennings in 1968 [9]. Parent ions collide with neutral gas atoms or molecules (typically helium, nitrogen
or argon), which result in the formation of b- and y-type ions. The efficacy of a CID experiment will
depend on the relative translational energy of the ion and target, the nature of the target, the number
of collisions that is likely to take place, and the m/z window of the instrument. Initial top-down
sequencing experiments exploited low-energy CID methods to induce protein fragmentation. However,
for large molecules, CID does not produce a fragmentation pattern comprehensive enough to fully
characterise proteins, but rather produces enough fragments or sequence tags to identify the protein.
Additionally, if the protein contains PTMs, low-energy CID most likely will not be sufficient to localise
the modified site or the PTM may be the preferred site of cleavage [10,11]. IS-CID is a proven albeit
seldom utilised fragmentation mode allowing single-stage instrumentation, such as single quadrupole
(Q) or ToF mass analysers, to produce spectra similar to those obtained with far more expensive
hybrid instruments. In this method, invented by Katta and colleagues in 1991 [12], CID is carried out
within the ion source in the high-pressure region between the capillary exit and the skimmer entrance
to the Q mass spectrometer. Because there is no prior selection of the precursor ion, this does not
qualify as a bona fide MS/MS experiment. By manipulating lens voltages that channel ions from the
source to the mass analyser, relatively low-energy ions formed in the atmospheric pressure region
of the source collide with residual background gas, usually nitrogen, in the transition region. As a
result, excited ions can undergo unimolecular decomposition to produce fragment ions. As for CID,
only b- and y-type ions are observed. Tandem spectra from protonated peptides produced by IS-CID
or low-energy CID are comparable [13,14]. In-source dissociation has also been demonstrated for
whole protein ions [15]. The time scale for IS-CID is on the order of a few hundred microseconds to a
few milliseconds, which is much faster than that of CID. IS-CID fragmentation can be reproducible
provided ion source parameters, such as temperature, pressure, voltage, and sample purity are tightly
controlled [16].
Kelleher in 2004 [17] rigorously defines top-down proteomics as a multistep process whereby the
molecular weights (MWs) of intact proteoforms are accurately measured using a high-resolution mass
analyser in combination with a direct fragmentation of the protein ions using tandem MS. Top-down
sequencing of intact proteins were initially performed using triple quadrupole (QQQ) instruments
and IS-CID [5]. In 1990, Loo and colleagues characterised a 14-kDa bovine ribonuclease A in its native
and reduced forms using CID [18]. Soon after, higher mass resolution was achieved by applying
FT-MS to equine cytochrome c, porcine albumin, thioredoxin and ubiquitin [19], myoglobin [20], and
carbonic anhydrase [15]. A hybrid Q-ToF instrument, also called Q-ToF [21], was invented in 1996 by
Morris and colleagues [22]. Q-ToF mass spectrometers combine the quadrupole one (Q1) in which ion
precursors are funnelled through and selected, the quadrupole collision cell (q) of a QQQ in which
selected precursor ions are fragmented usually through CID and more recently ETD, and a reflector ToF
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detector in which the fragment ions are mass analysed. Spectra obtained in both full-scan (MS1) and
MS/MS (MS2) modes exhibit clean spectra due to orthogonal pulsing into the ToF section, high mass
accuracy along with stable isotopic resolution across the m/z range, and high fidelity meaning accurate
isotopic ratios. This permits the determination of charge states and unambiguous assignment of the
mono-isotopic signal of the intact molecules. This leads to accurate prediction of AA sequence and
successful identification of peptides and proteins of medium MW via database searches by tightening
the search parameters and augmenting the confidence in the results. Q-ToF instruments perform
well for quantitative analyses [23] and for the identification of PTMs [24]. Q-ToF were demonstrated
to outperform QQQ mass spectrometers owing to both their enhanced sensitivity and resolution in
the region of one to two orders of magnitude [22]. This initial observation was further validated on
phosphopeptides; the higher resolving power of the Q-ToF improved the selectivity and sensitivity
of parent ions, thus minimising interference from other product ions and maximising sequencing
results [25].
The first use of LC-ESI-Q-ToF MS in top-down sequencing of intact proteins was reported by
Nemeth-Cawley and Rouse in 2002 [26], who used CID to fragment ion precursors from eight
known protein standards, ranging from 5 to 66 kDa. Peptide sequence tags thus obtained led to
the unambiguous identification of the analysed proteins, along with the characterisation of disulphide
bonds and glycosylation. While their method was successful, the authors noted some limitations: first,
it could not yet be applied to complex protein mixtures without prior separation; secondly, at a low
concentration, the signal-to-noise ratio was affected, thus necessitating longer MS/MS acquisition
times. Based on their experience, the following year, the same group applied their validated method
to characterise a recombinant immunoglobulin gamma-1 (IgG-1) fusion protein [27]. The top-down
strategy allowed them to demonstrate that the recombinant protein was expressed as a full-length form
as well as N- and C-processed truncated proteoforms [27]. In 2004, Ginter and colleagues exploited both
IS-CID and traditional CID mode of a Q-ToF mass spectrometer, thereby achieving pseudo-MS3 levels,
to top-down sequence seven known proteins spanning from 11 to 66 kDa [28]. Individual sequence
tags of 10 to 26 AAs were retrieved from both N- and C-termini, and unambiguous identification of
protein standards was achieved. IS-CID on its own was used to identify various purified recombinant
proteins using ESI-Q-ToF MS [29]; fragmentation efficiency depended on cone voltage and y-ions
formed predominantly by cleavage on the C-terminal side of nonpolar residues. An unknown 4.9 kDa
recombinant peptide was completely sequenced using LC-ESI-Q-ToF MS/MS of 10,000 resolution and
traditional CID fragmentation; complete y- and b-type ion series were obtained and the formation of
beta-mercaptoethanol adducts was reported [30]. In 2009 Armirotti and colleagues reported 90–100%
sequence coverage of horse myoglobin (17 kDa) and bovine carbonic anhydrase II (30 kDa) using
LC-ESI-Q-ToF MS/MS and CID fragmentation mode [31]. They could also identify an unknown
protein as superoxide dismutase (16 kDa) and locate one acetylation site. ESI CID Q-TOF MS/MS
was used to identify eight intact antimicrobial peptides from Asian frog skin and locate disulphide
bridges [32]. ESI-Q-ToF technology has also been employed to investigate the precise stoichiometry
of protein assemblies, the interactions between subunits and the position of subunits within the
complex [33].
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In our laboratory, we host a maXis HD UHR-Q-ToF (60,000 resolution) with an ESI source
on-line with a UHPLC 1290 Infinity Binary LC system (Agilent, Mulgrave, VIC, Australia), which
we have used to develop a top-down method to analyse cow’s milk proteins [23]. This method was
further implemented with CID MS/MS analysis and applied to the study of UHT milk shelf life [34].
The present study aimed at optimising MS/MS analysis by testing the effect of some of the parameters
pertaining to IS-CID in combination or not with conventional CID. A total of 11 MS/MS methods were
assessed on samples bearing increased complexity, namely individual milk protein standards, mixed
protein standards and cow’s raw milk samples from Jersey or Holstein breeds. Milk proteins exhibit
numerous PTMs, however in this initial study, we focused on optimising protein fragmentation to
achieve the greatest sequence coverage possible. To this end, nine of the most abundant proteoforms of
milk caseins and whey proteins, including genetic variants, were compared across samples and MS/MS
methods whose efficacy was assessed based on protein sequence coverage alone. This necessitated
developing processing workflows using the powerful Genedata Expressionist software to thoroughly
explore and annotate the MS1 and MS2 files.
2. Results and Discussion
2.1. Sample Complexity
In this experiment, we wanted to test whether sample complexity would impact the quality
of spectral acquisition. To this end, we prepared a set of samples displaying increasing proteome
complexity: from simple individual milk protein standards, albeit varying in their purity level from 70%
(α-CN) to 98% (β-CN), to a mixture of these standards, to the highly complex biological matrices raw
milk samples that were obtained from two common cow breeds. Figure 1 describes the experimental
design of this study.
2.1.1. UPLC-ESI-Q-ToF MS Can Handle Complex Samples
While the raw data clearly illustrate increasing complexity with more LC-MS1 peaks detected in
the milk samples compared to the individual protein standard samples (Figure 2A), the latter are more
complex than first anticipated, particularly the β-CN standard, which is claimed to be 98% pure.
These standards were analysed using a bottom-up shotgun approach and yielded many protein
hits [35]. The α-LA standard sample (85% pure) generated by far the simplest LC-MS1 pattern, with
clear elution from 14 to 19 min and distinct m/z peaks of the charged envelope (Figure 2A).
The LC-MS1 pattern of the mixed standard sample is quite similar and as complex as the patterns
of milk samples owing to the fact that the individual protein standards are far from pure. Indeed,
following protein mass deconvolution and the display of protein accurate masses separated by HPLC
(Figure 2B), many deconvoluted peaks appear besides the expected proteins of interest. Such a display
confirms that the α-LA standard is the least complex sample with only 211 deconvoluted peaks,
whereas the other individual standards display between 2194 (α-CN) and 3372 peaks (β-CN).
With 4819 deconvoluted peaks, the mixed standard sample is indeed of intermediate complexity
between the individual standards and the raw milk samples, which resolved 6988 and 7554 peaks in
Jersey and Holstein cows, respectively. While proteins displayed some degree of co-elution during the
HPLC separation, particularly in complex samples, separation along the m/z range could isotopically
resolve all proteins of less than 30 kDa, thus yielding deconvoluted monoisotopic masses (also shown
in [23]).
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Figure 1. Schematic diagram of the experimental design of the study.
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Figure 2. LC-MS maps of the different samples (individual protein standards, mixed protein standards,
Jersey milk, and Holstein milk) visualised in Genedata Refiner pre- and post-deconvolution with
m/z on the x axis and LC retention time in min on the y axis. (A) LC-MS1 unprocessed raw data.
(B) Deconvoluted data displaying proteins of interest in the red boxed areas. The total numbers
of deconvoluted peaks detected are indicated in yellow. (C) Close-ups of the boxed areas of the
individual protein standards; the nine proteoforms highlighted in red are the proteins targeted for
method validation.
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2.1.2. The 11 MS/MS Methods Are Assessed Using a Reference Set of Known Proteins
Another aim of our study was to optimise the MS/MS method by modifying key parameters and
devise objective tools to compare the different methods. We thought the best comparative approach
would be a targeted one relying on a small reference set of known proteins. The proteins of interest
are depicted in the boxed areas of Figure 2B which have been zoomed in in Figure 2C. We chose nine
prominent proteoforms, some of them displaying allelic variations, in each of the individual standards,
namely, α-CN type S1 variant B with 8 phosphorylations (αS1-CN B-8P, 23,600.3 Da), α-CN type S2
variant A with 11 phosphorylations (αS2-CN A-11P, 25,213.0 Da), β-CN variants A1 and A2 (β-CN A1
24,008.2 Da, β-CN A2 23,968.2 Da) each with five phosphorylations, κ-CN variants A and B with 1
phosphorylation (κ-CN A-1P 19,026.5 Da, κ-CN B-1P 18,993.6 Da), α-LA variant B (α-LA B 14,176.8 Da),
and β-LG variants A and B (β-LG A 18,355.5 Da, β-LG B 18269.4 Da). We have previously used these
proteins to optimise a quantitative LC-MS method [23]. The full primary sequence of these proteins is
known, and therefore fragmentation efficiency for top-down sequencing purpose could be assessed.
This is presented in the last chapter. While not included in this article, our MS/MS method also
allowed us to identify various PTMs of milk most abundant proteins such as lactosylation (+324 Da),
oxidation (+16 Da), glycosylation ([Hex(1)HexNAc(1)NeuAc(2)] + 947 Da), and degradation products,
as reported in [34].
2.2. Effect of IS-CID and CID on Their Own or Combined on Spectral Data
In a recent study [34], we have used conventional CID (Method 2 in the present study) to identify
the degradation products of milk’s most abundant proteins occurring following UHT treatment and
storage on the shelf. While this top-down sequencing method proved successful for the identification
of small proteins and degradation products, we wanted to optimise it for the analysis of intact
milk proteins. Our Q-ToF mass spectrometer allows us to perform both IS-CID and CID in a single
experiment. The benefits of both have been stated in the introduction of this manuscript. In the
present study, we have only slightly varied the parameters controlling CID fragmentation, choosing
to operate it in a fully automated manner. We have mostly fine-tuned the parameters pertaining to
IS-CID. We thus tested different energy values for IS-CID MS (ion funnel 1 exit) and IS-CID MS/MS
(ion funnel 2 entrance) parameters. A total of 11 MS/MS methods were thus devised that employed
either CID or IS-CID on their own or combined (Table 1).
In summary, Methods 2 and 3 employed CID only, Methods 4 and 12 employed IS-CID only, and
Methods 5–11 employed IS-CID within the ESI source/ion transfer region, followed by CID within the
collision cell.
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Figure 3 displays the LC-MS patterns for each of the 12 methods using the mixed protein
standards sample.
Figure 3. LC-MS maps of the mixed protein standards sample visualised in Genedata Refiner with
the scanned mass range (200–2000 m/z) on the x axis and LC retention time (3–28 min) on the y axis
across all 12 methods following data processing. White dots represent true MS/MS (MS2) events using
conventional CID fragmentation. AE, active exclusion.
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Table 2 compares all 12 methods based on LC-MS and LC-MS/MS observations
Table 2. Number of spectral peaks, clusters, groups and MS/MS spectra found in the mixed standard
sample across all 12 methods using Genedata Refiner workflow.
Method 1 2 3 4 5 6 7 8 9 10 11 12
LC separation
(min) 22.5 22.5 22.5 22.5 22.5 22.5 22.5 22.5 22.5 22.5 22.5 22.5
LC separation
(s) 1350 1350 1350 1350 1350 1350 1350 1350 1350 1350 1350 1350
Duty cycle (s) 2.7 13.7 13.7 5.6 13.7 13.7 13.8 19.1 24.6 24.6 24.6 5.5
No. of full MS1
scans 493 99 99 243 99 99 98 71 55 55 55 247
No. of
precursors 2 2 2 2 2 3 4 4 4
(a) Theor. no. of
MS2 events 0 197 198 0 197 198 196 212 219 219 220 0
(b) MS1 peaks
(300–3000 m/z) 8728 8402 5184 7141 4509 4415 3692 3321 3171 1816 3115 6614
(c) MS1 peaks
(700–3000 m/z) 8711 8387 5184 7124 4503 4415 3599 3040 3169 1628 3113 6599
(d) MS1 peaks
(300–700 m/z) 17 15 0 17 6 0 93 281 2 188 2 15
(d)/(b) (%) 0.2 0.2 0.0 0.2 0.1 0.0 2.5 8.5 0.1 10.4 0.1 0.2
MS1 clusters 1069 1044 601 869 551 536 530 654 386 405 371 769
MS1 groups 424 426 240 346 234 231 282 487 170 319 159 296
(e) Observed No.
of MS2 spectra 0 56 170 0 196 196 196 210 218 218 218 0
(e)/(a) (%) 28 86 99 99 100 99 99 99 99
(e)/(b) (%) 0.7 3.3 4.3 4.4 5.3 6.3 6.9 12.0 7.0
MS2 m/z range 730–1636 644–1854 643–1955 703–1955 657–1966 609–1913 607–1774 609–1966 634–1928
600–700 m/z 1 3 2 18 3 20 4
700–800 m/z 2 2 5 5 5 14 4 19 8
800–900 m/z 4 12 20 20 15 22 26 27 29
900–1000 m/z 20 53 45 44 21 34 56 36 54
1000–1100 m/z 28 77 53 51 47 23 63 24 57
1100–1200 m/z 5 29 26 35 24 30 18 23
1200–1300 m/z 2 19 21 26 26 20 29 18
1300–1400 m/z 2 3 7 17 14 8 7 2
1400–1500 m/z 2 2 5 4 11 2 10 5
1500–1600 m/z 2 3 4 5 8 3 9 3
1600–1700 m/z 2 6 4 4 7 7 1 8 7
1700–1800 m/z 3 4 3 3 1 2 5 5
1800–1900 m/z 3 4 4 7 7 4 1
1900–2000 m/z 2 2 2 1 2 2
2.2.1. Precursor Intensity Threshold Is a Key Parameter for CID Fragmentation
Methods 2 and 3 (CID only) only differed in the intensity threshold for precursor selection,
being almost 7 times higher in Method 2 (2550 counts) relative to Method 3 (17,302 counts) (Table 1).
This allows precursor ions of low signal intensity to undergo CID fragmentation. As expected, this
did not affect the LC-MS1 data; however, it did result in many more MS/MS events when Method 3
was used. If we consider the mixed standard sample as an example, Method 2 resulted in 8402 ions
with only 56 (0.7%) MS2 spectra, whereas Method 3 yielded 5184 peaks and 170 (3.3%) MS2 spectra
(Table 2). Consequently, the top-down sequencing efficiency varied between Methods 2 and 3, as will
be discussed in the following section.
Charge state preference aside, in this study we did not attempt to optimise CID conditions and took
full advantage of the automatic MS/MS mode available on our instrument with default parameters as
it proved efficient [34]. Using CID on its own, Nemeth-Cawley and colleagues successfully top-down
sequenced unknown intact proteins purified by affinity and size-exclusion chromatography from
mammalian cells using an ESI-Q-ToF MS/MS strategy [27].
2.2.2. Ion Funnel 1 Energy Has Little Impact on IS-CID Fragmentation
Methods 4 and 12 (IS-CID only) differed only in the energy applied to the ion funnel 1 exit during
the IS-CID MS1 step. Method 4 applied 3 eV and Method 12 applied 10 eV at ion funnel 1 (Table 1).
LC-MS patterns displayed only slight changes, with Method 4 yielding 7141 peaks, 869 clusters,
and 346 groups, and Method 12 producing 6614 peaks, 769 clusters, and 296 groups (Table 2 and
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Figure 3). Protein annotation by top-down sequencing was also comparable, as will be described in
the next chapter.
2.2.3. Charge State Preference Does Not Influence Precursor Selection
Methods 9 and 11 (IS-CID + CID) only differed in their charge state preferred range. No charge
state was specified in Method 11 (Table 1). In Method 9, a preference for the most abundant ions
bearing 7-15 charges was applied to assess whether it would favour the selection of highly protonated
ions for CID fragmentation. This parameter had no impact on the selection process of parent ions since
both methods generated similar numbers of peaks, clusters and groups and, most importantly, an
identical number of MS2 spectra (218) (Table 2). This indicated that the automatic MS2 mode of the
Q-ToF aptly selected highly charged protein ions for subsequent CID fragmentation.
2.2.4. A Long Duty Cycle Minimises MS/MS Events
To maximise signal sensitivity and minimise background noise, high summation values were
utilised, which resulted in duty cycles that lasted at least 2.7 s (MS1 only—Method 1) (Table 2).
Furthermore, these duty cycles were extended upon MS/MS analyses in a method-specific fashion
(from 5.5 s in Methods 4 and 12, 13.7 s in Methods 2–3 and 5–6, to 24.6 s in Methods 9–11), which
restricted the number of full MS1 scans (Table 2). Consequently, it limited how many ions could be
selected as parents for the CID process during the LC run.
Under our LC-MS/MS conditions, protein separation occurred from 2.5 to 25 min (22.5 min or
1350 s) with two to four precursors selected per duty cycle. The maximum number of MS2 events were
computed and reported in Table 2. Apart from the CID-only methods, which only realised 28% (56/197
in Method 2) and 86% (170/198 in Method 3) of their potential due to high threshold requirements, all
the other methods delivered 99–100% of the expected number of MS2 events (Table 2). However, these
numbers are low. Instruments of high resolution offering a faster scanning capability would therefore
be extremely advantageous.
In our study, the slow scanning rate was partially alleviated by resorting to IS-CID only (Methods
4 and 12), whose fast fragmentation mode allowed for shorter duty cycles (5.5 s) and up to 247 scans
during the 22.5-min separation (Table 2).
2.2.5. High Energy Fragmentation Produces Lower m/z Ions
Overall, low-energy fragmentation was applied at the ion funnel 1 exit during the IS-CID MS
mode (3, 5 or 10 eV), except for three methods for which high energy was applied. Methods 5–7 applied
30, 50, and 70 eV, respectively (Table 1). The consequences of high-energy IS-CID become visible
upon reaching 70 eV (Method 7), which generates many more ions of less than 700 m/z, indicative of
protein fragmentation. For instance, in the mixed standard sample, Method 1 (MS1 only) resulted in
8728 peaks, with the vast majority above 700 m/z (8711, 99.8%). Method 5 (30 eV) produced 4509 peaks
in total with only 6 (0.1%) below 700 m/z. Conversely, Method 7 (70 eV) produced 3692 peaks in total,
of which 93 (2.5%) were of less than 700 m/z (Table 2).
Similarly, low-energy fragmentation (10 or 15 eV) was applied at the ion funnel 2 entrance during
the IS-CID MS/MS mode, except for two methods for which greater energy was delivered. Methods
8 and 10 applied 20 and 30 eV, respectively (Table 1). Increasing the energy level during the IS-CID
MS/MS step proved even more effective at fragmenting intact proteins within the ESI source, as more
spectral peaks of low m/z were created (Figure 3). For instance, in the mixed standard sample, applying
20 eV (Method 8) or 30 eV (Method 10) resulted in the proportion of peaks below 700 m/z reaching
8.5% (281/3321 peaks) and 10.4% (188/1816 peaks) for Methods 8 and 10, respectively (Table 2).
This resulted in ions of lower m/z being selected as precursors for a subsequent CID process. In the
mixed standard sample, only three (1.5%) MS2 spectra resulted from precursors of less than 700 m/z
using Method 5, while 20 (9.2%) MS2 spectra were acquired from precursors of less than 700 m/z
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using Method 10 (Table 2). However, as will be reported in the next chapter, such enhanced in-source
fragmentation did not benefit the top-down sequencing output.
2.2.6. CID Versus IS-CID
While CID parameters mostly revolve around ion features (e.g., intensity threshold, charge state,
number of precursors) that allow for relatively controlled and robust conditions, IS-CID parameters
themselves pertain to factors operating globally within the ESI source and the ion transfer region, the
most important one being the DC voltage applied, which affects signal sensitivity. Owing to its less
controllable nature, the IS-CID fragmentation process is more complex and far less predictable than
MS/MS results. Therefore, a prerequisite of IS-CID efficacy is good chromatographic resolution with
little or no background contamination [16].
Our ESI-Q-ToF mass spectrometer establishes IS-CID fragmentation not within the ESI source
per se but more accurately within the ion transfer area called funnel 2. The two funnel-staged ion
transfer region separates the ions from the drying gas and solvent, as well as transfers these ions, with
minimal losses, to the quadrupole stage. The first and second funnel stages are separated by a DC
plate. By increasing the DC potentials of funnel 1, the ions are accelerated into funnel 2, which in turn
activates IS-CID. This ingenious, albeit unpredictable, fragmentation mode was invented 30 years
ago and reported to favour highly charged species at lower energetic collision (i.e., cone voltage)
akin to conventional CID process [5]. As with CID, as the ions’ m/z increase, the IS-CID efficacy
decreases. That was confirmed in our experiment. Parent ions were predominantly sampled from the
800–1300 m/z range, where the most intense ions resolved, and only a handful of precursors arose
from 1600 m/z and above (Table 2).
IS-CID in combination with conventional CID on a ESI-Q-ToF system was tested at increasing
cone voltage conditions (from 45 to 90 V) by Ginter and colleagues (2004) to top-down sequence a
mixture of seven protein standards; they reported that some proteins necessitated higher voltage than
others for in-source fragmentation to occur [28]. In a different study where only IS-CID was applied
to generate MS2 spectra using a ESI-Q-ToF instrument, source cone voltage varied from 20 to 70 V
and was evaluated on a sample mixture of 13 protein standards [29]. The authors also concluded that
IS-CID efficient fragmentation greatly depended on cone voltage; in their experience, 40–60 V proved
the most optimal range.
2.3. Top-Down Sequencing of Milk Proteins
In the present study, a total of 11 MS/MS methods (Methods 2–12) were compared and the
ultimate validation criterium was the coverage depth resulting from top-down sequencing annotation.
The nine most abundant proteins known from milk were chosen to systematically assess AA sequence
coverage across the 11 methods using Genedata Expressionist program. These proteoforms were
αS1-CN B-8P, αS2-CN A-11P, β-CN A1, β-CN A2, κ-CN A-1P, κ-CN B-1P, α-LA B, β-LG A, and β-LG B.
Table 3 documents the number of AAs top-down sequenced for each protein from either individual or
mixed standards, or milk samples from Jerseys or Holsteins.
Results were consistent from sample to sample, particularly for the proteins that responded very
well to top-down sequencing such as β-CN A2 with a coefficient of variation (CV) as low as 0.4%.
For ease of interpretation, the values reported in Table 2 were converted to percentages and
displayed as histograms (Figure 4).
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Figure 4. Comparison of the 11 MS/MS methods based on the AA sequence coverage in percent
of the nine most prominent milk proteins. (A) Cumulative coverage in the individual standards.
(B) Cumulative coverage in the mixed standards. (C) Cumulative coverage in the Jersey milk sample.
(D) Cumulative coverage in the Holstein milk sample. (E) Illustration of AA sequence coverage for one
particular protein, β-LG A, in increasingly complex samples. (F) Averaged sequence coverage for all
eight proteins sorted by method efficacy; the fragmentation modes are reported as well.
2.3.1. Reproducibility and Protein Specificity
While being both protein- and method-specific, top-down sequencing results were reproducible
across samples of increasing complexity, from the least (individual standards, Figure 4A) and mildly
(mixed standards, Figure 4B) complex, to the most complex samples (raw milk, Figure 4C–D).
The sample reproducibility was also demonstrated on one particular protein, β-LG A, which exhibited
CV values spanning from 1.0% (Method 7) to 1.9% (Methods 9 and 12), omitting Methods 8 and
10, which were not only the least efficient but also the least reproducible (Figure 4E). As observed
in previous studies [28,29], top-down sequencing success is protein-dependent. In our conditions,
αS2-CN A-10P was the least responsive, possibly due to its elevated number of phosphorylation sites,
while β-LGs and β-CNs were the most responsive.
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2.3.2. Low-Energy Fragmentation Drives Top-Down Sequencing Efficacy
The histograms in Figure 4 also clearly demonstrate which methods were suitable for top-down
sequencing and which were not. In Figure 4F, the methods have been sorted in descending order
of AA sequence coverage. Under our conditions, the best methods were Methods 4 and 12 (90.6%
sequence coverage on average), closely followed by Methods 3 (88.6%), 11 (87.4%), 9 (86.8%), 5 and 2
(86.7%), 6 (86.6%), and 7 (83.6%). The worst-performing methods were 8 (60.2%) and 10 (38.6%). Based
on our observations, we can conclude that the methods that resorted to IS-CID on its own with little
energy applied, in combination with CID or not, were best suited to top-down sequence prominent
milk proteins.
Optimal conditions in our case involved applying 3 eV (Method 4) or 10 eV (Method 12) to the
ion funnel 1 exit during the IS-CID MS step and 15 eV to the ion funnel 2 entrance during the IS-CID
MS/MS step. What seemed to be detrimental for our purposes was using too much energy (20 eV in
Method 8 and 30 eV in Method 10) during the IS-CID MS/MS step. Moreover, we do not recommend
applying an energy level higher than 10 eV during the IS-CID MS step, as was tested in Methods 5
(30 eV), 6 (50 eV), and 7 (70 eV).
2.3.3. AA Position Has No Influence on Fragmentation
In an attempt to further explain how CID-based fragmentation operated under our conditions,
we aligned side by side all the AA sequences of the nine proteins of interest for each of the 11 MS/MS
methods and blackened the AAs that were successfully top-down sequenced. For each protein, the
sequenced AAs were counted across the methods and, as a result, we generated a score from 0 (not
sequenced at all) to 11 (sequenced in all methods). Based on this scoring system, the corresponding
position in the sequence was coloured red (the higher the score, the darker the shade). This is
represented in Supplementary Figure S1. This display allowed for the quick visualisation of regions that
remained unfragmented under our various conditions. Such recalcitrant regions were scattered along
the protein sequence, suggesting that the AA position had no influence over fragmentation efficiency.
All cow’s milk caseins are heavily phosphorylated. There was no visible pattern associated
with phosphorylation sites (highlighted in yellow) either, apart from αS2-CN A-10P, for which five
phosphorylated serine residues (S at positions 7, 13, 31, 56, and 143) resisted fragmentation. PTMs
were not investigated in this study. Milk proteins are also glycosylated, as has been well documented
for κ-CN, for instance [36]. Glycosylation sites could account for areas difficult to fragment, but we
could not test this hypothesis in the present study.
2.3.4. Hydrophobicity Affects Fragmentation
To further elucidate whether AAs themselves influenced fragmentation efficiency, we converted
the AA counts from Supplementary Figure S1 into percentages, sorted them according to their
highest fragmentation efficiency (meaning sequenced across all 11 MS/MS methods) and plotted
them (Supplementary Figure S2). Underneath the chart we listed the physical properties attributed to
AAs (ThermoFisher Scientific website) to assist us in finding a pattern.
In this representation, leucine, glycine, cysteine, tryptophan, histidine, and isoleucine displayed
the best response to top-down sequencing with a success rate above 17% across 11 MS/MS methods
(Supplementary Figure S2). These AAs are moderately to highly hydrophobic. Conversely, threonine,
asparagine and arginine showed the lowest success rate (less than 9% across the 11 methods).
Such AAs are hydrophilic. Our results suggest that AA hydrophobicity level has an impact on
fragmentation efficiency.
2.3.5. High Sequence Coverage Is Critical for Allelic Variants
High sequence coverage is a prerequisite to successfully distinguishing between protein allelic
variants such as β-CN A1 and A2, which only vary at position 67 (H to P); κ-CN A and B, which
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vary at positions 136 (T to I) and 148 (D to A); and β-LG A and B, which vary at positions 64 (D to G)
and 118 (V to A). The mixed standard sample, Method 10, and, in the case of κ-CNs, Method 8 failed
to deliver such relevant information since AAs at the aforementioned positions were not sequenced
(Supplementary Figure S1).
Interestingly, some genetic variants proved more amenable to top-down sequencing than others.
For instance, in the mixed standard sample processed with Method 12, β-CN A2 (97%) was more
thoroughly sequenced than β-CN A1 (83%). Likewise, β-LG A (96%) displayed greater sequence
coverage than β-LG B (77%); this was also observed for κ-CN A (73%) and κ-CN B (68%) (Table 3
and Figure S1). In Holstein milk samples, we managed to reach 100% sequence coverage of β-LG B
in six out of 11 MS/MS methods. Complete top-down sequencing was also achieved for β-LG A in
individual standard samples in four MS/MS methods (Table 3).
In the early days of top-down proteomics on ESI-Q-ToF platforms, the resulting short sequence
tags from C- and N-termini from small to medium-sized proteins were just long enough to
unambiguously identify the protein family, but not their allelic variants [26–30]. Almost complete
top-down sequencing was achieved in 2009 with 17 kDa horse myoglobin and 30 kDa bovine carbonic
anhydrase II being 92% and 96% sequenced, respectively [31]. Since then and to our knowledge,
Q-ToF instruments have not been employed for top-down sequencing of intact proteins from complex
biological matrices because they have been superseded by more expensive platforms such as FT mass
spectrometers, offering better power resolution and alternative fragmentation methods like ETD, HCD,
and ECD.
3. Materials and Methods
3.1. Materials and Sample Preparation
The experimental design is schematised in Figure 1. Protein standards purchased from
Sigma-Aldrich (Castle Hill, NSW, Australia) were alpha-casein (α-CN) from bovine milk (C6780-250MG,
70% pure), beta-casein (β-CN) from bovine milk (C6905-250MG, 98% pure), kappa-casein (κ-CN) from
bovine milk (C0406-250MG, 70% pure), alpha-lactalbumin (α-LA) from bovine milk (L5385-25MG, 85%
pure), and beta-lactoglobulin (β-LG) from bovine milk (L3908-250MG, 90% pure). These lyophilised
standards were prepared as described in [23]. Briefly, they were fully solubilised at a 10 mg/mL
concentration in 50% MilliQ (MerckMillipore, Bayswater, VIC, Australia) water/50% solution A (0.1 M
Bis-Tris, 6 M Guanidine-HCl, 5.37 mM sodium citrate tribasic dehydrate, and 20 mM DTT). A volume
of 50% acetic acid to reach 1% acetic acid final concentration was added to the standards. A 0.1-mL
aliquot of the solubilised standard was transferred into a 100-μL glass insert placed in a 2-mL glass vial
for immediate analysis by LC-MS. A standard mixture was prepared by mixing individual standards in
the following proportions to account for various ionisation efficiency [23]: 25% α-CN, 25% κ-CN, 20%
β-LG, 20% β-CN, and 10% α-LA.
Milk collection from Holstein-Friesian cows (coded H) and Jersey cows (coded J) was described
in [35]. Milk sample preparation was described in [23]. Briefly, 0.5 mL of cold skim milk was transferred
into a 1.5-mL tube and 0.5 mL of Solution A was added. A 0.02 mL volume of 50% acetic acid (1%
acetic acid final concentration, pH 5.8) was then added. A 0.1-mL aliquot of the milk protein extract
was transferred into a 100-μL glass insert placed in a 2-mL glass vial for immediate analysis by LC-MS.
3.2. HPLC Separation of Intact Proteins
The separation of intact proteins by UHPLC 1290 Infinity Binary LC system (Agilent) through
a Aeris™ WIDEPORE XB-C8 (3.6 μm particle size, 200 Å pore size, 150 × 2.1 mm dimensions, C8
reverse phase core-shell silica from Phenomenex (Lane Cove, NSW, Australia) column at 75 ◦C was
described in [23]. In brief, 3 μL of sample was injected and separated as followed: starting conditions
20% B, ramping to 28% B in 2.5 min, ramping to 40% B in 27.5 min, ramping to 99% B in 1 min and
held for 4 min, lowering to 20% B in 0.1 min, equilibration at 20% B for 4.9 min. Mobile phase flow
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rates was 200 μL/min. Mobile phase A contained ACN with 0.1% FA and 0.02% trifluoroacetic acid
(TFA), and mobile phase B contained H2O with 0.1% FA and 0.02% TFA. The diode array detector
(DAD) spectrum was acquired from 190 to 400 nm. The pressure limit was set at 600 bars.
3.3. MS1 Analysis
MS1 analysis was described in [23]. The UHPLC was on-line with a maXis HD UHR-Q-ToF
(60,000 resolution) fitted with a standard ESI Apollo-source (BrukerDaltonikGmbh, Preston, VIC,
Australia). To ensure mass accuracy, a Na-formate solution was infused continuously at 0.1 mL/h
and the first 2.5 min of each run were used to re-calibrate masses post-acquisition. Each 40-min run
was thus segmented as follows: 2.5 min to waste and the following 37.5 min to source. Capillary
voltage was set at 4500 V. The nebuliser was set at 1.5 bar. The dry gas was set at 8 L/min. The dry
temperature was set at 190 ◦C. The transfer funnel RF and multipole RF were set at 400 Vpp; no IS-CID
energy was applied. The quadrupole ion energy was 5 eV, the collision cell energy was 10eV, and the
collision RF 1800 Vpp. The ion cooler transfer time was 120 μs, with a prepulse storage of 10 μs and a
RF of 400 Vpp. The ion polarity was positive and scan mode was MS. The rolling average mode was
activated and set at 2. This MS1 method is called Method 1 hereafter.
3.4. MS2 Analyses and Top-Down Sequencing
MS/MS experiments were performed using the same LC parameters and MS1 parameters on the
Q-TOF mass spectrometer as described above. A total of 11 MS2 methods were tested; their parameters
are indicated in Table 1. These methods are referred to as Method 2 to Method 12 hereafter. LC-MS
files were visualised using Bruker Compass DataAnalysis version 4.2. MS2 spectra were annotated
using Bruker Biotools version 3.2 and SequenceEditor version 3.2. The retrieval of AA sequences was
detailed in [23].
3.5. Protein Annotation in Genedata Expressionist
The data files obtained following LC-MS analysis using MS2 methods 2 to 12 were curated in
the Refiner MS module of Genedata Expressionist® version 11.0 with the following parameters: (1)
Conversion of MS/MS to primary MS. (2) Chromatogram chemical noise subtraction using moving
average algorithm and a five-scan window. (3) Spectrum smoothing using a moving average algorithm
and a five-point m/z window. (4) Chromatogram peak detection using a five-scan summation window,
a minimum peak size of four scans with boundaries merge strategy and five-point maximum merge
distance, a curvature-based peak detection with 70% intensity threshold and inflection points boundary
determination. (5) Chromatogram isotope clustering using a 0.2 min and 20 ppm tolerances, a peptide
isotope shaping with 1-8 protons, a 0.6 log-ration maximum distance, mono-isotopic computation,
linear charge dependency with a minimum size ratio of 0.65. (6) Singleton filtering. (7) Peptide mapping
with a 50 ppm tolerance, unspecific enzyme, three missed cleavage maximum, 10 AAs minimum
length, and variable modifications, as explained hereafter. The peptide mapping was performed
using a text file containing all 49 AA sequences in FASTA format of the bovine allelic variants of milk
caseins, alpha-lactalbumin, and beta-lactoglobulin (Farrell et al., 2004) with the following variable
modifications: pyro-Glu (N-term Q) and Phospho (ST). Some aspects of this workflow are illustrated
in Figure S3.
Protein deconvolution was also performed on Method 1 files in the Refiner MS module of
Genedata Expressionist® version 11.0 with the following parameters. (1) Data sweep to remove
UV data. (2) Chromatogram chemical noise subtraction using moving average algorithm, with a
subtraction method, a 71 scan window, and 60% quantile. (3) Chromatogram lock mass using the
Na-formate ion series. (4) Retention time range restriction from 4 to 25 min. (5) Intact protein activity
using the harmonic suppression deconvolution method with 0.02 Da steps and 5-30 kDa masses.
(6) Intensity thresholding using a clipping method with an intensity of 50. (7) Spectrum baseline
76
Molecules 2018, 23, 2777
subtraction using a 99% quantile and 30 kDa m/z window. (8) Chromatogram retention time alignment
using a pairwise alignment-based tree scheme with 50-scan search interval and a gap penalty of 1.
All MS1 and MS2 files are available from the stable public repository MassIVE at the following
URL: http://massive.ucsd.edu/ProteoSAFe/datasets.jsp with the accession number MSV000082070.
3.6. Validation and Computational Analyses
Top-down sequencing results were visualised and validated in Genedata Expressionist® version
11.0 Refiner MS module within the Peptide Mapping activity and all its subsidiary tabs as well as
using Bruker Biotools version 3.2 and SequenceEditor version 3.2, as exemplified in Figure S3.
Top-down sequencing annotations (including b- and y-ions series) for each of the nine proteins of
interest in every sample and each of the 11 MS/MS methods were exported from Refiner MS module as
.csv files. The .csv files contained the list of peptides identified for each protein along with the peptide
AA lengths and their position in the protein sequence they matched to. The .csv files were imported
into Microsoft® Excel 2016 software for further processing. Coverage information was derived from the
length and position of the identified peptides relative to their matching protein sequence to produce
Table 3 and Figure 4. AA responsiveness to MS2 fragmentation was obtained using the positions of the
first and last AA of the identified peptides. These analyses produced Figures S1 and S2.
4. Conclusions
In this experiment, we have fine-tuned IS-CID parameters with and without traditional CID
using a LC-ESI-Q-ToF system in order to optimise the top-down sequencing of milk intact proteins.
The most efficient methods utilised IS-CID on its own at low energy. Full (100%) sequence covering
could be obtained on β-LGs, and overall enough coverage was achieved to distinguish between allelic
proteoforms, varying only by one or two AAs. Such information is highly biologically relevant as
alleles influence function and phenotypic features. In bovine milk, for instance, 12 allelic variants of
beta-caseins have been identified across different breeds and populations [37]. The most common
variants, A1 and A2, differ at amino acid position 67 with histidine in A1 and proline in A2 milk, as a
result of a single nucleotide difference. One application of this research would be screening for the
presence of the A1 variant in cow’s milk samples.
Supplementary Materials: The following are available online, Figure S1: Top-down sequencing responsiveness
of AAs for each of the eight most abundant proteins from the mixed standard sample, Figure S2: CID-friendly
amino acids from top-down sequenced milk proteins, Figure S3: Data processing of MS/MS files using Genedata
Refiner and DataAnalysis/Biotools exemplified on the Holstein milk sample processed using Method 3.
Author Contributions: Conceptualisation, D.V.; methodology, D.V. and D.M.; software, D.V. and D.M.; validation,
D.V.; formal analysis, D.V.; investigation, D.V.; resources, S.R.; data curation, D.V.; writing—original draft
preparation, D.V.; writing—review and editing, D.V., D.M., and S.R.; visualisation, D.V.; supervision, S.R.; project
administration, D.V.; funding acquisition, S.R.
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CAD Collisionally activated dissociation
CID Collision-induced dissociation
CV Coefficient of variation
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DAD Diode array detector
DC Direct current
ECD Electron capture dissociation
ESI Electrospray ionisation




HCD Higher-energy collisional dissociation




LC-MS Liquid chromatography-mass spectrometry
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MW Molecular weight
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Abstract: As one of most important traditional Chinese medicine resources, the oviduct of female
Rana chensinensis (Chinese brown frog) was widely used in the treatment of asthenia after sickness
or delivery, deficiency in vigor, palpitation, and insomnia. Unlike other vertebrates, the oviduct of
Rana chensinensis oviduct significantly expands during prehibernation, in contrast to the breeding
period. To explain this phenomenon at the molecular level, the protein expression profiles of
Rana chensinensis oviduct during the breeding period and prehibernation were observed using
isobaric tags for relative and absolute quantitation (iTRAQ) technique. Then, all identified proteins
were used to obtain gene ontology (GO) annotation. Ultimately, KEGG (Kyoto Encyclopedia of
Genes and Genomes) enrichment analysis was performed to predict the pathway on differentially
expressed proteins (DEPs). A total of 4479 proteins were identified, and 312 of them presented different
expression profiling between prehibernation and breeding period. Compared with prehibernation
group, 86 proteins were upregulated, and 226 proteins were downregulated in breeding period.
After KEGG enrichment analysis, 163 DEPs were involved in 6 pathways, which were lysosome, RNA
transport, glycosaminoglycan degradation, extracellular matrix (ECM)–receptor interaction, metabolic
pathways and focal adhesion. This is the first report on the protein profiling of Rana chensinensis
oviduct during the breeding period and prehibernation. Results show that this distinctive physiological
phenomenon of Rana chensinensis oviduct was mainly involved in ECM–receptor interaction, metabolic
pathways, and focal adhesion.
Keywords: iTRAQ; proteomics; Rana chensinensis oviduct; regulation; differentially expressed proteins
1. Introduction
The oviduct is a reproductive organ of females, which plays several important roles in the
events related to fertilization and embryo development. The oviduct is not only a passive channel
for sperm and eggs transport, but is also a highly active secretory organ, such as estrous cycle and
ovulation [1]. It provides the most efficient environment for the success of fertilization and early
embryo development [2,3]. The component of oviduct of Rana chensinensis is rich in glands, including
glycoprotein (such as mucins, collagen, enzymes, and hormones, etc.) and lipoprotein [4]. The dry
oviduct of female Rana chensinensis, which is recorded in the Chinese Pharmacopoeia, possesses the
function of improving immune system and lung function [5].
Molecules 2018, 23, 1384; doi:10.3390/molecules23061384 www.mdpi.com/journal/molecules81
Molecules 2018, 23, 1384
The hibernation for Rana chensinensis ranges from October to February next year, followed by
the breeding period from February to June. After the breeding period, Rana chensinensis goes into
the prehibernation period until October [6]. Distinguishing from the oviduct expansion during the
breeding period in other species, a unique physiological phenomenon of Rana chensinensis is that its
oviduct starts to expand after breeding, reaching a peak by October during the prehibernation [7].
For this reason, Rana chensinensis oviduct, as traditional Chinese medicine, was collected from frog in
the autumn before hibernation. To ascertain the signaling pathways involved in the timing of oviduct
expansion, we should clarify the changes of macromolecular components between prehibernation
and breeding period. Proteomics is an efficient methodology to analyze protein expression, and it
will disclose protein expression profiles in different physiological phases [8]. It is widely used to
tackle biological problems, whereby the raw data obtained from proteomics is studied further by
bioinformatic methodologies [8]. Isobaric tags for relative and absolute quantitation (iTRAQ) is an
isobaric labeling method applied in quantitative proteomics by tandem mass spectrometry to identify
the amount of proteins from different samples in a single experiment [9]. iTRAQ can separate and
identify a variety of proteins, including membrane proteins, proteins of high molecular weight,
insoluble proteins, acidic proteins, and alkaline proteins [10].
2. Results
2.1. Protein Identified through Itraq Technology
13216 unique peptides and 4479 proteins were identified using the iTRAQ technology (see
Tables S1 and S2 in Supplementary Material). Among these identified proteins, 2422 were 0–20 kDa,
1758 were 20–60 kDa, and 299 were over 60 kDa (Figure 1A). Accordingly, we found that identified
proteins were primarily below 20 kDa. To further prove the credibility of protein identification, peptide
sequence coverage and the unique peptide numbers of proteins were also regarded as two important
quality evaluation parameters. Figure 1B showed that peptide sequence coverage of these proteins
was basically less than 30%. The number of unique peptides for identified proteins were mainly
concentrated in 1 and 2, which makes up approximately 71% of the total unique peptides (Figure 1C).
Figure 1. Cont.
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Figure 1. Summary for iTRAQ data: (A) The protein mass distribution shown as a histogram; (B) The
peptide sequence coverage distribution shown as a histogram; (C) The number of unique peptides
distribution shown as a histogram.
2.2. Differentially Expressed Proteins
Hereon, we defined proteins with expression level fold changes >2.0 or <0.5 with p-values < 0.05 as
differentially expressed proteins (DEPs). Changes in the protein profile were analyzed, and 312 proteins
exhibited a difference. Compared with the prehibernation group, 86 proteins were increased by more
than 2-fold, and 226 proteins decreased to less than 0.5-fold during the breeding period. The detailed
information of differential expressed proteins was shown in Table S3.
2.3. Gene Ontology Annotation and Classification Profiles
With annotating those 312 DEPs into Gene Ontology (GO) database, we found that 240 DEPs
were classified into biological process, 245 DEPs were classified into molecular function, 244 DEPs
were classified into cellular component (Table S4 in Supplementary Material). Further analysis of
DEPs clustered into biological processes disclosed that 193 DEPs were related to cellular process,
single-organism process (172 DEPs) second, and the next were metabolic process (142 DEPs), biological
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regulation (117 DEPs), and regulation of biological process (108 DEPs) (Figure 2A). In the molecular
function categories, DEPs were primarily associated with binding, indicating that proteins related
in binding function will experience significant changes in the breeding period (Figure 2B). Cellular
component ontology annotation showed that cell and cell parts possessed two-thirds of the whole
DEPs, followed by organelles (Figure 2C).
Figure 2. Pie diagrams and bar diagrams for gene ontology analysis of differentially expressed proteins
between breeding period group and prehibernation group: (A) biological process, (B) molecular
function, (C) cellular component.
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2.4. KEGG Pathway Annotation and Reasonable Enrichment Analysis
By annotating the 312 DEPs into KEGG database, we found 177 pathways (Table S5 in
Supplementary Material). The top 10 pathways were pathways in cancer, RNA transport, spliceosome,
focal adhesion, PI3K–Akt signaling pathway, Huntington’s disease, Alzheimer’s disease, metabolism,
extracellular matrix (ECM)–receptor interaction, and amoebiasis (Table 1).
Table 1. Top 10 pathway terms of differentially expressed proteins (DEPs) in KEGG annotation.
Pathway Terms 1 DEPs with KEGG Annotation 2 DEPs with KEGG Enrichment 3
Pathways in cancer 9 0
RNA transport 8 4
Spliceosome 8 0
Focal adhesion 7 4
PI3K–Akt signaling 7 0
Huntington’s disease 7 0
Alzheimer’s disease 6 0
Metabolic pathways 24 11
ECM–receptor interaction 6 3
Amoebiasis 6 0
1 Pathway terms in KEGG database; 2 The number of differentially expressed proteins annotated in KEGG database;
3 The number of differentially expressed proteins enriched in top 10 pathway terms.
KEGG can be used for systematic analysis of gene functions, which is linked with genomic
information combined with information stored in the pathway database. The KEGG pathway
is an aggregate of pathway maps showing the present knowledge on the molecular interaction
networks. In our research, a database based on transcriptome data was used for identification of
Rana oviduct proteins, which originated from different species. As a result, it is arduous for these
DEPs to process KEGG pathway enrichment analysis, because the proteins were slightly different
in various species. The distribution of differentially expressed proteins in various species is shown
in Table 2. In the present study, the largest protein group (163 proteins, 52%) and the second largest
one (61 proteins, 20%) of total DEPs was from Xenopus tropicalis and Xenopus laevis, respectively.
To discover the possible signaling pathways underlying the oviduct of Rana chensinensis, the largest
two groups of DEPs were used to process KEGG pathway analysis through KOBAS separately [11,12].
The result of KEGG enrichment was shown in Table S6. After enrichment analysis, 163 DEPs
from Xenopus tropicalis were involved in 6 pathway terms, which were lysosome, RNA transport,
glycosaminoglycan degradation, ECM–receptor interaction, metabolic pathways, and focal adhesion
(Table 3). While 61 DEPs from Xenopus laevis were input into KEGG database for enrichment analysis,
only one pathway term, pyruvate metabolism, was obtained (Table 3). Hence, KEGG enrichment
for DEPs from Xenopus tropicalis and Xenopus laevis were selected to logically interpret physiological
changes between prehibernation period and breeding period.
Table 2. The distribution of DEPs in different species.
Organism 1 Number of Proteins 2 Organism Number of Proteins
Xenopus tropicalis 163 Salmo salar 2
Xenopus laevis 61 Bos taurus 2
Rana catesbeiana 13 Oryctolagus cuniculus 1
Taeniopygia guttata 11 Mus musculus 1
Gallus gallus 8 Ovis aries 1
Monodelphis domestica 7 Zonotrichia albicollis 1
Homo sapiens 5 Pan troglodytes 1
Rana esculenta 4 Pyrrhocoris apterus 1
Mus musculus 4 Canis familiaris 1
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Table 2. Cont.
Organism 1 Number of Proteins 2 Organism Number of Proteins
Ailuropoda melanoleuca 4 Oryzias latipes 1
Ornithorhynchus anatinus 3 Equus caballus 1
Danio rerio 3 Trepomonas agilis 1
Rattus norvegicus 3 Anoplopoma fimbria 1
Macaca mulatta 2 Helicoverpa zea 1
Bufo japonicus 2 Sus scrofa 1
Callithrix jacchus 2
1 Organism to which protein belongs; 2 The number of differentially expressed proteins originates from one species.
Table 3. KEGG enrichment analysis of DEPs.
Pathway Terms 1 Input Number 2 Background Number 3 Gene Symbol of Input DEPs 4 p-Value
Lysosome 5 123 acp2, lamp1, lgmn, hexb,LOC100496969 0.0049
RNA transport 4 140 thoc6, eif3a, eif4a2, eif4b 0.0292
Glycosaminoglycan
degradation 2 18 LOC100496969, hexb 0.0292
ECM–receptor interaction 3 75 lama2, lamb2, col4a1 0.0292
Metabolic pathways 11 1163
idh3b, rpn2, coq3, pla2g6, lpin1,
ak7, alas2, gamt, hexb,
LOC100496969, acat2
0.0292
Pyruvate metabolism 3 43 acss2.2.L, pc.1.L, ldha.S 0.0338
Focal adhesion 4 191 lama2, lamb2, col4a1, actn1 0.0451
1 Pathway terms in KEGG database; 2 The number of differentially expressed proteins enriched in one of pathway
terms in KEGG database; 3 The total number of differentially expressed proteins in one of pathway terms in KEGG
database; 4 The corresponding gene symbol of differentially expressed proteins enriched in one of pathway terms in
KEGG database.
3. Discussion
3.1. Changes in Proteins Associated with Focal Adhesion and Extracellular Martix
There are three differential expressed proteins enriched in ECM (extracellular matrix)–receptor
interaction pathway through KEGG enrichment analysis, collagen alpha-1 (IV) chain (COL4A1), laminin
subunit alpha 2 (LAMA2), and laminin subunit beta 2 (LAMB2) (Table 3). These different kinds of ECM
and ECM-associated proteins, which bind to cells through ECM receptor, play an important role in
building the complex meshwork of extracellular matrices [13]. Therefore, the assembled manner of these
macromolecules from ECM, including collagens, proteoglycans, laminins, and fibronectin, determine
the structure and function of cell and tissue [14]. Furthermore, the resultant ECM will facilitate the
biological function of a specific tissue. According to previous study, we know that the differential
expression of extracellular matrix (ECM) proteins in tissue-specific cells will perform different biological
processes and molecular functions [15]. Compared with the prehibernation group, COL4A1 protein
in oviduct during the breeding period was upregulated with a 5-fold change. Type IV collagen, along
with related other ECM proteins, is widely distributed in the basement membrane of various specific
tissues [16]. Similarly, the membrane protein relevant to the morphology of oviduct was changed
significantly across the estrous cycle through the bovine oviduct proteome [17]. The morphology of
the oviduct muscle will be changed in COL4A1 mutants, which then causes severe myopathy with
centronuclear myofibers. The lack of biological function because of COL4A1 mutants will lead to
the gradual development of female sterility [18]. Accordingly, COL4A1 protein plays a vital role
in maintaining the structure and function of the oviduct muscle. In our research, the expression
of COL4A1 protein increases significantly during breeding period. Therefore, the upregulation of
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COL4A1 protein in breeding period may be one of notable key factors for Rana chensinensis to allow
the oviduct to maintain optimal morphology for ovulation.
Laminins are heterotrimeric molecules consisting of three subunit chains, named α, β, γ chain,
and they significantly influence the biological processes related to cell adhesion, growth, morphology,
differentiation, and migration [19,20]. There are another two laminin proteins (LAMA2, LAMB2)
enriched in the ECM–receptor interaction pathway. Laminin, as a ubiquitous connective glycoprotein,
is still also the predominant component of basement membrane in a specific tissue [21]. In a previous
study, we know that laminin is the major component of the basement membrane in the oviduct of
Japanese quail [22]. The oviduct is a key site for reproductive events that involve gamete maturation,
fertilization, and early embryo development, processes that finally determine breeding success.
The upregulation of LAMA2 and LAMB2, as important ECM components, could have a positive
influence on the reproduction of Rana chensinensis. In this study, these two upregulated proteins during
breeding period are supposed to be involved in preparing the oviduct for breeding time.
The second highly enriched pathway is focal adhesion, which involves four differentially
expressed proteins. Focal adhesions are integrin-containing, multiplex protein structures that form
mechanical connections between intracellular actin bundles and the extracellular matrix components in
various cell types [23]. Besides three differentially expressed proteins from ECM–receptor interaction
pathway, α-actinin (ACTN1) is enriched in the focal adhesion pathway. A previous research
study has shown that mating will change the expression of α-actinin in Drosophila oviduct [24].
The oviduct muscles are visceral muscles that are supercontractile, meaning they have Z-bands with
perforations that enlarge during contraction. The α-actinin is specific to the Z-band with perforation
of supercontractile muscle, in which it crosslinks actin filaments from adjacent sarcomeres [25].
With mating of Drosophila, the abundance of the muscle protein α-actinin will increase markedly in the
oviduct. The results in our research are consistent with this finding. By comparison with prehibernation
group, the expression of α-actinin in Rana chensinensis oviduct is significantly upregulated during
breeding time. Hence, we get the conclusion that upregulation of α-actinin (ACTN1) will probably
play a vital role in maintaining reproductive function of the oviduct after hibernation.
3.2. Enzymes Involved in Energy Metabolism Pathway
Isocitrate dehydrogenase (NAD) subunit beta is an enzyme that, in humans, is encoded by the
IDH3B gene. As an isocitrate dehydrogenase, IDH3 catalyzes the reversible oxidative decarboxylation
of isocitrate to form α-ketoglutarate (α-KG) and CO2 as part of the tricarboxylic acid (TCA) cycle in
glucose metabolism [26]. This step also participates in the reduction of NAD+ to NADH, which is then
applied to produce ATP through the electron transport chain. Notably, IDH3 acts as NAD-specific
electron acceptor, in contrast to NADP-dependent IDH1 and IDH2 [27,28]. IDH3 activity is regulated
by the energy demands of the cell [27,29]. When the energy metabolism of cells is under insufficiency,
IDH3 is activated by ADP. Conversely, IDH3 is inhibited by ATP and NADH under sufficiency.
According to Karl’s research [30], ATP consuming processes during the breeding period could be
compensated through the upregulation of ATP production. Our research has found that isocitrate
dehydrogenase (IDH3B) was significantly upregulated in the breeding period, which is a method of
upregulation of ATP production. The previous study also showed that the expression of isocitrate
dehydrogenase (IDH) was upregulated in oviduct fluid from ewes during estrus [31]. The energy
metabolism of Rana chensinensis oviduct, as an important site for fertilization, will involve the regulation
of energy substrate and related enzymes during breeding period [32].
In this research, one another upregulated protein in energy metabolism is ubiquinone biosynthesis
O-methyltransferase (COQ3) during the breeding period. This O-methyltransferase (COQ3) played
a part in two steps of the reactions in the biosynthesis of ubiquinone (coenzyme Q). This enzyme
methylated an early coenzyme Q intermediate, 3,4-dihydroxy-5-polyprenylbenzoic acid, as well as
the final intermediate in the pathway, converting demethylated ubiquinone to coenzyme Q [33].
It is a component of the electron transport chain, and participates in aerobic cellular respiration,
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which generates energy in the form of ATP [34]. The complex process of fertilization required energy,
which is produced by mitochondria mostly via oxidative phosphorylation [34,35]. To compensate for
excess energy consumption during the breeding period, the efficiency of electron transport chain was
improved through the upregulation of O-methyltransferase.
Guanidinoacetate N-methyltransferase (GAMT) is an enzyme that converts guanidinoacetate to
creatine, and is encoded by the gene GAMT. Creatine is involved in recycling of adenosine triphosphate
(ATP), the energy currency of the cell, primarily in muscle and brain tissue. This is achieved by recycling
adenosine diphosphate (ADP) to adenosine triphosphate ATP via donation of phosphate groups [36].
Maternal creatine homeostasis was influenced by the expression of creatine biosynthesis-related
enzymes. In a previous study, the expression of GAMT protein in heart and brain tissue was decreased
in pregnant spiny mouse [37]. The finding in our research showed that the expression of GAMT was
also downregulated in breeding period. Without feeding during the hibernation and breeding periods,
L-arginine and glycine, as staring material of creatine biosynthesis, were inevitably at low levels in
Rana chensinensis. Hence, the expression of GAMT was down-regulated due to deficiency of starting
material. Accordingly, this result indicated that creatine biosynthesis pathway was switched off.
Adenylate kinase 7 (AK7) is a member of the adenylate kinase family of enzymes, which catalyzes
the reversible phosphorylation of adenine nucleotides. It has been proven that adenylate kinase (AK)
isoforms have an essential role in ciliary function and energy homeostasis [38], and mutations of
AK7 in the mouse result in primary ciliary dyskinesia [39]. The tissue specificity of Ak7, which is
abundant in trachea and oviduct, has been found by Fernandez-Gonzalez et al. [39]. The expression
profile of genes related to the ciliary function of the oviduct have been analyzed in porcine oviduct
transcriptome [40]. It has reported that differentially expressed genes (DEGs) of porcine oviduct
were enriched in GO term “cell motion” in preovulatory phase [40]. Our research has shown that
AK7 expression was upregulated in oviduct during the breeding period. It is known that eggs in the
ovary of Rana chensinensis undergo the last stages of oogenesis, and are then released into the body
cavity. Finally, they are driven into the oviduct by ciliary action. In order to maintain ciliary action,
AK7 provided an efficient way to transport energy from ATP production sites to the ciliary of oviducts.
Hence, upregulation of AK7 will help eggs of Rana chensinensis to be transferred into oviduct through
ciliary movement.
3.3. Enzymes Changed in Pyruvate Metabolism Pathway
There are three differentially expressed proteins enriched in pyruvate metabolism pathway.
In contrast to prehibernation period, the expression level of pyruvate carboxylase (PC.1) and lactate
dehydrogenase A (LDHA.S) during breeding period were upregulated and acetyl-CoA synthase
(ACSS2.2) was downregulated. The environmental hypoxia during hibernation period contributed to
metabolic acidosis in amphibians, and increased lactate concentrations in amphibian tissues [41,42].
Hence, lactate levels during breeding time should be significantly higher in Rana chensinensis oviduct
after long hibernation times, compared with prehibernation period. The upregulated expression of
lactate dehydrogenase A (LDHA) in breeding time will catalyze the transformation from lactate to
pyruvic acid when environmental stress in hibernation period is relieved [43]. Moreover, the upregulation
of pyruvate carboxylase will increase the production of oxaloacetate (OAA), which can be converted
to phosphoenolpyruvate in gluconeogenesis, or directly enter into the TCA cycle [44]. Without eating
in hibernation and breeding period, the gluconeogenesis pathway will consume the accumulation of
lactate in hibernation period to reduce metabolic acidosis and increase adipose [45,46]. Accordingly,
we predict that the gluconeogenesis pathway is potentially at an active stage in breeding time
to decrease lactate levels in oviduct tissue. Acetyl-CoA synthetase, which is downregulated in
breeding time, plays key roles in the production of acetyl-CoA from free acetate for the synthesis
of fatty acid [47]. The expression of acetyl-CoA synthetase drops down when animals are starved,
which leads to a decline in fatty acid synthesis [48]. While animals was refed with high carbohydrate
diet, the upregulated expression of acetyl-CoA synthetase will increase fatty acid synthesis [48].
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Due to no eating during the whole breeding time, the deficiency of carbon source could lead to the
downregulation of acetyl-CoA synthetase.
3.4. Down-Regulation of Lipid Metabolism during Breeding Period
Lipin-1, encoded by the LPIN1 gene, possesses phosphatidate phosphatase activity [49]. In the
mouse, the expression of lipin-1 is at high levels in adipose tissue and skeletal muscle, consistent with
functions in lipid metabolism in these specific tissues. Actually, adipocytes in lipin-1-deficient mice
fail to accumulate triacylglycerol (TAG), and do not develop mature adipocyte function [50]. In this
study, the expression of lipin-1 was downregulated in the oviduct tissue during the breeding period.
Accordingly, the accumulation of triacylglycerol significantly decreased. As a result, the morphology
of oviduct appeared to be in a shriveled state, due to this reason. Another protein related with lipid
metabolism, calcium-independent phospholipase A2 (PLA2G6), is also downregulated. PLA2 enzyme
is involved in phospholipid metabolism, which is very important for many biological processes,
including resembling cell membrane during cell cycle [51]. PLA2G6 helps to regulate the levels of
phosphatidylcholine, which is a major membrane phospholipid [52]. Downregulation of PLA2G6
expression inhibited cell proliferation in culture, and tumorigenicity of ovarian cancer cell lines in
nude mice [53]. Another reason for the shriveled state of the oviduct is that cell proliferation in
Rana chensinensis oviduct was suppressed by the downregulation of PLA2G6 in the breeding period.
Acetyl-CoA acetyltransferase 2 (ACAT2), an enzyme converting cholesterol and fatty acid to
cholesteryl esters, is involved in lipid metabolism [54]. The previous study shows that cholesterol and
fatty acid stabilize ACAT2, which is ubiquitylated on cystine residue to degrade [55]. Lipids including
cholesterol and fatty acid induce the generation of reactive oxygen species, which oxidize Cys277 of
ACAT2, and subsequently prevent ACAT2 from degradation [55,56]. A low level of lipid induced
ubiquitylation on Cys277 for degradation of ACAT2. Accordingly, the downregulation of ACAT2
protein in this study indicated that the concentration of sterol and fatty acid was at a relatively low
level in the breeding period.
3.5. Expression of 5-Aminolevulinate Synthase (ALAS2) in Heme Biosynthesis
The expression of 5-aminolevulinate synthase (ALAS2) was upregulated during the breeding
period. ALAS is the rate-limiting enzyme in protoporphyrin IX (PPIX) production, which is the final
intermediate in the heme biosynthetic pathway. Transcription of ALAS2, unlike ALAS1, is regulated
by erythroid-specific transcription factors, such as GATA1 [57]. Regarding the post-transcription
of ALAS2, it is affected by the content of iron. In the absence of iron, the iron-free form of iron
regulatory protein (IRP) binds to iron regulatory element (IRE), forming an IRE–IRP complex that
prevents translation of ALAS2 [58]. Heme, also as a downregulation factor, inhibits the translation of
ALAS2 and the import of ALAS2 precursor into mitochondria [59]. According to our results about the
expression of ALAS2, we concluded that the content of heme in oviduct tissue is at low levels after
hibernation. Otherwise, the expression of ALAS2 was inhibited by the adequate heme.
4. Materials and Methods
4.1. Animals and Treatment Procedure
In this study, we performed iTRAQ proteomic analysis to identify differentially expressed proteins
from the oviduct of female Rana chensinensis between the breeding period and the prehibernation period.
Sixty adult female Rana chensinensis were obtained in April (n = 30, the breeding period), and October
(n = 30, the prehibernation period), 2017 from Jilin Province (125◦16′57” E~131◦19′12” E, 40◦51′55”
N~44◦38′54” N), China. All animals were treated in strict accordance with the recommendations in
the Guide for the International Cooperation Committee Animal Welfare (ICCAW). All experimental
procedures were approved by the Committee on the Ethics of Animal Experiments of Changchun
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University of Chinese Medicine. Frogs were anesthetized by diethyl ether. Each pair of oviducts was
collected from Rana chensinensis.
4.2. Protein Extraction, Digestion, and iTRAQ Labeling
Each sample of 20 mg were frozen in liquid nitrogen and ground with a mortar and pestle.
One milliliter of 10% TCA/acetone (v/v, 1:9) was added to the powder, and mixed by vortexing.
The mixture was placed at −20 ◦C for 4 h, and then the precipitate was washed with acetone at 4 ◦C,
until colorless. The resulting pellet was resolubilized in STD buffer (4% SDS, 100 mM DTT, 150 mM
Tris-HCl, pH 8.0). The protein concentration was measured by the BCA Protein Assay kit (Beyotime,
Hangzhou, China). Proteins were digested according to the FASP method [60]. The resulting mixture of
each sample was labeled using iTRAQ reagent according to the manufacturer’s instructions (Applied
Biosystems, Branchburg, NJ, USA). The samples of Rana dybowskii oviduct in prehibernation period
were labeled with iTRAQ tag 113 (A) and 114 (B), and samples from the breeding period were labeled
with iTRAQ tag 115 (C) and 116 (D).
4.3. Peptide Fractionation with Strong Cation Exchange (SCX) Chromatography
The peptide mixture was constituted again and acidified with buffer A (10 mM KH2PO4 in 25% of
ACN, pH 3.0), and loaded onto a polysulfethyl column (5 μm, 4.6 × 100 mm, 200 Å, PolyLC Inc.,
Columbia, MD, USA). The peptides were fractionated at a flow rate of 1 mL/min with a gradient of
0–10% buffer B (500 mM KCl, 10 mM KH2PO4 in 25% of ACN, pH 3.0) for 30 min, 10–60% buffer B
during 30–50 min, 60–100% buffer B during 50–55 min, 100% buffer B during 55–60 min, and finally,
buffer B was set to 0% after 60 min. The detector was set at 214 nm, and fractions were collected every
1 min. The collected fractions were desalted on C18 Cartridges (Empore™ SPE Cartridges C18, Sigma,
St. Louis, MO, USA) and concentrated by vacuum centrifugation.
4.4. LC-MS/MS Analysis
Experiments were performed as described previously [61] using a Q Exactive mass spectrometer
coupled to Easy nLC (Thermo Fisher Scientific, Waltham, MA, USA). Ten microliters of each fraction
was injected for nano LC-MS/MS analysis. The peptide mixture (5 μg) was loaded onto a the
C18-reversed phase column (3μm, 75 μm × 10 cm) in buffer A (0.1% formic acid) and separated
with a linear gradient of buffer B (80% ACN and 0.1% formic acid) at a flow rate of 250 nL/min
controlled by IntelliFlow technology over 140 min. MS data was acquired using a data-dependent
top10 method dynamically. The duration of dynamic exclusion was 60 s. Survey scans were acquired
at a resolution of 70,000 at m/z 200 and the resolution for HCD spectra was set to 17,500 at m/z 200.
Normalized collision energy was 30 eV and the underfill ratio, which means the minimum percentage
of the target value at maximum fill time, was set to 0.1%. The instrument was run with peptide
recognition mode enabled.
4.5. Protein Identification and Data Analysis
In our previous study, the transcriptome of OR was sequenced, and the corresponding unigenes
were generated [62]. In the present study, the amino acid sequences translated from the CDS of
unigenes were used as the protein database. The raw files were analyzed using the Proteome Discoverer
1.3 software (Thermo Electron, San Jose, CA, USA). A search for the fragmentation spectra was
performed using the MASCOT search engine [63]. The results were filtered based on a false discovery
rate (FDR) of no more than 0.01. The protein identification was supported by at least one unique
peptide. Isobaric Labeling Multiple File Distiller and Identified Protein iTRAQ Statistic Builder were
applied to calculate the ratios of protein, in which REF was used as the reference, based on the
weighted average of the intensities of report ions in each identified peptide [64]. The final ratios
were then normalized with the median average protein ratio, assuming that most proteins remained
unchanged in abundance. Protein ratios represent the median of the unique peptides of the protein [65].
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For statistical analysis, two-way ANOVA was performed for each protein, and Student’s t-test was
used to evaluate the significant differences. The differentially expressed proteins ratio meets the fold
change (≥2.0 or ≤0.5, at p < 0.05).
4.6. Bioinformatics Analysis of Differentially Expressed Proteins
We carried out gene ontology (GO) annotation analysis on the differentially expressed proteins
to catalog the molecular functions, biological processes, and cellular components [66]. Mapping the
function of Blast2GO (Version 3.3.5) was applied to determine GO terms correlated with DEPs [67].
To further explore the interaction of differentially expressed protein physiological process in the
body and discover relationships between DEPs, KEGG enrichment analysis was performed based
on KOBAS server (Version 3.0) [11,12]. KEGG pathway enrichment analyses were applied based on
the Fisher’ exact test, considering the whole quantified protein annotations as background dataset.
Only functional categories and pathways with p-values under a threshold of 0.05 were considered
as significant.
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Abstract: A targeted proteome analysis was conducted to investigate the SigE dependent-regulation
of central metabolism in Synechocystis sp. PCC 6803 by directly comparing the protein abundance
profiles among the wild type, a sigE deletion mutant (ΔsigE), and a sigE over-expression (sigEox)
strains. Expression levels of 112 target proteins, including the central metabolism related-enzymes and
the subunits of the photosystems, were determined by quantifying the tryptic peptides in the multiple
reaction monitoring (MRM) mode of liquid-chromatography–triple quadrupole mass spectrometry
(LC–MS/MS). Comparison with gene-expression data showed that although the abundance of Gnd
protein was closely correlated with that of gnd mRNA, there were poor correlations for GdhA/gdhA
and glycogen degradation-related genes such as GlgX/glgX and GlgP/glgP pairs. These results
suggested that the regulation of protein translation and degradation played a role in regulating
protein abundance. The protein abundance profile suggested that SigE overexpression reduced
the proteins involved in photosynthesis and increased GdhA abundance, which is involved in
the nitrogen assimilation pathway using NADPH. The results obtained in this study successfully
demonstrated that targeted proteome analysis enables direct comparison of the abundance of central
metabolism- and photosystem-related proteins.
Keywords: central carbon metabolism; targeted proteome analysis; NAPDH balance; Synechocystis sp.
PCC 6803; sigE
1. Introduction
As a photosynthetic organism, cyanobacteria can be used as a host organism for the direct
production of bioenergy and chemicals from solar energy and CO2 [1–4]. A model cyanobacteria,
Synechocystis sp. PCC 6803, can adapt metabolically to environmental perturbations by modulating
protein expression levels [5,6]. A sigma factor, SigE, is a global regulator of central carbon metabolism,
whose expression is induced under nitrogen-starved conditions in an NtcA-dependent manner [7–11].
The expression of SigE is also induced at the end of day time or 12 h after light exposure, suggesting
that SigE is responsible for a metabolic regulation required to survive in dark conditions [12].
For a detailed investigation of SigE functions, Synechocystis sp. PCC 6803 strains lacking
(ΔsigE) and over-expressing (sigEox) the sigE gene have been constructed in previous studies [10,13].
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Transcriptome analysis of the ΔsigE strain under normal photoautotrophic conditions showed that
the expression levels of genes involved in the pentose phosphate pathway (zwf, gnd, tal, and opcA),
glycolysis (gap1, pfkA (sll1196), and pyk1), and glycogen degradation (glgX (slr0237), glgP (sll1356)) were
reduced by the loss of SigE function [10]. These sugar-metabolism genes that were down-regulated
in the ΔsigE strain were also down-regulated in ΔsigCDE [14]. It was also reported that sigE
over-expression in the sigEox strain induced an increase in the expression of genes in the pentose
phosphate pathway (zwf, gnd, tal, and opcA) and glycogen degradation pathways (glgX and glgP) [13].
These findings indicated that SigE is a global positive regulator of genes in the pentose phosphate
and glycogen degradation pathways. Gene-expression analysis also suggested that the degradation of
glycogen into glucose and the regeneration of NADPH by the oxidative pentose phosphate pathway
were activated under dark conditions by the function of SigE. NADPH would be used for the
maintenance of vital functions in dark conditions instead of being supplied from the photosystem.
A proteome-level analysis is required for a more detailed investigation of the metabolic
regulation mechanism. Western blotting analysis of the sigEox strain showed that the expression
of enzyme proteins in the oxidative pentose phosphate pathway (Zwf, Gnd) and glycogen degradation
pathways (GlgX and GlgP) increased and were consistent with that of gene-expression data [13,15].
A more comprehensive analysis is required because proteome analysis has disclosed the multiple
post-transcriptional mechanisms that play important roles in the regulation of protein expression,
protein–protein interactions, signaling, and enzymatic activity [16–18]. Thus, in this study,
the SigE-dependent regulation of central metabolism in Synechocystis sp. PCC 6803 was confirmed by
the targeted proteome analysis for the direct comparison of the protein abundance profiles among the
wild-type (WT), ΔsigE, and sigEox strains.
Shotgun proteomics has been employed for the discovery of novel regulation mechanisms in
Synechocystis sp. PCC 6803 [19–23]. For instance, 45% of Synechocystis proteins were simultaneously
identified and quantified by shotgun proteomics [20]. Data analysis showed that 155 proteins
were differentially expressed across autotrophic, heterotrophic, photoheterotrophic and mixotrophic
conditions [20]. On the other hand, targeted proteomics is a method for sensitive, precise quantification
of expression levels of preselected proteins [24,25]. In targeted proteomics, a crude protein extract from
cyanobacteria cells is digested by trypsin [26]. Expression levels of target proteins are determined by
quantifying amounts of the preselected tryptic peptides by the selected or multiple reaction monitoring
(MRM) mode of triple quadrupole mass spectrometry. The MRM assay method for cyanobacteria
has been comprehensively developed for the central metabolism-related enzymes [27,28]. Targeted
proteome analysis using the MRM assay method successfully quantified more proteins than shotgun
proteome analysis in Synechocystis sp. PCC 6803 grown in iron-deficient conditions [29].
In this study, a targeted proteome analysis was conducted to measure directly the abundance
of 144 target proteins in the central metabolism related-enzymes and the photosynthetic apparatus.
The protein abundance data, including 112 proteins, were successfully obtained from the WT, ΔsigE,
and sigEox strains cultured under photoautotrophic conditions to understand the SigE-dependent
regulation of central metabolism and photosynthesis at the protein layer. The results showed that
one of the most important roles of SigE was as a positive regulator of oxidative pentose phosphate
pathway (OxPPP) activity and NADPH reproduction, because the abundances of Gnd in OxPPP and
NADPH/NADP+ ratios were significantly changed in ΔsigE and sigEox. The protein abundance profile
also suggested that SigE overexpression increases GdhA abundance, which is involved in the nitrogen
assimilation pathway using NADPH and downregulates the proteins involved in photosynthesis.
Those results confirmed the SigE-dependent regulation of the C/N balance at the proteome level in
Synechocystis sp. PCC 6803.
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2. Results and Discussion
2.1. Targeted Proteome Analysis of Wild-Type, sigE Deleted and Overexpressed Strains of Synechocystis sp.
PCC 6803
Three strains of Synechocystis sp. PCC 6803, WT, sigE-deleted (ΔsigE), and overexpressed
(sigEox) strains were cultivated in flasks under photoautotrophic conditions with continuous light
at 40 μmol m−2 s−1. Modified BG11 medium containing 5 mM NH4Cl as a nitrogen source was
employed throughout this study. The culture profile data (Figure 1) showed that cells actively grew
until 48 h after the start of cultivation. Although the cell growth rate was reduced after 48 h, cell density
was gradually increased and reached an OD730 = 2–3 (WT: 2.4, ΔsigE: 2.8, and sigEox: 2.3) at 168 h.
The growth curves of the three strains including WT, ΔsigE, and sigEox were essentially similar to each
other, as demonstrated in previous studies [10,13].
 
Figure 1. Cell growth curve of wild-type (WT), sigE deleted (ΔsigE) and overexpressed (sigEox) strains
of Synechocystis sp. PCC 6803. Flask-scale cultivations were performed in modified BG11 medium
containing 5 mM NH4Cl as a nitrogen source under photoautotrophic conditions with continuous light
at 40 μmol m−2 s−1. Means of triplicate cultivations were represented with standard deviations.
For the targeted proteome analysis, crude protein extracts were obtained from cells collected
at mid-log phase (OD730 = 0.4–0.7). Following reductive alkylation and digestion by trypsin,
the tryptic peptide samples were served for the nano liquid-chromatography–triple quadrupole
mass spectrometry (LC–MS/MS) analysis. Here, we employed a series of MRM assay methods with
3065 channels to analyze 686 tryptic peptides derived from 144 target proteins including enzyme and
subunit proteins responsible for central metabolism and photosynthetic apparatus (Table S1). In order
to compare protein levels precisely, fully 15N-labeled tryptic peptide samples were prepared from WT,
ΔsigE, and sigEox strains grown in modified BG11 medium containing 15NH4Cl as the nitrogen source.
The fully 15N-labeled tryptic peptide samples were used as internal standards. The tryptic peptides,
whose signals were commonly observed among 3 strains in the targeted proteomics data with the
largest signal-to-noise ratios, were employed for protein quantification (Table S2). The MRM assays
in this study successfully determined the levels of tryptic peptides derived from the 112 proteins
(Table S2, Figures S1–S5). Because the signal change of multiple peptides constituting one protein were
not significantly different, one of these peptides was selected as a representative for the quantification
of protein (Figures S1–S4).
Figures 2 and 3 show the heat map representations of the fold change in the relative abundance
of central metabolic enzymes (Figure 2) and photosynthetic proteins (Figure 3) in ΔsigE (ΔsigE/WT)
and sigEox (sigEox/WT) compared to those in WT. The enzyme abundance profiles were compared by
volcano plots using thresholds with fold of change (FC) > 1.5, FC < 0.667 and p value < 0.05 (Figure 4).
The comparison of the protein abundance levels of 112 target proteins between WT and ΔsigE showed
that the abundances of four proteins decreased in ΔsigE including Fda, Gnd, TalB, and GltA (Figure 4A).
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Although it was not statistically significant, the abundance of CbbA increased in ΔsigE (Figure 2).
Although GltA is an enzyme for citrate synthase in the tricarboxylic acid (TCA) cycle, four proteins
including CbbA, Fda, Gnd, and TalB were commonly responsible for the Calvin–Benson cycle and
the OxPPP.
The protein abundance profile data showed that two enzymes in the pentose phosphate
pathway (PPP), Gnd and TalB, were upregulated in sigEox, whereas abundances of these enzymes
were decreased in ΔsigE (Figure 2, Figure 4). These results suggested that the expression of Gnd
and TalB are positively regulated by SigE. Furthermore, the relative abundances of Fda (Slr0943,
fructose-1,6-bisphosphate aldolase, class I) levels decreased in both the ΔsigE and sigEox strains
while the expression of another aldolase, CbbA (Sll0018, fructose-1,6-bisphosphate aldolase class II),
was negatively regulated by SigE (Figure 2, Figure 4). These results suggested that two aldolases,
Fda and CbbA, had distinct roles in regulating the Calvin–Benson cycle. Indeed, it has been reported
that sedoheptulose-1,7-bisphosphate (SBP) in addition to fructose-1,6-bisphosphate (FBP) could be
a substrate of both Fda and CbbA. However, the SBP/FBP activity ratio of the CbbA was two times
higher than that of the Fda [30]. The up- and down-regulation of proteins, however, did not affect the
normal cell metabolic functions, as the three strains showed similar growth curves (Figure 1).
 
Figure 2. Effect of sigE deletion and overexpression on the expression of the central metabolism
proteins of Synechocystis sp. PCC 6803. Relative expression levels [ΔsigE/WT (A) and sigEox/WT (B)]
of proteins determined by the targeted proteome analysis are represented by heat maps. Asterisks
indicate a significant difference in terms of both two-sided Student’s t-test (α 0.05) and the fold increase
(>1.5 and <0.67).
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Figure 3. Effect of sigE deletion and overexpression on the expression of photosystem-related proteins
in Synechocystis sp. PCC 6803. Relative expression levels [ΔsigE/WT (A) and sigEox/WT (B)] of
proteins determined by the targeted proteome analysis were represented by heat maps. Asterisks
indicate a significant difference in terms of both two-sided Student’s t-test (α 0.05) and the fold increase
(>1.5 and <0.67).
 
Figure 4. Volcano plot for finding proteins whose abundances were significantly changed in terms
of both two-sided Student’s t-test (α 0.05) and the fold increase (>1.5 and <0.67). (A) ΔsigE vs. WT.
(B) sigEox vs. WT. Values are means of three independent experiments.
99
Molecules 2018, 23, 1051
2.2. Comparison with the Gene-Expression Data
The relative protein abundance levels determined by the targeted proteome analysis in this study
were compared with the gene-expression data obtained by the transcriptome analysis performed in a
previous study (Figure 5). As shown in the above section, the abundances of Gnd protein in ΔsigE and
sigEox strains were significantly lower and higher than that of WT, respectively. Essentially identical
patterns were observed for gnd mRNA expression levels determined by the previous microarray
analysis (Figure 5). The similarities between protein abundance and gene-expression patterns were
also observed for Zwf/zwf and TalB/talB in the PPP, and CbbA/cbbA, and Gap1/gap1 in glycolysis
(Figure 5). For instance, protein abundances of GlnA and GdhA in the nitrogen assimilation pathway
were different from that of the corresponding genes (Figure 5). Furthermore, the microarray analyses
in the previous studies pointed out that the expression levels of glycogen degradation-related genes
such as glgX (slr0237) and glgP (sll1356) were significantly changed by the regulation of sigE. However,
this regulation was not observed in protein levels as the relative protein abundances of GlgP and GlgX
were different from those of gene expressions (Figure 5). Although this discrepancy may be derived
from differences in culture conditions (shaking flask in this study vs. bubbling flask in the previous
study), results also suggested that the regulation of protein translation and degradation played a role
in regulating protein abundance.
 
Figure 5. Comparison between gene expression and protein abundance in the wild-type (WT), ΔsigE,
and sigEox strains. The gene expression data obtained by the microarray analysis was obtained from a
previous study [13]. Values are means ± standard deviation (SD) of three independent experiments.
Asterisks indicate a significant difference assessed with two-sided Student’s t-test with an α level
of 0.05.
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2.3. Effect of sigE Deletion and Overexpression on NADPH/NADP+ Ratio
The targeted proteome analysis revealed that among the investigated proteins, the abundance of
proteins in the PPP, such as Gnd and TalB, were most significantly and directly affected by SigE deletion
and overexpression (Figure 2, Figure 4). The direct measurement of protein abundance confirmed that
the activation and inactivation of the PPP via Gnd and TalB expression was a key mechanism in the
SigE-dependent metabolic regulation in Synechocystis sp. PCC 6803.
Although TalB (transaldolase) is a part of the Calvin–Benson cycle for carbon fixation,
Gnd (gluconate-6-phosphate dehydratase) is responsible for NADPH regeneration in the OxPPP.
Therefore, the SigE-dependent regulation of Gnd level could affect the NADPH regeneration rate.
The NADPH/NADP+ assay shown in Figure 6A showed that the NADPH/NADP+ ratio in sigEox
was 1.33 times larger than that of ΔsigE, and that the NADPH/NADP+ ratios in ΔsigE and sigEox
tended to decrease and increase compared to that of wild type, respectively. These results revealed
that the abundance of Gnd in the OxPPP was significantly under the control of SigE and that changes
in Gnd abundance should affect the NADPH balance via the OxPPP. It has been demonstrated that
the metabolic flux level in the OxPPP is up-regulated by treatment with the PSII inhibitor, DCMU
[3-(3,4-dichlorophenyl)-1,1-dimethylurea]. In photoheterotrophic conditions, cyanobacteria utilize
glucose or glycogen as carbon sources and survive by reproducing NADPH through the OxPPP [31,32].
 
Figure 6. Effect of sigE deletion and overexpression on phenotypes of Synechocystis sp. PCC 6803.
(A) NADPH/NADP+ ratio. (B) NH3 concentration in the medium. Values are means ± SD of three
independent experiments. Differences were assessed with two-sided Student’s t-tests with an alpha
level of 0.05. Asterisks indicate a significant difference (p < 0.05). (C) UV-VIS spectra. Absorbance
levels were normalized as ABS730 as 1.0.
2.4. SigE-Dependent Regulation of the Nitrogen Assimilation Pathway
In cyanobacteria, ammonium is incorporated into 2-oxoglutarate (2-OG) via the glutamine
synthetase (GS, GlnA) and glutamate synthase (GOGAT, GltB) cycle, known as the GS–GOGAT
pathway [33]. The GS-GOGAT cycle is regulated by the global nitrogen assimilation regulator NtcA.
Alternatively, ammonium can be incorporated directly into glutamate by NADP-dependent glutamate
dehydrogenase (GdhA), in a less efficient but less energy-consuming manner [34]. The targeted
proteome analysis performed in this study showed that the abundance of GdhA was significantly
changed in ΔsigE strains (Figure 2, Figure 4). The increase in GdhA abundances in sigEox strains should
associate with the regulation of the OxPPP as GdhA consumes NADPH for the nitrogen assimilation
in Synechocystis sp. PCC 6803 [35]. However, increased expression of the gdhA gene was not found in
the previous transcriptome analysis (Figure 5), suggesting that the regulation of GdhA abundance was
sensitive to culture conditions and that protein translation and degradation play a role.
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In order to confirm the effect of sigE deletion and over-expression on nitrogen assimilation, WT,
sigEox, and ΔsigE strains were cultivated again under the same conditions to determine concentrations
of remaining ammonium in the medium (Figure 6B). The analysis showed that the ammonium
concentration of ΔsigE at 48 h was 4.3 mM, which was 1.11 times larger than that of WT (Figure 6B).
On the other hand, the concentration of remaining ammonium in the sigEox strain was similar to that
of WT. Similar results were also observed at 144 h (Figure 6B). Those results suggested that deleting
SigE could reduce nitrogen assimilation, probably by decreasing the GS-GOGAT pathway genes such
as GdhA abundance and NADPH supply from the oxidative pentose phosphate pathway.
2.5. Protein Abundance Profiles of the Photosynthetic Apparatus
It was expected that the assimilated nitrogen was mainly used for the biosynthesis of proteins
such as the photosynthetic apparatus. The volcano plot of the targeted proteome data (Figure 4)
showed that the abundance of PsbO, RubA, AtpA and PetE was significantly decreased in the sigEox
strains. PsbO is a manganese-stabilizing polypeptide in PSII that binds to a putative Mn-binding
protein and keeps 2 of the 4 Mn-atoms. The absence of PsbO in Synechocystis affects the coordination
of photosynthesis/respiration [36]. RubA is an iron-sulfur protein (rubredoxin) responsible for the
assembly of PSI [37]. AtpA is the alpha subunit of ATP synthase. PetE is a plastocyanin that participates
in electron transfer between P700 and the cytochrome b6-f complex in PSI [38]. The abundances of
antenna proteins such as ApcA, ApcB and ApcC tended to decrease in the sigEox strain although this
effect was not statistically significant.
The comparison of ultraviolet–visible (UV–VIS) spectra among the WT, sigEox, and ΔsigE strains
revealed that the absorbance spectrum of ΔsigE was essentially similar to that of WT (Figure 6C).
The result was consistent with the targeted proteome data as the abundance of the photosystem-related
proteins was not significantly changed in ΔsigE. On the other hand, the absorbance of the carotenoid,
the phycocyanin and the chlorophyll in the photosynthetic apparatus (about 550 nm, 630 nm and
680 nm, respectively) was reduced in sigEox, suggesting that photosynthetic apparatus construction
was disturbed by SigE overexpression. In particular, the significant decrease of the carotenoid is
consistent with the previous studies in which photosynthesis activity was decreased under high light
conditions and the activity of non-photochemical quenching (NPQ) was down-regulated in the sigEox
strain [15,39]. The decrease of the carotenoid may be related to the fact that metabolic flow was
directed to synthesis of the polyhydroxybutyrate (PHB) [15]. However, the photosynthesis activity
was maintained under usual light [39]. Accordingly, NADPH/NADP+ ratio in sigEox strain was
not significantly different from WT strain (Figure 6A). In sigEox strain, PPP and gdhA expression
were much higher and photosystems expression were lower than in WT, but NADPH/ NADP+ ratio,
nitrogen assimilation and growth rate were not different. These results indicate that NADPH from
PPP reduces the need from photosynthesis.
The down-regulation of photosynthetic apparatus could be explained in the context of the
C/N balance [40]. As the photosynthetic apparatus are the most abundant protein complexes
in cyanobacteria, it has been considered that antenna proteins could be a nitrogen sink in these
species. For instance, phycobilisome and the associated linkers are degraded to supply nitrogen
under conditions of N starvation [41]. It was reported that degradation of the nitrogen-rich
phycobilisomes starts 12 h after nitrogen starvation [42], and also that reduced CO2 fixation leads to
the down-regulation of genes encoding proteins involved in nitrogen assimilation [43]. The targeted
proteome analysis conducted in this study suggested that sigE globally regulated the metabolism
to increase nitrogen assimilation in sigEox. These results suggested that the overexpression of sigE
mimicked the nitrogen-limiting condition in Synechocystis cell. This is consistent with in the previous
studies, in which sigE plays a role in recovery from nitrogen deprivation [44–46]. Decreases in the
antenna protein would be compensated by improved light reaction efficiency in the photosystem.
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3. Materials and Methods
3.1. Bacterial Strains and Culture Conditions
Synechocystis sp. PCC 6803 GT strain, isolated by Williams [47], the ΔsigE strain [10] in which
the sigE (sll1689) gene in the genome was disrupted, and the sigEox strain [13] which constitutively
expresses the gene were used in this study. These strains were grown in modified BG11 medium,
containing 5 mM NH4Cl as a nitrogen source. Cells were grown in 100 mL of medium in 500 mL
Erlenmeyer flasks for batch culture under photoautotrophic conditions under continuous light (about
40 μmol m−2 s−1) and 34 ◦C, and cells in the linear growth phase (OD730 = 0.4–0.7) [48] were collected
for analysis. Kanamycin (10 μg mL−1) was added in the precultures of ΔsigE and sigEox.
3.2. Sample Preparation for Proteome Analysis
Total proteins were extracted as described in Picotti et al. [49]. Cell-culture medium containing
cells in the logarithmic growth phase (100 mL, OD730 = 0.4–0.7) was collected by centrifugation
(5000× g, 4 ◦C, 5 min). Pellets were resuspended in 1 mL of lysis buffer [50 mM HEPES, 15% Glycerol,
15 mM DTT (Dithiothreitol), 100 mM KCl, 5 mM EDTA (Ethylenediamine-N,N,N′,N′-tetraacetic acid,
disodium salt, dihydrate), and one cOmplete protease inhibitors cocktail (Roche, Basel, Switzerland)].
The suspension was transferred to an Eppendorf tube containing zirconia beads (0.6 and 6 mm
beads) and disrupted with a Beads Crusher μT-12 (TAITEC, Saitama, Japan) (3000 min−1, 6 min).
The resulting solution was centrifuged (15,000 rpm, 4 ◦C, 5 min), and the supernatant was transferred
to a proteomics Eppendorf tube (protein low-adsorption tube) to obtain protein extraction samples.
The protein concentration of the extracted sample was measured by the Bradford method, and the
total protein amount was adjusted to 50 μg. Denatured buffer (500 mM Tris-HCl, 10 mM EDTA, 7 M
Guanidine HCl) was added to the adjusted sample to a total volume of 220 μL.
3.3. Reduction and Alkylation/Methanol Chloroform Precipitation
One microliter of 50 mg mL−1 DTT was added and shaken at room temperature for 1 h using a
tube mixer (CM-1000 Cute Mixer, EYELA, Tokyo, Japan), then 2.5 μL of 50 mg mL−1 iodoacetamide
(IAA) was added and shaken for 1 h to reduce/alkylate the proteins. Next, the proteins were purified
by methanol/chloroform precipitation. Proteins were purified as described in Wessel and Flügge [50].
Cold methanol (600 μL) was added to the sample solution and mixed by inversion, then 150 μL of cold
chloroform was added and mixed by inversion. Cold milli-Q water (450 μL) was added and mixed
by inversion, followed by centrifugation (15,000 rpm, 4 ◦C, 5 min). The upper layer was removed,
and 450 mL of cold methanol was added and mixed gently by inversion. After centrifuging (15,000 rpm,
4 ◦C, 5 min) using a swing rotor, the supernatant was removed then additional centrifugation
(15,000 rpm, 4 ◦C, 1 min) was performed to completely remove the supernatant.
3.4. Trypsin/LysC Digestion
Trypsin hydrolyzed the ester bonds on the carboxyl side of Arg and Lys and LysC on the carboxyl
side of Lys. With trypsin alone, Lys which can not be leaved remains, but by combining LysC,
the overall degradation efficiency and reproducibility are improved. Trypsin/LysC digestion was
performed as described previously [26]. To the supernatant obtained from the above steps, 9 μL of
6 M urea was added and shaken for about 10 min at room temperature using a tube mixer. Thirty-six
microliters of 0.1 M Tris-HCl (pH 8.5) was added and ultrasonic treatment and standing on ice were
repeated twice for 30 s using an ultrasonic washer (Branson 2510, Danbury, CT, USA) to resuspend
the protein precipitate. One microliter of 0.5 mg mL−1 LysC solution and 2.5 μL of 1% Protease
Max solution ware added and mixed by tapping, then incubated at 25 ◦C for 3 h. One microliter of
0.5 mg mL−1 trypsin solution was added and mixed by tapping, then incubated at 37 ◦C for 16 h.
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3.5. Desalting Samples
Sample desalination was performed as described previously [51–53]. Milli-Q water (7.5 μL)
and 3 μL of 50% formic acid aqueous solution were added to the trypsin digestion product, and
the mixture was stirred with a vortex mixer and centrifuged (15,000 rpm, 4 ◦C, 5 min). Fifty-eight
microliters of the supernatant were obtained as a result. In order to carry out relative quantitative
analysis, 15N samples, obtained by culturing Synechocystis sp. PCC 6803 in BG11 medium whose
nitrogen source was replaced with 15NH4Cl, and 14N samples were mixed so that the protein amount
became 1:1 to prepare an analytical sample. The samples were diluted five times by Reagent A
(5% acetonitrile, 0.1% formic acid). The diluted samples were desalted by handmade Stage-tip (3M
Empore disk C18). The column was equilibrated with the same bed volume of Reagent B (80%
acetonitrile, 0.1% formic acid). Then the column was washed with reagent A by centrifugation
(4000× g, 10 min, RT). The samples corresponding to 5.8 μg were loaded onto the column, followed
by centrifugation (4000× g, 10 min, RT). The column was washed by a bed volume of reagent
A by centrifugation (4000× g, 10 min, RT) twice. The same volume of reagent B was added and
centrifuged (4000× g, 10 min, RT), and the prepared sample was dried and solidified with a centrifugal
concentrator, and then dissolved with 36 μL of 0.1% formic acid before nano LC–MS/MS analysis.
3.6. Design of Multiple Reaction Monitoring (MRM) Assay
First, the target 144 proteins related to the central metabolic pathway and photosynthetic
apparatus were selected from the Kyoto Encyclopedia of Genes and Genomes (KEGG) database
(http://www.genome.jp/kegg/kegg2.html). The amino acid sequences of target proteins were
obtained from Cyanobase (http://genome.microbedb.jp/CyanoBase). The MRM method used to
quantify these 144 proteins was created by the open software Skyline version 2.6 [54]. Each protein
was subjected to a tryptic peptide filter of 8 to 25 residues and five y-fragments (y1 to y5) were selected
for each peptide. Samples of Synechocystis sp. PCC 6803 were analyzed once by nano LC–MS/MS
(LCMS-8060, Shimadzu, Kyoto, Japan) by the provisional MRM method. From the results obtained by
the analysis, peak picking was performed based on the shape, coelution, and intensity of the peak,
and the best transitions up to 5 were selected, respectively. For proteins with no suitable tryptic
peptides and transitions, transitions were quantified for all y fragments and b fragments, from which
the tryptic peptides suitable for quantitation were selected again to create the final MRM method.
3.7. Nano Liquid-Chromatography–Triple Quadrupole Mass Spectrometry (LC–MS/MS) Analysis by
MRM Assay
The trypsin-digested samples were analyzed by a quadrupole mass spectrometer (LCMS-8060,
Shimadzu) as described previously [55]. Electrospray ionization (ESI) was performed, and sample
separation was performed by nanoLC (LC-20ADnano, Shimadzu). The analytical conditions were as
follows: high-performance liquid chromatography (HPLC) column, L-column ODS (pore size: 5 μm,
0.1 × 150 mm, CERI, Tokyo, Japan); trap column, L-column ODS (pore size: 5 μm, 0.3 × 5 mm, CERI);
solvent system, water (0.1% formic acid) : acetonitrile (0.1% formic acid); gradient program, 10:90,
v/v at 0 min, 10:90 at 10 min, 40:60 at 45 min, 95:5 at 55 min, and 90:10 at 65 min; and flow rate,
400 nL min−1. Mass spectrometry was performed in MRM mode, ESI was 1.6 kV, capillary temperature
was 150 ◦C, collision gas was 270 kPa, resolution of Q 1 and Q 3 was Low, dwell time was 1.0 ms,
pause time was 1.0 ms, retention time window was 2 min. One tryptic peptide was selected for each
protein and quantified by the peak area ratio of 14N sample to 15N sample.
3.8. Quantification of NH3 in the Medium
The extracellular NH3 assay was performed by F-kit (JK International) according to the
manufacturer’s protocol. Briefly, the medium was centrifuged (15,000 rpm, 4 ◦C, 1 min) and the
supernatant was obtained, followed by heating at 80 ◦C for 20 min to inactivate remaining enzyme.
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Reagent Mix (200 μL) was reacted with 6.7 μL of the sample and incubated. A340 was measured after 5
and 20 min.
3.9. Ultraviolet–Visible (UV–VIS) Spectrum
A DU 8000 was used to measure the UV–VIS spectrum. Absorption spectra of cell suspensions
were measured according to the ‘opal glass method,’ with a translucent cuvette placed in front of the
detector to minimize the effect of light scattering [56]. The results obtained were normalized to the
absorbance at 730 nm of chlorophyll as 1.0.
4. Conclusions
Targeted proteome analysis was conducted in this study to directly compare the abundance of
the central metabolism- and the photosystem-related proteins among WT, ΔsigE, and sigEox strains of
Synechocystis sp. PCC 6803. The analysis showed the SigE-dependent regulation of central metabolism
at the protein abundance level. Among the investigated proteins, the most direct or tight regulation via
gene expression was observed for the proteins in the pentose phosphate pathway such as TalB and Gnd.
Further investigations of protein abundance and their modification states such as phosphorylation by
proteomic analysis should uncover the detailed regulatory mechanism of central carbon metabolism
in cyanobacteria.
Supplementary Materials: The following are available online, Figure S1: Selected reaction monitoring (SRM)
spectra of the peptide EVTASLVGADAGK (ApcB), Figure S2: SRM spectra of the peptide SYFASGELR (ApcB),
Figure S3: SRM spectra of the peptide AVLPQNLTQAQR (Gnd), Figure S4: SRM spectra of the peptide ELEPILTK
(Gnd), Figure S5: SRM spectra of the peptide VPATIEEIAAR (Eno), Figure S6: Comparison with the relative
abundances of mRNAs and proteins, Table S1: MRM assay method used in this study, Table S2: Targeted
proteomics data; Table S3: All analyzed peptides.
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Abstract: Since the cost of Ophiocordyceps sinensis, an important fungal drug used in Chinese
medicine, has increased dramatically, and the counterfeits may have adverse health effects, a rapid
and precise marker using the peptide mass spectrometry identification system could significantly
enhance the regulatory capacity. In this study, we determined the marker peptides in the digested
mixtures of fungal proteins in wild O. sinensis fruiting bodies and various commercially available
mycelium fermented powders using ultra-performance liquid chromatography/Orbitrap Fusion
mass spectrometry coupled with chemometrics. The results indicated the following marker peptides:
TLLEAIDSIEPPK (m/z 713.39) was identified in the wild O. sinensis fruiting body, AVLSDAITLVR
(m/z 579.34) was detected in the fermented O. sinensis mycelium powder, FAELLEK (m/z 849.47) was
found in the fermented Ophiocordyceps mycelium powder, LESVVTSFTK (m/z 555.80) was discovered
in the artificial Ophiocordyceps mycelium powder, and VPSSAVLR (m/z 414.75) was observed in
O. mortierella mycelium powder. In order to verify the specificity and applicability of the method,
the five marker peptides were synthesized and tested on all samples. All in all, to the best of our
knowledge, this is the first time that mass spectrometry has been employed to detect the marker
peptides of O.sinensis and its related products.
Keywords: Ophiocordyceps sinensis; ultra-performance liquid chromatography/Orbitrap Fusion mass
spectrometry; chemometrics; fungi marker peptide; quality control
1. Introduction
Chongcao (the sexual stage of the Ophiocordyceps sinensis) is an important traditional fungal
drug that has been commonly used for hundreds of years as a tonic and/or drug. However, its
safety was questioned, because the wild Ophiocordyceps sinensis was reported to contain a high
amount of arsenic likely due to soil contamination [1]. Then Ophiocordyceps sinensis had the clinical
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effect of tonifying the kidney and replenishing lung, stanching bleeding, and resolving phlegm.
It could be used to treat 21 ailments and also be a potential adjuvant chemotherapeutic agent in
non-small cell lung cancer, liver cancer, and breast therapy [2,3]. Despite the hazardous effects to the
humanhealth, chongcao possesses manyanti-tumor and antioxidant activities, as well asthe capacity
to modulate the immune system and treat fatigue, night sweating, hyposexuality, hyperglycemia,
liver disease, and heart disease [4–9]. In recent years, due tothe limited natural resources and
simultaneously increasing demand, thecost of O. sinensis has increased dramatically. In spite of
the increasing price, its manufacture and sales were strictly regulated in 2016 by the China Food and
Drug Administration (CFDA), because its natural fruiting bodies usually contain high amounts of
arsenic, which is an environmental pollutant and could decrease neuronal migration, as well as cellular
maturation, and it inhibits the proliferation of neural progenitor cells [1,10]. Considering the safe
clinical use and the discrepancy between need and availability, other Ophiocordyceps-related fungi
and the conidial forms of the artificially cultured O. sinensis fermentation mycelia have been used as
substitutes in Chinese medicine and healthy food [11,12].
From the numerous species that have been reportedly isolated from O. sinensis [13,14], it is widely
accepted among researchers that Hirsutella sinensis is a unique anamorph of O. sinensis [11,15–17],
while other species such as Paecilomyces hepialid, Gliocladium roseum, and Tolypocladium sinensis represent
endoparasitic fungi commonly found in natural O. sinensis [18,19]. Currently, four species isolated from
O. sinensis, namely, fermented O. sinensis mycelium powder (Hirsutella sinensis species), fermented
Ophiocordyceps mycelium powder (Paecilomyces hepialid species), artificial Ophiocordyceps mycelium
powder (Gliocladium roseum species), and O. mortierella mycelium powder (Tolypocladium sinensis
species), all of which are usually confused with the O. sinensis name, have been successfully cultured.
Four more standardized mycelia fermentation products of Ophiocordyceps have been produced [20–24]
and are widely employed as Chinese medical material in preparations in China [25].
Since different Ophiocordyceps species may have different health effects, authentication of
O. sinensis-related products is essential in order to ensure safeuse and efficacy. Traditionally, O. sinensis
is identified through morphological description, microscopic identification, or chemical composition
assay [23,26–29]. However, since these methods lack objective standards or a specific component index,
it is difficult to effectively identify and distinguish O. sinensis from various cultured O. mycelia [30–34].
Furthermore, although the polymerase chain reaction (PCR) has been successfully applied in the
identification of Ophiocordyceps sinensis (O.S.) fruiting bodies [14,15,35], it cannot be used for cultured
Ophiocordyceps mycelia, because the integrity of the DNA genome is compromised during the drying
process [18,36,37].
Since species identification is an important and necessary procedure to control the quality and
standardization of herbal medicines, it is crucial to develop methods to authenticate O. sinensis and
the four aforementioned cultured O. mycelia. One approach to that could be the detection of the
fungal proteins in the species. The fungal protein is a special protein, the amino acid sequence of
which is different in the different fungi, thereby making it an important factor in the identification
of species [38,39]. Moreover, these proteins are among the bioactive components in O.S. and, to the
best of our knowledge, have rarely been studied and reported [40]. Biological mass spectrometry has
been developed as an efficient method for proteomic analysis that exhibits superior mass accuracy and
ultra-high resolution, and employs a segmented quadruple mass filter with improved selectivity and
ion transmissibility [38,39,41–46]. However, for a specific genus, there is only limited data available
to characterize the fungal protein. One example is the marker peptide in the digested mixture of
O. sinensis-related products.
In this study, we first determinedthe digested mixture peptides by ultra-performance liquid
chromatography/Orbitrap Fusion mass-spectrometry (UPLC/MS/MS). Then, the marker peptide ion
was detected using chemometrics, and the marker peptide sequence was confirmed by comparisonwith
the database for the identification of O. sinensis and relevant cultured Ophiocordyceps mycelia.
The results demonstrated that this method could be used to authenticate not only wild O. sinensis
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and its related cultured Ophiocordyceps mycelia powder but also the mixed commercial products.
Moreover, the work presented herein is, to the best of our knowledge, the first extensive study on
the authentication of O. sinensis and cultured Ophiocordyceps mycelia using mass spectrometry and
chemometrics, thereby providing a powerful quality control tool.
2. Results
2.1. Size-Exclusion Chromatographic Analysis ofFungal Proteinsand Their Tryptic Digest Mixtures
Figure 1 shows the size-exclusion chromatograms (SEC) of fungal proteins in fermented O. sinensis
mycelia and the sample aliquots withdrawn during the digestion process. It was found that the
fungal proteins had a wide molecular weight range (Figure 1A). When the amount of trypsin was
increased, the peak intensities arising from the digest mixture gradually increased, indicating that
more peptides in the mixture were degraded (Figure 1B–D). Once the sample-to-trypsin ratio exceeded
100:10, no significant changes in the peak intensity in the elution profile were observed (Figure 1E).
The molecular-weight ranges of the fungal proteins and the digest mixtures incubated at 37 ◦C for
18 h were assessed against a series of protein standards, namely immunoglobulin G (molecular
weight (MW = 150 kDa), bovine albumin (MW = 68 kDa), globular actin (MW = 42 kDa), trypsinogen
(MW = 24 kDa), lysozyme (MW = 14 kDa), and bovine insulin (MW = 6 kDa), which were analyzed
by SEC under the same conditions. The results revealed that the molecular weights of the fungal
proteins ranged from 42 to 14 kDa, whereas the molecular weights of the peptides in the digest mixture
were <5 kDa, which is consistent with the theoretical molecular weight range of peptides resulting
from the digestion of fungal proteins [47].
2.2. Multivariate Data Analysis
The total ion chromatograms (TICs) of the wild O. sinensis and four cultured Ophiocordyceps
mycelia fungal proteins digested at 37 ◦C for 18 h, over the 350–1550 m/z scan range, are displayed
in Figure 2. The results show that the marker peptides of each mycelium were concealed by a
large number of tryptic peptides that were indistinguishable in the TICs at higher concentrations
due to the homologies of the fungal proteins. As a consequence, the different types of mycelia
were difficult to detect simply by visual inspection of their chromatograms, and further sample
profiling of the digest mixtures was performed using multivariate statistical software tools.
In this study, the three-dimensional (3-D) ultra-performance liquid chromatography/Orbitrap
Fusion mass-spectrometry (UPLC/MS/MS) data were first converted into a 2-D matrix containing
exact-mass/retention-time (EMRT) pairs using the Progenesis QI for Proteomics, which is the
application manager for Progenesis QITM. The data set was visualized using unsupervised principal
component analysis (PCA) in order to check for outliers and classification trends among the mycelia.
Preliminary PCA was performed on all observations using pareto-scaled variables. The final PCA
score plot revealed that five different types of mycelia clusters formed, all of which lay inside the
Hotelling T2 (0.95) ellipse (Figure 3a). In the PCA scores plot, the fermented Ophiocordyceps mycelia
powder and O. mortierella mycelia powder lay close to each other but were located much further
away from the wild O. sinensis, the fermented O.S. mycelia powder, and the artificial Ophiocordyceps
mycelia powder.
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Figure 1. The gelfiltration chromatograms of (A) fungal protein from fermented O. sinensis mycelia
powder and (B–E) therespective digest peptidesincubated at 37 ◦C for 18 h with sample-to-trypsin
ratios of (B) 100:1; (C) 100:2; (D) 100:5; and (E) 100:10.
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Figure 2. The positive-ion base-peak-intensity chromatograms of the digest peptides of: (A) wild
O. sinensis fruiting body; (B) fermented O. sinensis mycelia powder; (C) fermented Ophiocordyceps
mycelia powder; (D) artificial Ophiocordyceps mycelia powder; and (E) O. mortierella mycelia powder.
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Figure 3. (a) The principal component analysis score plot of ( ): wild O. sinensis fruiting body,
( ): fermented O.S. mycelia powder, ( ): artificial Ophiocordyceps mycelia powder, ( ): fermented
Ophiocordyceps mycelia powder, ( ): O. mortierella mycelia powder, and (b) the loading plot of wild
O. sinensis and four cultured Ophiocordyceps mycelia.
2.3. Identification of Marker Peptides in Digested Mixtures
The results from this study demonstrate that it is possible to isolate and identify marker peptides
that play important roles in the authentication of various Ophiocordyceps mycelia. The loading
plot from the PCA, based on the UPLC/MS data, is shown in Figure 3b. The ions that
correspond to the EMRT pairs of 41.17–713.3967, 35.03–579.3498, 22.68–849.4741, 26.05–555.8072,
and 13.60–414.7517 were chosen as marker peptides for each sample. The amino acid sequence of
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the marker peptides was determined using Mascot v2.5.1. Mascot was calibrated by searching the
data on O. sinensis, Hirsutella sinensis, Paecilomyces hepialid, Gliocladium roseum, and Tolypocladium
sinensis, which was obtained from the Universal Protein (UniProt) database. The Mascot search
was performed with a fragment ion mass tolerance of 0.60 Da and a parent ion tolerance of
15.0 ppm. Carbamidomethylated iodoacetamide (IAM) was specified in Mascot as a fixed modification,
while oxidized dithiothreitol (DTT) was specified as a variable modification.
The results of the study showed that the ion with m/z = 713.3967 was only found in the spectrum
of the digested mixture of the wild O.S. fruiting body (Figure 4A). Moreover, extracted-ion mass
spectrometry (MSE) revealed that this ion was doubly charged and that the MS/MS spectrum indicated
that it corresponded to the TLLEAIDSIEPPK amino acid sequence. The partial LEAIDSIEPPK amino
acid sequence was derived from the observed single charged y(11) m/z 1211.6518 ion, while the
partial TL amino acid sequence was confirmed by the b(2) m/z 215.1390 ion. In contrast, the ion
with m/z = 579.3498 was only detected in the spectrum of the digested mixture of the fermented O.S.
mycelia powder (Figure 4B). Similarly, the respective MSE spectrum revealed that this ion was doubly
charged, while the MS/MS spectrum indicated that it corresponded to the AVLSDAITLV amino acid
sequence. The partial AVL amino acid sequence was derived from the observed doubly charged b++(3)
m/z 142.6021 ion, while the partial SDAITLVR amino acid sequence was confirmed by the y(8) m/z
874.4993 ion. In addition, the ion with m/z =849.4741 was only found in the spectrum of the digested
mixture of the fermented Ophiocordyceps mycelia powder (Figure 4C). The MSE spectrum revealed
that this ion was single charged, and that its MS/MS spectrum indicated that it corresponded to the
FAELLEK amino acid sequence. The partial FAE amino acid sequence was derived from the observed
single charged b(3) m/z 348.1554 ion, while the partial LLEK amino acid sequence was confirmed by
the y(4) m/z 502.3235 ion. Moreover, the ion with m/z = 555.8072 was only detected in the spectrum of
the digested mixture of the artificial Ophiocordyceps mycelia powder (Figure 4D). The MSE spectrum
revealed that this ion was doubly charged, and that its MS/MS spectrum indicated that it corresponded
to the LESVVTSFTK amino acid sequence. The partial LESV amino acid sequence was derived from
the observed doubly charged b++(4) m/z 215.1208 ion, while the partial VTSFTK amino acid sequence
was confirmed by the y(6) m/z 682.3770 ion. Lastly, the ion with m/z = 414.7517 was only found in the
spectrum of the digested mixture of the O. mortierella mycelia powder (Figure 4E). The corresponding
MSE spectrum revealed that this ion was doubly charged, and that its MS/MS spectrum indicated that
it corresponded to the VPSSAVLR amino acid sequence. The partial VPS amino acid sequence was
derived from the observed doubly charged b++(3) m/z 142.5839 ion, while the partial SAVLR amino
acid sequence was confirmed by the y(5) m/z 545.3406 ion.
The amino acid sequences of the marker peptides of each Ophiocordyceps species were aligned
using the Basic Local Alignment Search Tool (BLAST) of the UniProt database in order to identify the
original protein types. The results were as follows: translation elongation factor 1-α (gi:A4U9H1),
belonging to Ophiocordyceps brunneipunctata (Table 1) and recognized by Mascot matching as a
precursor of the tryptic peptide TLLEAIDSIEPPK (m/z 713.3967), was chosen as a marker of the
wild O. sinensis fruiting body; linoleate diol synthase (gi: T5AC53), belonging to Hirsutella sinensis and
recognized by Mascot matching as a precursor of tryptic peptide AVLSDAITLVR (m/z 579.3498),
was chosen as a marker for unambiguous identification of the fermented O. sinensis mycelia
powder; the adenosine triphosphate (ATP) synthase subunit α (gi: A0A0B7JUZ6), belonging to
Bionectria ochroleuca (Gliocladium roseum) and recognized by Mascot matching as a precursor of tryptic
peptide LESVVTSFTK (m/z 555.8072), was chosen as a marker of the artificial Ophiocordyceps mycelia
powder(Gliocladium roseum species). However, the two ions at m/z 849.4741 and 414.7517 were not
assigned to any protein by the Mascot matching. The selected ion monitoring chromatograms of the
marker peptides and the corresponding spectra (MSE) are shown in Figure 4. In most cases, the amino
acid sequences were recognized to belong to specific proteins of the analyzed species, while in other
cases, the peptide was not assigned to any protein, with the engine indicating only partial matching
(in brackets, Table 1).
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Figure 4. The selected ion-monitoring chromatograms of marker peptides in (A) wild O. sinensis fruiting
body, m/z 713.39, a doubly charged TLLEAIDSIEPPK fragment ion; (B) fermented O. sinensis mycelia
powder, m/z 579.34, a doubly charged AVLSDAITLVR fragment ion; (C) fermented Ophiocordyceps
mycelia powder, m/z 849.47, a singly charged FAELLEK fragment ion; (D) artificial Ophiocordyceps
mycelia powder, m/z 555.80, a doubly charged LESVVTSFTK fragment ion; and (E) O. mortierella
mycelia powder, m/z 414.75, a doubly charged VPSSAVLR fragment ion. Correspondingly, the fragment
ion mass spectrogram of marker peptides in (a) wild O. sinensis fruiting body; (b) fermented O. sinensis
mycelia powder; (c) fermented Ophiocordyceps mycelia powder; (d) artificial Ophiocordyceps mycelia
powder; and (e) O. mortierella mycelia powder.
3. Discussion
Due to its apparent beneficial clinical and health effects, O. sinensis has been employed in China
as a highly valued traditional Chinese medicine for centuries. Recently, it has become increasingly
popular and is now widely used, especially by elderly and unhealthy people in China and abroad, as a
dietary supplement or natural remedy [25,48]. However, the market price for O. sinensis has increased
remarkably due to insufficient resources and growing demand. Moreover, other Ophiocordyceps-related
fungi and the conidial form of the artificially cultured O. sinensis fermentation mycelia have also
been used as substitutes in Chinese medicine and healthy foods [11,12], thereby causing confusion
in the market management and challenging the safe use of O. sinensis. Therefore, it is crucial to
develop a reliable and practical method to differentiate O. sinensis from its substitutes, especially the
cultured mycelia.
In this study, the marker peptides in the digest mixtures of fungal proteins were determined by
UPLC/MS/MS coupled with chemometrics using wild O.S. fruiting bodies and several commercially
available mycelium fermented powders. Moreover, the marker peptides were detected, and the amino
acid sequences of the marker peptides were identified. The obtained results showed that the marker
peptides could provide accurate species identification for the Ophiocordyceps samples by biological
mass spectrometry. To the best of our knowledge, the first extensive study on the authentication of
O. sinensis and revelent-cultured Ophiocordyceps mycelia by biological mass spectrometry combined
with chemometrics, thereby provided a powerful quality control tool.
Previous studies report different macroscopic and microscopic methods that can be used
to identify O. sinensis-related products [23,26–29]. Nevertheless, the probability of the accurate
identification of the species level was not the same for the different species [32,49–52]. Most studies
focused on morphological characterizations, microscopy studies, determination of the chemical
composition, and PCR amplifications. However, none of them analyzed the specific fungal protein or,
more specifically, the marker peptide that identifies the species level of O. sinensis.
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The fungal protein is a special protein that is differentiated by the type of fungus [40]. One efficient
method for proteomic analysis is biological mass spectrometry [39,53,54]. In recent years, many
studies have focused on the fungal proteins. Two dimensional electrophoresis (2-DE) and sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was used to examine and identify
O. sinensis [40,55]. Then, five proteins were identified using MALDI-TOF-TOF/MS. Based on the
proteomic profile of O. sinensis, 2-DE identification pattern was provided, and this approach was
a foundation for intensive study of O. sinensis proteins. Another isobaric tag for relative and
absolute quantification (i TRAQ)-coupled two-dimensional liquid chromatography tandem mass
spectrometry(2D LC-MS/MS) proteomics approach was used to analyze the protein profiles of samples
of the larva and various development stages of Chinese Cordyceps. This bioinformatics analysis
revealed that i TRAQ-coupled 2D LC-MS/MS was a unique method for identifying protein groups
of Chinese Cordyceps at different development stages [56]. None of these methods can effectively
identify and distinguish Ophiocordyceps sinensis and its revelent-fermented Ophiocordyceps mycelia.
In this study, we employed this approach to identify the marker peptides of the specific fungal
proteins in wild O. sinensis and four revelent-fermented Ophiocordyceps mycelia powders. Then, as a
result, TLLEAIDSIEPPK (m/z 713.39) was detected in wild O. sinensis fruiting bodies, which was
matched to protein of translation elongation factor 1-α, belonging to Ophiocordyceps brunneipunctata.
AVLSDAITLVR (m/z 579.34) was discovered in the fermented O. sinensis mycelium powder, which was
matched to protein of linoleate diol synthase, belonging to Hirsutella sinensis. FAELLEK (m/z 849.47)
was found in fermented O. mycelium powder, which was not matched to any protein. LESVVTSFTK
(m/z 555.80) was identified in artificial O. mycelium powder, which was matched to protein of
ATP synthase subunit α, belonging to Gliocladium roseum. VPSSAVLR (m/z 414.75) was detected
in O. mortierella mycelium powder, which was not matched to any protein. All in all, three marker
peptides were matched to the corresponding species; two marker peptides were not matched to
corresponding species, but they were specific peptides.
In order to verify their specificity, all marker peptides were synthesized and tested on the
samples. The results from the measurements of the aforementioned five samples revealed the
following information on the marker peptides: TLLEAIDSIEPPK was only present in wild O. sinensis,
AVLSDAITLVR was only detected in fermented O. sinensis mycelium powder, FAELLEK was only
observed in fermented Ophiocordyceps mycelium powder, LESVVTSFTK was only present in artificial
O. mycelium powder, and VPSSAVLR was only found in O. mortierella mycelium powder. Previous
studies revealed the proteins from 26 different producing areas were obviously different in the numbers
and abundance of protein spots of protein profiles, and this showed certain association with producing
areas [40]. Another report revealed five proteins of O. sinensis were identified in 2-DE, but the specific
protein was not reported [55]. Isobaric tags for relative and absolute quantification (i TRAQ)-coupled
two-dimensional liquid chromatography tandem mass spectrometry (2D LC-MS/MS) proteomics
approach was used to analyze the protein profiles of samples of the larva and various development
stages of Chinese Cordyceps. The results indicated that protein composition of mummified larva,
sclerotium, and stroma were significantly different from commercial cordyceps [56]. These were the
results of studying the producing area and various development stages of O. sinensis. Few study
results of the differential proteins of O. sinensis and various cultured Ophiocordyceps mycelia were
reported. In our study, the specific marker peptides were found by chemomatrics first and identified
the sequence using MASCOT. Thus, we could examine the marker peptides to identify the O. sinensis
and revelent-fermented Ophiocordyceps mycelia products.
The method developed in this study could be applied not only to qualitatively identify the
O. sinensis-related species, but also to quantitatively determine the contents of the marker peptides to
control the qualityof the Ophiocordyceps related products. Moreover, the biological mass spectrometry
method is also suitable for the identification of Chinese medicinal materials derived from animals,
especially processed animal medicinal materials such as Cicadae periostracum, processed Manis squama,
etc. However, because Chinese herbal medicine contains many complex ingredients, the extraction
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of high-purity and high-quality protein components is a key requirement of this method and its
application to traditional Chinese medicine (TCM).
4. Materials and Methods
4.1. Materials and Reagents
Polyacrylamide and Coomassie Brilliant Blue were purchased from Sigma-Aldrich (St. Louis,
MO, USA). Acetic acid was purchased from Beijing Chemical Reagent Co. (Beijing, China),
while dithiothreitol (DTT), iodoacetamide (IAM), and trifluoroacetic acid (TFA) were purchased
from Sigma-Aldrich (St. Louis, MO, USA). The reagents used were either of chemical or analytical
reagent grade. Ammonium hydrogen carbonate (analytical reagent grade) was purchased from Beijing
Chemical Reagent Co. (Beijing, China); formic acid was obtained from Sigma-Aldrich (St. Louis,
MO, USA); and acetonitrile (HPLC grade) was purchased from Fisher Scientific (Fair Lawn, NJ, USA).
The ultra-high-purity water was prepared using a Milli-Q water purification system (Millipore
Corporation, Bedford, MA, USA). Trypsin (sequencing grade) was obtained from Pierce (Thermo
Scientific, Waltham, MA, USA). The syringe filters (diameter: 0.22 μm) were purchased from Millipore
(Billerica, MA, USA). Four wild O.S. samples were collected from the Tibetan province in China.
The sources were identified by Chief Pharmacist Zhang nan-ping of National Institutes for Food
and Drug Control (NIFDC) in China. Five fermented O. sinensis mycelia samples were provided
by Hangzhou Sino-US Huadong Pharmaceutical Co., Ltd. (Hangzhou, China), and six fermented
Ophiocordyceps mycelia samples were obtained from Jiangxi Jiminkexin Pharmaceutical Co. Ltd.
(Nanchang, China). Eight artificial Ophiocordyceps mycelia samples were provided by Hebei Chang Tian
Pharmaceutical Co., Ltd. (Shijiazhuang, China), and five O. mortierella mycelia samples were obtained
from Zhejiang Changxing Pharmaceutical Co. Ltd. (Hangzhou, China) (Table 2). These strains of four
fermented Ophiocordyceps mycelia were identified by Institute of Microbiology, Chinese Academy of
Sciences in China.
Table 2. The Ophiocordyceps-related samples’ information included in this study.
Sample Status Claimed Names a No. of Samples Locations
Wild fruiting body Ophiocordyceps sinensis 4 Tibet
Cultured mycelium
powder b
Fermented O.S. mycelia 5 Zhejiang
Fermented Ophiocordyceps mycelia 6 Jiangxi
Artificial Ophiocordyceps mycelia 8 Hebei
O. mortierella mycelia 5 Zhejiang
a Sample names when they were collected; b cultured mycelium powder was collected from the manufacturing
enterprise of each sample.
4.2. Extraction of Ophiocordyceps Fungal Proteins
First, deionized water (0.5 mL) was added to a collected sample (10 mg) in a 1.5-mL microfuge
tube. The sample was mixed, centrifuged for 5 min at 20,000× g, and the supernatant was completely
removed. Subsequently, a lysis buffer (30 μL) and silica powder (Φ 0.5 mm) were added to the
tube, and its contents were ground repeatedly with a plastic pestle for 2 min using twisting motions.
Next, lysis buffer (150 μL) was added, and the sample was ground again for 30 s with the same
pestle. The tube was centrifuged for 5 min at 14,000× g, the supernatant was collected in a new
tube, and another aliquot of a lysis buffer (150 μL) was added to the prime tube. The sample was
ground again for 30 s with the same pestle, and the tube was centrifuged for 5 min at 14,000× g.
The supernatant was collected and transferred to a Millipore 3K ultrafiltration spin column placed
in a 2-mL collection tube. The spin column was centrifuged for 25 min at 12,000× g, after which the
filtrate was discarded and NH4HCO3 (300 μL, 0.05 mol/L, pH 8.0) was added. The spin column was
centrifuged for 25 min at 12,000× g, and the filtrate was discarded again. This step was repeated twice
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before the spin column was inverted into a new2-mL collection tube and centrifuged for 5 min at
14,000× g. Finally, another aliquot of NH4HCO3 (300 μL, 0.05 mol/L, pH 8.0) was added, and the
sample was diluted to a concentration of 1 mg/mL [57–59].
4.3. Purification and Tryptic Digestion
Each protein solution (100 μL) was purified by polyacrylamide gel electrophoresis with a 16%
polyacrylamide concentrate gel at 100 V for 10 min. The protein gel was stained with Coomassie
Brilliant Blue for 2 h and then decolorized with acetic acid for 2 h. The blue bands were cut into
small pieces and rinsed three times with water. Subsequently, DTT (10 mM) was added to the gel
pieces at 56 ◦C, and the mixture was incubated for 45 min. After this, the solution was removed,
and iodoacetamide (55 mM) was added to the gel. The reaction was left to proceed for 30 min at
room temperature in the dark. Next, the NH4HCO3 (0.05 M)/ACN (1:1, v/v) solution (20 mL) was
used to decolorize the gel, and then, the decolorizing agent was added twice every 30 min. The gel
pieces were dehydrated rapidly with acetonitrile and vacuum-dried for 30 min. A trypsin/0.05 M
NH4HCO3solution (1:20, v/v) was employed to digest the proteins in the gel. Each mixture was
incubated at 37 ◦C for 18 h, and then eachsolution was transferred into a new 2-mL tube. The gel pieces
were incubated at 37 ◦C overnight after adding ACN/H2O (1:1, v/v, containing 5% TFA). Subsequently,
the solution was collected and dried using a vacuum centrifugal concentrator. The residue was
dissolved in aqueous formic acid (0.1%) and analyzed by UPLC/Orbitrap Fusion MS/MS [60–62].
4.4. Size Exclusion Chromatography of the Digest Mixture
The molecular weight ranges of the digest mixtures were determined on a TSK G2000SWL column
(7.8 mm id × 300 mm length; particle size, 5 μm) (Tosoh Bioscience, Tokyo, Japan) using a Waters
2695–2998 liquid chromatography system (Waters Instruments Co., Rochester, MN, USA). The mobile
phase was comprised of a phosphate buffer (0.02 mol/L) containing sodium sulfate (0.1 mol/L).
The flow rate was set to 0.5 mL/min. A 10-μL aliquot of the sample was withdrawn from the digest
mixture and injected directly onto the column. The UV detection was recorded at 220 nm. The size
exclusion chromatography results are displayed in Figure 1.
4.5. Chromatographic Separation and Mass Spectrometry
The liquid chromatography (LC) separation was conducted using a Thermo Scientific™
EASY-nLC™ 1000 HPLC system (Thermo Fisher Scientific Inc., Waltham, MA, USA). The mobile
phases were composed of (A)water (with 0.1% of formic acid) and (B)acetonitrile (with 0.1% of
formic acid). The peptides were loaded directly onto a homemade C18 column (75 μm id × 15 cm,
3 μm, 120 Å). The analytical mobile phase gradient was 2–6% B from 0–1 min, 6–25% B from 1–46 min,
25–35% B from 46–61 min, 35–80% B from 61–62 min, and finally 80% B for an additional 8 min.
The flow rate was set to 300 nL/min for these analytical gradients. The column and autosampler were
maintained at temperatures of 40 and 8 ◦C, respectively. The injection volume was 5 μL [63,64].
All the separated peptide fractions were analyzed using a Thermo Orbitrap FusionTM (Thermo
Fisher Scientific, Waltham, MA, USA) mass spectrometer. The data were acquired at a resolution
of 120,000 (@ 200 m/z) for full MS scans, followed by a high-energy-collision dissociation (HCD)
fragmentation and detection of the fragment ions in the ion trap. The MS parameters were set
as follows. Full Scan for MS: resolution (@ m/z 200) 120,000; scan range (m/z): 350–1550; max
injection (ms): 50; and automatic gain control (AGC) target: 2.00 × 105. Data-dependent MS/MS:
Fragmentation HCD; NCE (%): 35; detector type: Orbitrap; AGC target: 5.00 × 104; max injection (ms):
35; and dynamic exclusion (s): 60. All acquisitions and data analyses were controlled using the
Progenesis QI for proteomics v3.0 (QIP) (Waters, Great Bookham, UK) and Mascot v2.5.1 (Matrix
Science, London, UK) software.
LC/MS peptides mass spectrogram fingerprint method was validated under the regulation of
Chinese Pharmacopoeia Commission. Seven different ions (RT 4.29 min, m/z 330.1976; RT 7.47 min,
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m/z 508.2743; RT 10.52 min, m/z 615.3333; RT 14.47 min, m/z 577.2941; RT 20.56 min, m/z 218.2128;
RT 26.49 min, m/z 802.4413; and RT 31.95 min, m/z 246.2455) were selected for repeatability, precision,
and stability, because the detected ion intensities were generated using the RT and m/z data pairs in
LC/MS peptides mass spectrogram. In six mass spectrograms of the same sample solution, the RSD
values of retention time and exact mass of seven ions were less than 1.0%. This suggested that the
precision of method was better. In six mass spectrograms of six sample solutions prepared from the
same sample, the RSD values of retention time and exact mass of seven ions were also less than 1.0%,
and it revealed the repeatability of the method was better. The RSD values of retention time and exact
mass of seven ions detected in 0, 2, 4, 6, 8, and 10 h were less than 1.2%, which showed the sample
solution was quite stable within 10 h.
4.6. Multivariate Data Analyses
Progenesis QIP was used to analyze the raw data. The following parameters were employed:
retention time range: 1.0–61.0 min; detected mass range: 100–2000 Da; mass tolerance: 0.05 Da; noise
elimination level: 6.00; intensity threshold: 100 counts; mass window: 0.05 amu; and retention time (RT)
window: 0.2 min. No specific mass or adduct was excluded. A list of the detected peak intensities was
generated using the RT and m/z data pairs. Ions in different samples were considered to be identical
when they demonstrated identical RT (tolerance of 0.2 min) and m/z values (tolerance of 0.05 Da).
The ion intensities for each detected peak were normalized against the sum of the peak intensities
within that sample using Progenesis QIP. The resulting three-dimensional data comprising of the
peak number (RT-m/z pair), sample name, and ion intensity were analyzed via unsupervised PCA.
All variables were pareto-scaled prior to analysis. The scheme of the developed method was shown in
Figure 5.
Figure 5. Scheme of the developed method.
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5. Conclusions
In this work, we established an efficient method that employs UPLC/Orbitrap-Fusion-MS/MS
coupled with chemometrics for the identification of wild O. sinensis and four cultured O. mycelia
products by identifying the marker peptide. This approach allowed for the profiling of the details of
each sample so that the different marker peptides could be detected. Hence, the marker peptides could
be used as powerful indexes for the identification of these mycelia and to distinguish the different
mycelia in mixtures. The present approach provided a foundation for detecting the ion pairs, which
came from parent ion and fragment ion of marker peptides using the MRM mode by LC/MS/MS and
for developing the sensitive, stable, rapid quality control standard of the valuable Chinese medicine
O. sinensis and its various cultured mycelia products.
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Abstract: Modern mass spectrometry is one of the most frequently used methods of quantitative
proteomics, enabling determination of the amount of peptides in a sample. Although mass
spectrometry is not inherently a quantitative method due to differences in the ionization efficiency of
various analytes, the application of isotope-coded labeling allows relative quantification of proteins
and proteins. Over the past decade, a new method for derivatization of tryptic peptides using isobaric
labels has been proposed. The labels consist of reporter and balanced groups. They have the same
molecular weights and chemical properties, but differ in the distribution of stable heavy isotopes.
These tags are designed in such a way that during high energy collision induced dissociation (CID)
by tandem mass spectrometry, the isobaric tag is fragmented in the specific linker region, yielding
reporter ions with different masses. The mass shifts among the reporter groups are compensated by
the balancing groups so that the overall mass is the same for all forms of the reagent. Samples of
peptides are labeled with the isobaric mass tags in parallel and combined for analysis. Quantification
of individual peptides is achieved by comparing the intensity of reporter ions in the tandem mass
(MS/MS) spectra. Isobaric markers have found a wide range of potential applications in proteomics.
However, the currently available isobaric labeling reagents have some drawbacks, such as high cost
of production, insufficient selectivity of the derivatization, and relatively limited enhancement of
sensitivity of the analysis. Therefore, efforts have been devoted to the development of new isobaric
markers with increased usability. The search for new isobaric markers is focused on developing a
more selective method of introducing a tag into a peptide molecule, increasing the multiplexicity
of markers, lowering the cost of synthesis, and increasing the sensitivity of measurement by using
ionization tags containing quaternary ammonium salts. Here, the trends in the design of new isobaric
labeling reagents for quantitative proteomics isobaric derivatization strategies in proteomics are
reviewed, with a particular emphasis on isobaric ionization tags. The presented review focused on
different types of isobaric reagents used in quantitative proteomics, their chemistry, and advantages
offer by their application.
Keywords: isobaric labeling reagents; quantitative proteomics; ESI-MS; ionization enhancers;
quaternary ammonium salts
1. Introduction
Mass spectrometry (MS) has become a powerful tool for the analysis of complex protein mixtures.
This method combined with various separation techniques offers extremely high resolution and
sensitivity; however, obtaining quantitative results is often problematic. Nowadays the problem
of quantification is solved in two ways: using label free methods based on spectral count or
chromatographic peak area/height, or by methods using stable isotopes. The literature data suggest
Molecules 2019, 24, 701; doi:10.3390/molecules24040701 www.mdpi.com/journal/molecules130
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that the label-free method is more efficient in terms of number of identified and quantified proteins;
however, isotopic methods are characterized by better reproducibility and precision [1]. Another
advantage of the methods based on isotopic labeling is multiplexing, allowing parallel analysis of
several samples, which saves analysis time and increases the overall reliability of the method.
The incorporation of isotopic label may be performed on various stages of analytical procedure.
Currently used methods allow the labeling of intact proteins or the peptides obtained by the enzymatic
hydrolysis of the analyzed sample. The labeling of whole proteins is often based on biological systems
including cell cultures (SILAC—stable isotope labeling by amino acids in cell culture) [2], or whole
organisms (SILAM—stable isotope labeling in mammals [3], HILEP—hydroponic isotope labeling of
entire plants [4]). The recombinant proteins or constructs composed of many sequences corresponding
to peptides present in the analyzed sample (QconCAT—quantitative concatenation) may be used as
isotopically labeled standards [5]. The labeling of whole proteins has many advantages, since standard
and sample may be combined before analytical separation, e.g., by electrophoresis, and this procedure
is not compromised for the incomplete tryptic hydrolysis.
The most frequently used method uses chemical modification of peptides obtained by the
enzymatic hydrolysis of protein sample. The specially designed reagents target amino, sulfhydryl and
carboxyl groups of peptides. These labeling reagents incorporate stable heavy isotopes like 13C, 15N,
18O and 2H. The incorporation of isotopic label should result in formation of two isotopologues of
peptide, which have the same chemical and chromatographic properties, but differ in molecular masses
and can be distinguished in the MS spectrum, allowing direct comparison of the abundance of peptide
in labeled and unlabeled sample. It is worth noting that the deuterium isotope is easily available
and relatively inexpensive, but may affect a retention time of isotopologues during chromatographic
separation of labeled peptides [6].
The isotopic dilution method is efficient in the analysis of samples of moderate complexity.
However, the proteomic samples often contain thousands of components. In such situations,
the presence of compounds with similar molecular masses and retention times may cause severe
quantification errors resulting from the overlapping of the matrix component peaks and peaks of
analyte or isotopically labeled standards. Moreover, the system based on the mass differences caused
by isotopic substitution is limited to a binary (2-plex), ternary (3-plex) or quaternary (4-plex) set of
tags. Therefore, the comparison of samples corresponding to multiple states cannot be achieved in one
experiment [7]. The problem of multiplicity in peptide analysis was solved by designing the sets of
isobaric reagents with different distribution of heavy isotopes. The products obtained by chemical
modification of peptides with these labels are isobaric, with the same chemical and physical properties,
and therefore are chromatographically indistinguishable. The relative abundancies of two isotopic
variants of peptide is revealed in MS/MS experiment, when fragmentation produces reporter ions with
different molecular masses. At the same time, the peptide fragment ions are used for identification
of peptide sequences characteristic for the analyzed protein. The structure of isobaric reagents is in
general composed of three groups. First of all, they contain a reporter group, a moiety which is easily
released from the labeled peptide during collision induced dissociation (CID). The reporter groups may
have different molecular masses because of isotopic substitution. This difference allows distinguishing
and quantification of peptides from various samples. Another component of the isobaric reagent is a
balance group. The balance group is also isotopically substituted assuring that the total mass of the
reporter ion and the balance group is the same in all versions of the reagent. The isobaric reagents
contain also a reactive group —the moiety responsible for selective reaction of reagent with selected
functional groups in a peptide. The most common reactive group is the succinimidyl ester, which
reacts with moderate selectivity with amino groups in peptides forming stable amide bond [8]. The
active esters react also with phenolic group of tyrosine, imidazole in histidine side chain as well as SH
group of cysteine. There are also reports on applying other reactive groups like pentafluorophenyl
esters [9], dimetoxytriazyne esters [10], groups selective for thiol moiety, e.g., iodoacetamide [11]
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and groups targeting carbonyl moiety in carbonylated proteins, e.g., substituted hydrazines [12] and
hydroxylamines [13].
The first example of isobaric tag, Tandem Mass Tag (TMT, duplex), was demonstrated by
Thomson [14] who has shown that in this strategy, a very high signal-to-noise ratio is achieved
compared to MS1 mode. The structure of TMT reagent was a relatively complex and involved
deuterium substitution, which may lead to the chromatographic separation of labeled peptides
and quantification errors. Another example of isobaric tag, isobaric tags for relative and absolute
quantification (iTRAQ), was demonstrated by Ross et al. who tested this reagent for comparison of
protein expression in isogenic yeast strains [15]. The isobaric iTRAQ in version developed by Ross
was available as a tetraplex. Over the past decade, chemical labeling with isobaric tandem mass tags,
such as iTRAQ and TMT reagents, has been employed in a wide range of different clinically orientated
serum and plasma proteomics studies [16].
Currently, labeling with isobaric tags is a routine method in quantitative proteomics studies,
including comparative proteomics and absolute protein quantification. However, there are some
limitations of this group of reagents.
The recent papers demonstrate many examples of the modified isobaric tags. The main directions
in development of a new classes of isobaric labeling reagents for quantitative proteomics include:
• Increase in sensitivity of detection of the labeled peptides. This goal may be accomplished by
incorporating the permanent electric charge to the labeled molecule, which facilitates electrospray
ionization (ESI).
• Increase in the multiplexing capacity of isobaric markers. This modification allows to compare
bigger number of proteomic samples in a single experiment.
• Modification of reactive group in isobaric tags in order to increase the selectivity and yield
of derivatization.
• Simplification of the structure of isobaric tag in order to reduce prices of this group of reagents.
These trends in a development of isobaric tags will be discussed herein.
The mass spectrometry-based quantitative proteomics can be applied as an absolute or relative
method. The first of them allows the quantification of changes in protein expression, whereas the
second one is commonly use to establish the protein downregulation in a relation to the control sample.
Therefore, in the relative type of analysis, the introduction of a chemically equivalent differential
isotopic mass tag is required for comparative quantitation of proteins in different samples. The
role of the applied tag consists of the protein or peptide mass change without peptide or protein
molecules; this may be achieved by metabolic or in vivo labeling, involving the incorporation of stable
isotopes during protein biosynthesis, enzymatic reaction or chemical modification [17]. Among all the
developed and applied methods for quantitative proteomic analysis, chemical labeling with isobaric
tags is now one of the most popular solutions in proteomics. Isobaric labeling-based quantification has
many advantages compared to other stable isotope labeling techniques, one of which is the ability to
perform high-throughput quantification due to sample multiplexing. Over the years, several different
chemical labeling methods have been proposed for isobaric peptide or protein formation. Usually the
modification is performed before protein digestion, which requires complete denaturation to overcome
errors in quantitation. One of the oldest and cost-efficient methods of isotopically peptide labeling
is H3/D3 acetylation and H5/D5 propionylation. This solution is similar to the as isotope-coded
protein label (ICPL) technique discussed below, except that the proteins are labeled with H6- or
D6-acetic anhydride or H10- or D10-propionic anhydride [17]. In 2002, Zhang and co-workers [18]
applied H5/D5 propionylation as a method for phosphopeptide quantification. They used a gentle
chemical labeling of N-termini of all peptides with the H5/D5 propionyl group and measurement of
abundance ratio of the isotopically labeled/non-labeled pairs using mass spectrometry. The method,
although easy to perform and cost-efficient, requires protein denaturation prior to labeling, whereas
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for complex samples, the presence of the overlapping isotopes clusters may require a high-resolution
mass instrument like FT-ICR mass spectrometer (Fourier-Transform Ion Cyclotron Resonance).
2. ICPL
In 2000, James and co-workers developed a method based on isotopic labeling of all free
amino groups in the protein called isotope-coded protein label (ICPL) [19]. The D4 or H4 forms
of nicotinyl-N-hydroxysuccinimide (Nic-NHS) were used for N-terminal nicotinylation of peptides for
their quantitative analysis, resulting in a mass difference of 4 Da per label (Figure 1). Lottspeich and
co-workers developed H4 or D4-labeled N-nicotinoyloxy-succinimide to label free amino groups in
peptides for their relative quantitation [20]. The ICPL reagent is now marketed by Bruker Daltonics
(Bremen, Germany). In December 2008, Bruker introduced a 4-plex version of this reagent, the Serva
ICPL 4plex Kit. This means that there are actually 4 closely related labels: (1) all natural isotopes,
(2) X = D, shift of 4 Da relative to all natural isotopes version, (3) X = H, 6 × 13C, shift of 6 Da relative
to natural version, (4) X = D, 6 × 13C, shift of 10 Da relative to all natural isotopes.
Figure 1. The D4/H4 forms of nicotinyl-N-hydroxysuccinimide (Nic-NHS) developed by James et
al. [19] and N-terminally labeled peptide, which can be applied for quantitation. X-H or D atom.
3. ICAT
Gygi and co-workers introduced in 1999 one of the earliest chemical reagents for quantitative
proteomics called Isotope Coded Affinity Tag (ICAT) [21]. The proposed solution of labeling involved
iodoacetamide as a thiol-reactive group, biotin, no deuterium atoms in the light form and 8 deuterium
atoms in a heavy form of the tag (Figure 2). The biotin-avidin pair was used for selective affinity
purification of thiopeptides.
Figure 2. Isotope Coded Affinity Tag proposed by Gygi et al. [21]. X depicts H or D atoms in
the molecule.
A new version of the ICAT reagent, where nine 13C atoms were introduced instead of 8 deuteriums
and biotin moiety was acid-cleavable, was proposed in 2003 and called cICAT [22,23]. The new form
of ICAT reagent eliminates the isotope effect of deuterium during chromatographic separation and
removes the potential confusion between a double ICAT label and oxidation, both resulting in a +16 Da
mass shift. It was observed that the heavy form is retained stronger than the light form [24]. The use
of the 13C stable label removed this retention time shift. The known advantage of ICAT reagent is
the reduction in sample complexity, because the label specifically targets cysteines, a relatively rare
amino acid making up only 1.42% of all amino acids [25]. However, this simultaneously reduces
the reliability of the quantification, as the experiment is based on a limited number of peptides per
protein. It also makes it impossible to detect changes in the ~10–13% of proteins that do not contain
cysteine residues [26,27]. Additional limitation of ICAT is that there are only two label forms available,
which could result in multiple experiments if more than two versions need to be compared, and
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would increase the cost accordingly. The need for comparisons of larger numbers of treatments led
to the development of the 2- or 4-plex ICPL, the 4- or 8-plex iTRAQ, and the 2- or 6-plex Tandem
Mass Tag (TMT) labeling techniques, which can compare up to four, eight or six samples in a single
analysis, respectively. Unlike the previously described labeling techniques, which use the parent
ion peak heights or peak areas from the MS spectra, the iTRAQ labels are currently the only tagging
technologies commercially available where quantitation is carried out in the MS/MS mode.
4. mTRAQ
Mass differential tags for relative and absolute quantification (mTRAQ) are amine-reactive,
non-isobaric peptide-labeling reagents introduced by Applied Biosystems, providing the
absolute quantification by multiple reaction monitoring (MRM) [28]. The mTRAQ contains a
N-hydroxysuccinimide ester group enabling primary amine labeling. Specifically, there are two
versions of the mTRAQ reagent available: the “heavy” version, which is identical to the iTRAQ 117
tag, and the “light” version that is devoid of any intentional isotopic enrichment. Consequently,
labeling of a peptide with the light version adds 140 Da, whereas 144 Da is gained by labeling with
the heavy version. This mass difference allows unique MRM transition to be generated for any given
peptide labeled with mTRAQ tags. In turn, this implies that, in a sample mixture where peptides
originating from different sources are tagged separately with heavy and light labels, the two versions
can be monitored independently and distinctly. The mTRAQ comes in three forms, and is not an
isobaric tag like iTRAQ [28]. The mTRAQ was designed to be used after the biomarker discovery
stage, during the validation stage of a project, as an alternative to having to synthesize deuterated
standard peptides for MRM-based quantitation [17]. The precursor-ion mass shifts of these 13C and
15N-labeled reagents are 0, 4 and 8 Da for arginine and 0, 8 and 16 Da for lysine C-terminal tryptic
peptides. The mTRAQ technique has already been successfully applied by the Siu laboratory to
the quantitation of endogenous levels of a potential cancer biomarker in endometrial tissues [29].
Interestingly, in this study, the expression ratios found by mTRAQ were significantly higher than those
found in the iTRAQ-based discovery phase. This provides more evidence of the ‘compression’ of
iTRAQ-determined expression ratios.
5. iTRAQ and TMTs
In 2004, Ross and co-workers described the isobaric tags for relative and absolute quantification
(iTRAQ) [15], which were commercialized by Applied Biosystems. The iTRAQ reagent contains
three regions, namely a mass reporter group, a mass balancer group and a protein reactive group
N-hydroxysuccinimide ester (NHS) that introduces a highly basic group at lysine side chains and at
peptide N-termini (Figure 3). The first type of iTRAQ reagent, a 4-plex has the variable mass between
114–117 Da within the reporter group.
Figure 3. Schematic presentation of iTRAQ structure (A) and peptide labeled by iTRAQ (B).
The modification of 4-plex iTRAQ based on the introduction of larger balancing group resulted in
the formation of 8-plex iTRAQ reagent with masses between 113–121 Da in the reporter group. In a MS
scan mode, the iTRAQ labeled peptides are characterized by a single peak due to the isobaric masses.
The signal intensity summing from all forms of a given labeled peptide in both MS and MS/MS modes
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increases the sensitivity of detection of analyzed compounds. Additionally, the presence of a basic
group having higher affinity to the H+ cation under standard ionization conditions increases ionization
efficiency. The MS/MS analysis of iTRAQ labeled peptides causes the release of the reporter group in
a form of singly charged ions at m/z 114–117 (for 4-plex) or m/z 113, 114, 115, 116, 117, 118, 119 and
121 (for 8-plex). The m/z 120 iTRAQ 8-plex was omitted to avoid overlapping with the phenylalanine
immonium ion (m/z 120.08). The relative quantitation of peptides in the sample is based on the analysis
of intensities of these reporter ions in the MS/MS mode. Based on the presence of such reporter ions,
the iTRAQ labeling reagent can be applied in the analysis of four different samples using 4-plex kit, or
up to eight samples using the 8-plex kit. Both 4-plex and 8-plex are commonly used in the quantitative
proteomic analysis of peptides; however, some differences in identification rates have been observed.
In 2010, Pichler and co-workers revealed that 8-plex allowed to identify the lowest number of peptides
in comparison to 4-plex labeling using iTRAQ or 6-plex TMT [30]. It was concluded that the bulkier
structure of the 8-plex label may restrict peptide identification. This results were questioned in 2012
by Pottiez et al., as they achieved more accurate quantitation using 8-plex iTRAQ over 4-plex iTRAQ
without sacrificing protein identification rates [31]. However, the observed differences may result from
the different instruments and search algorithms used in both experiments [32].
6. TMT
The tandem mass tags (TMTs) are chemical labeling reagents commonly used for mass
spectrometry-based quantification and identification of peptides and proteins. The idea of TMTs
is based on a similar principle in comparison to iTRAQ, with up to six possible labels. The TMT
reagent, proposed by Thompson et al. in 2003, is composed of a mass normalization group (balance
group) that balances mass differences from individual reporter ions to ensure the same overall mass of
the reagents, a reporter group that provides the abundance of a peptide upon MS/MS in individual
samples being mixed, and an amino group reactive functionality making the modification of primary
amines possible (Figure 4) [14].
Figure 4. First (A) and second (B) generation of tandem mass tags developed by Thomson and
co-workers [14].
Several TMT reagents are commercially available as TMTzero, TMT duplex, TMT 6-plex, and
TMT 10-plex. They have the same chemical structure but contain different numbers and combinations
of 13C and 15N isotopes in the reporter group (Figure 5). The chemical structure of the TMT tag enables
the introduction of five heavy isotopes (13C or 15N) in the reporter group and five heavy isotopes (13C
or 15N) in the balancer group to provide six isobaric tags. Each of the six tags of TMT 6-plex has a
specific reporter ion that appears at m/z 126, 127, 128, 129, 130, and 131.
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Figure 5. The structure of commercially available TMT (A) and the peptide modified by tandem mass
tag (B) [17].
TMT 10-plex is an expansion of TMT 6-plex generated by combining current TMT 6-plex reagents
with four isotope variants of the tag with 6.32 mDa mass differences between 15N and 13C isotopes [32].
Even though the mass difference between these reporter ion isotopologues is incredibly small, current
generation high resolution and high mass accuracy analyzers can resolve these ions. The numbers of
identified peptides and proteins in shotgun proteomics experiments have been compared for the three
commercially available isobaric mass tags: iTRAQ 4-plex, TMT 6-plex, and iTRAQ 8-plex [30,32]. Even
though the number of identified proteins and peptides was highest with iTRAQ 4-plex, followed by
TMT 6-plex, and lowest with iTRAQ 8-plex, the precision at the level of peptide−spectrum matches
and protein level dynamic range was similar.
Recently, to increase the multiplexing capacity of quantitative strategies, isobaric labeling and
mass difference labeling have been combined [33]. One of the proposed strategy includes triplex
labeling with TMT 6-plex, which achieved 18-plex quantitation and with the addition of medium and
heavy sets of 6-plex TMT, 54-plex quantitation was demonstrated. Reagents have been produced to
permit 2, 4, 6, 8, 10, and 12-plex comparisons. With the use of isotopologues, where the 6.32 mDa
mass difference between positional variations of 13C and 15N substitutions are combined (as are
currently used in the 10 and 12-plex reagents), multiplexing up to 18-plex has been suggested as a
future possibility [34].
Previously, Sonnet and co-workers devised a system of protein quantification using complement
reporter ions (TMTc), which nearly eliminates interference [35]. Additional complement reporter ions
are formed as a result of the intact peptide remaining fused to the mass balancing region of the TMT
tag. The TMTc ions encode different experimental conditions in the same way the low m/z reporter
ions do, with the added benefit that the TMTc ions’ mass is different for each peptide. The TMTc
quantification does not need the additional gas-phase isolation step of the slow MS3 scan; it holds
potential to be significantly more sensitive and is compatible with comparatively simple instruments
like iontrap Orbitraps, quadrupole Orbitraps, and Q-TOFs.
However, the commercially available reagents for isobaric peptides labeling (TMT and iTRAQ)
have some drawbacks, such as high cost in experiments, especially in quantitation for the modified
peptides, and inconvenient handling for variable sizes of samples. Recently, Ren and co-workers [36]
developed a set of 10-plex isobaric tags (IBT) with high stability and low cost, which is an improved
version of 6-plex DiART. IBT 10-plex reagents were applied for dynamic monitoring of the quantitative
responses of stimulated phosphoproteome.
7. Advantages and Disadvantages
The iTRAQ and other isobaric-tag labeling are performed on digested protein; therefore, every
peptide formed during proteolysis should be labeled. The detection of multiple peptides originating
from one protein may be achieved providing multiple quantitation per protein. This feature makes
possible the identification and quantification of low-abundance proteins in complex samples. The
ability of analysing of up to eight samples in parallel suggests that iTRAQ and similar mass balanced
labeling tags offer the most promise for quantitative biomarker discovery [37]. However, the
disadvantages of the described labeling methods include possible variability in labeling efficiencies,
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difficulties in protein digestion, and price of the reagents. The protocol of sample preparation
involves several steps to achieve reproducible and reliable results. The increasing multiplexicity
of labeling reagents also entails a necessity of application of high resolution mass spectrometer to
avoid erroneous analysis.
8. DiLeu
The attractive alternative for iTRAQ and TMT based on the N,N-dimethyl leucine (DiLeu) was
proposed in 2010 by Xiang and co-workers (Figure 6) [10]. DiLeu provides relative quantification of
peptides and amine-containing metabolites [38]. The amino-reactive group of this reagent targets the
N-terminus and ε-amino group of the lysine side chain of a peptide. During the MS/MS experiment,
this isobaric-labeling reagent produces reporter ions at m/z 115, 116, 117, and 118. Other characteristic
features of DiLeu reagent are modest mass of the tag (mass shift of 145.1 Da), higher intensity of
reporter ions compared to iTRAQ and TMT, and enhanced collision-induced MSn fragmentation of
labeled peptides at reduced collision energies.
Figure 6. N,N-dimethyl leucine (DiLeu) tag (A) developed by Xiang and co-workers [10] and DiLeu
modified peptide (B).
In 2015, inventors of the DiLeu isobaric labeling reagent developed the synthesis of a 12-plex
set of DiLeu reagents, which was made possible by exploiting subtle mass differences imparted by
mass defects between 12C/13C, 14N/15N, and 1H/2H [39]. This approach enabled a 3-fold increase in
multiplexing capacity, keeping the simplicity of synthesis characteristic for the 4-plex set of reagents.
However, the small mass difference of ~6 mDa separating the 115, 116, 117, and 118 variants of the
12-plex DiLeu reporters can be baseline-resolved for accurate quantitation at an MSn resolving power of
30 k (at 400 m/z), which is achievable on the Orbitrap, FTICR, and some QTOF instruments. Acquiring
at a resolving power of 60 k baseline resolves isotopic peaks and allows more accurate isotopic
interference correction at full multiplexing capacity. Reduced multiplexing configurations allow for
highly accurate 9-plex and 7-plex quantitation at resolving powers of 30 k and 15 k, respectively.
Additionally, Frost and co-workers [40] presented a cost-effective chemical labeling approach that
couples duplex stable isotope dimethyl labeling with 12-plex DiLeu isobaric tags in a combined
precursor isotopic labeling and isobaric tagging (cPILOT) strategy. It was found that this approach is
compatible with a wide variety of biological samples and permits 24-plex quantification in a single
LC-MS/MS experiment.
9. DiART
A good alternative to iTRAQ and TMT for isobaric tagging in quantitative proteomic analysis is
Deuterium isobaric Amine Reactive Tag (DiART) [41,42]. DiART reagents consist of an amine-reactive
site (NHS ester) for coupling, a balancer, and a reporter (N,N′-dimethylleucine) with a m/z range of
114–119 (Figure 7). This labeling reagent uses the same labeling protocol as TMT and iTRAQ.
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Figure 7. Schematic presentation of Deuterium isobaric Amine Reactive Tag (DiART) [32] (A) and
DiART modified peptide (B).
The application of DiART allows labeling and MS analysis up to six samples. This reagent is
characterized by high isotope purity; therefore, the isotopic impurities’ correction characteristic for
iTRAQ, TMT, or DiLeu labeling is not required during data analysis of DiART-labeled samples. DiART
tags allow generation of high-intensity reporter ions compared to those with iTRAQ. In comparison
to iTRAQ or TMT reagents, the reporter ions of DiART may easily undergo fragmentation; therefore,
a lower collision energy during MS/MS experiment is required.
Protein Post-Translational Modifications
Co- and post-translational modifications pose a particular challenge to proteome analysis;
however, they are frequently transient, substoichiometric, or chemically unstable (or all of the three),
and may negatively affect analysis by mass spectrometry, for example by interfering with ionization
or fragmentation [43]. Isobaric labeling-based quantification was successfully applied in the analysis
of post-translational modifications of some protein, including carbonylated residues in protein. The
iTRAQ hydrazide (iTRAQH) was proposed by Palmese et al. as a novel reagent providing the selective
labeling of carbonyl groups in proteins and their relative quantification (Figure 8) [12]. The reaction
between iTRAQH and carbonylated peptide involves the hydrazine moiety. The iTRAQH reporter
ions in the low m/z region of the MS/MS spectrum provide relative abundance information on the
carbonylated proteins in the analyzed samples.
Figure 8. iTRAQ hydrazide (iTRAQH) proposed by Palmese et al. [12].
The proposed solution facilitates the analysis of carbonylated peptides by elimination of some
sample preparation steps, including enrichment of modified peptides prior to LC-MS/MS analysis.
Additional isotopically-labeled carbonyl-reactive tandem mass tags (glyco-TMTs) have been developed
and successfully applied for quantification of N-linked glycans [13]. These tags are TMT derivatives,
containing hydrazide or aminoxy carbonyl-reactive groups (Figure 9).
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Figure 9. Schematic presentation of the glyco-TMT reagents containing hydrazide (A) or aminoxy
carbonyl-reactive groups (B) [13].
The proposed glyco-TMT tags can be applied in the quantification of a broad range of biologically
important molecules containing carbonyl groups, including oxidized proteins, carbohydrates, and
steroids. The aminoxy-functionalized glyco-TMTs are commercially available from Thermo Scientific
(Rockford, IL, USA) as aminoxyTMT zero and aminoxyTMT sixplex reagents.
Cysteine, a proteinogenic amino acid containing thiol group, plays a crucial role in protein
structure and function. Moreover, the cysteine sulfhydryl groups in proteins are potential sites of
reversible oxidative modification because of the unique redox chemistry of this amino acid [11]. It was
found that 91% of the proteins contain at least one cysteine residue, which is present in more than 24%
of the predicted tryptic peptides [44]. That makes the cysteine-containing peptides an attractive target
for proteomic analysis.
In 2012, Tambor et al. [45] reported a novel method of cysteine-containing peptide quantification
based on amine-reactive iTRAQ labeling with enrichment of thiol-containing peptides in an approach
named cysTRAQ. The proposed methodology allows deeper sampling of the cysteinyl proteome in a
manner similar to the ICAT reagents [32].
In 2014, Pan et al. developed a selective reagent for isobaric labeling of cysteine-containing
peptides based on TMT, containing the iodoacetyl reactive group (Figure 10) [46]. iodoTMT zero and
iodoTMT sixplex are commercially available from Thermo Scientific (Rockford, IL, USA). The proposed
isobaric iodoTMT 6-plex reagent within a set has the same nominal mass and consists of a thiol reactive
iodoacetyl functional group for covalent and irreversible labeling of cysteine, a balancer, and a reporter
group. The iodoTMT sixplex has been commonly used to specifically detect and quantify protein
S-nitrosylation [47]. The proposed iodoTMT reagent facilitates the procedure of proteomic analysis of
cysteine-containing peptides by reducing the necessity of their enrichment.
Figure 10. The iodoTMT reagent for cystein-containing peptide labeling and quantification proposed
by Pan and co-workers [46].
The isobaric labeling-based proteomic has many advantages in comparison to other stable isotope
labeling techniques, one of which is the ability to perform high-throughput quantification due to sample
multiplexing. The ability to combine and analyze several samples within one experiment eliminates the
need to compare multiple LC-MS/MS data sets, thereby reducing overall analytical time and run-to-run
variation. The isobaric mass tags also offer advantages in the MS/MS mode—there is no interference
with peptide fragmentation, as the peptide length distribution profile and amino acid content of the
isobarically derivatized peptides are similar to those obtained using other MS-based approaches [48].
139
Molecules 2019, 24, 701
In fact, isobaric tags have been reported to improve the efficiency of MS/MS fragmentation and
result in increased signal intensities of native peptides in samples of human parotid saliva that, in
general, lack the uniform architecture of tryptic cleavage products, e.g., a basic C-terminal amino
acid residue [49]. Isobaric labeling-based methods in proteomics have been successfully applied
in the analysis of endogenous levels of a potential cancer biomarker in endometrial tissues [29],
quantification of human plasma samples [39], and other organisms [17,32]. However, the structure of
commercially available isobaric-labeling reagents does not provide a high-proton affinity group and
partly introduces hydrophobicity, which may lead to higher ionization efficiency of modified peptides.
Additionally, the synthesis of 13C, 15N and 18O isotopically labeled reagents is relatively expensive.
Access to deuterated compounds could be significantly more efficient and cost-effective by exchange
of hydrogen by deuterium in the target molecule than by de novo synthesis. However, the deuterated
compounds are not considered as good internal standards due to the possible chromatographic
deuterium effect, which may affect the isotopologues’ co-elution during LC-MS. The synthesis of
isotopically labeled tags could be performed using commercially available precursors; however, it
frequently involves long synthetic routes and high costs of starting materials. Therefore, labeling by
direct hydrogen/deuterium exchange may be faster and a more cost-effective method for preparation
of isotopically labeled reagents. Recently, we observed an unusual hydrogen-deuterium exchange
(HDX) at the α-C of acetylated N-methylglycine (sarcosine) residue in peptides, which occurs in 1%
N,N,N-triethylamine (TEA)/D2O mixture (pD = 12.3) at room temperature [50]. Additionally, the
back exchange (DHX) of introduced deuterons was not observed at neutral pH. The results were
confirmed by ESI-MS and NMR data. We also found that such exchange does not occur in the case of
N-methylalanine residue in model peptides [51]. The method was successfully applied for deuterium
labeling of denatonium benzoate (Bitrex) via HDX reaction at the α-carbon situated between carbonyl
and the quaternary ammonium group [52]. The proposed strategy is rapid, cost-efficient, and does
not require special derivatization reagents or further purification. The LC-MS analysis of denatonium
cation isotopologues revealed that the introduced deuterons do not undergo back-exchange under
acidic conditions and the co-elution of deuterated and non-deuterated forms was observed. We also
developed a method of preparation of deuterium-labeled cyclosporine A standards via H/D exchange
of their α-carbon hydrogen atoms occurring in D2O under basic conditions [53]. We proved that the
preparation of deuterated standards of several different compounds may be obtained by simple H/D
exchange, where the cost of the reaction depends only on the price of D2O. However, to provide the
multiplexity required in the design of isobaric reagents for quantitative proteomics, the introduction of
other isotopes is required, which is discussed below.
10. Sensitivity Problem
Sensitivity of detection is one of the most important issues in mass spectrometry, which in
combination with liquid chromatography systems allows to analyze enormously complex mixtures of
peptides. Although this technique has been considered as the most versatile and sensitive for analysis
of peptides, there are many problems and limitations in analysis of trace amounts of peptides. This
issue results from insufficient ionization efficiency of several peptides, which in turn causes the limited
detection of these compounds. Moreover, the insufficient intensity of fragmentation peaks may result
in ambiguous sequencing, which impedes the successful interpretation of obtained data.
The aforementioned techniques based on the formation of isobaric peptides as well as the
multiplexion of samples do not solve the problem of analysis of trace amounts of peptides. Although
the multiplexion has been very useful and enables analysis of up to 12 samples simultaneously (12-plex),
it may result in decrease of sensitivity. According to literature data and protocols of producers, 25–50 μg
of tagged protein has usually been used for the iTRAQ experiment. However, there are some losses
during sample cleanup; therefore, using 200–500 μg of proteins is recommended [54,55]. Thus, a great
effort is made on improving the sensitivity of the analysis.
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One of the common practices to increase sensitivity in mass spectrometry is based on the
introduction of permanent charge to the molecule of interest, thereby further ionization (i.e.,
protonation) is not required for the detection. This approach includes formation of quaternary
ammonium salts (QAS) [56–58] or phosphonium salts (QPS) [59]. The commonly used example
of derivatization was coupling of a peptide with N,N,N-trimethylammonium acetyl (TMAA, betaine).
Although the introduction of fixed charge resulted in observation of N-terminal fragment principally,
the QAS modified peptides did not exhibit signal enhancement [60]. The comparison of signal
intensity for derivatized and unmodified compounds showed the higher peaks for unmodified
peptides. One of the possible reasons is improvement of the hydrophilic character of peptide
due to the presence of fixed charge. Thus, there was a need to change the TMAA for more
hydrophobic group, which in turn allowed to overcome this issue. It was also described that the
N,N,N-trialkilammonium modified peptides undergo Hofmann elimination [61]. This phenomenon
has been regarded as problematic, since it complicates the analysis of obtained data. Moreover, the
induction of peptide degradation via intramolecular cyclization was observed. Setner and co-workers
solved this problem developing QAS-peptide conjugates based on bicyclic 1-azabicyclo[2.2.2]octane
(ABCO) and 1,4-diazabicyklo[2.2.2]octane (DABCO) [62,63]. These structures are cyclic, thereby not
susceptible to Hofmann elimination. The sequencing of peptides containing the above-mentioned
modifications is facilitated, due to the presence of mainly a and b ion type series. One of the most
interesting features of ABCO and DABCO modified peptides is high tolerance for salt concentration,
which means that peptides can be detected even in the presence of 10 mM NaCl. This may be of
interest during the analysis of trace amounts of peptides, especially if there are concerns about the
loss of the sample during desalting on solid support. Bąchor and co-workers studied the limit of
detection for DABCO modified peptides and showed the possibility of detection of 15 attomole
sample using nano-LC-ESI-MRM [64]. Moreover, these results were used to design a novel quaternary

































Figure 11. The structures of QAS-iTRAQ 2-plex (X = Br, I) [9].
One form of tag is synthesized using commercially available 4-bromobenzyl[d2] bromide, the other
is a result of facile H/D exchange in the presence of 1% triethylamine, which results in the introduction
of two deuterium atoms in the balance group [65]. This new tag liberates stable benzylic-type cationic
reporter upon collisional activation. Thus, this approach introduces an ionization tag, which enables
isotopic labeling as well as results in increased ionization efficiency. Although this approach is
cost-effective and allows sensitive analysis due to the presence of an ionization enhancer, there are still
problems related to limited selectivity because of the active ester reactivity.
We recently proposed another class of ionization tags based on 2,4,6-trisubstituted pyridinium
scaffold [66]. The reaction relies on a simple conversion of ε-amino groups of lysine to
2,4,6-trisubstituted pyridinium derivative using pyrylium salt; hence, the highly improved sensitivity
of peptide detection by mass spectrometry. Pyrylium salts have been known for their reactivity towards
sterically unhindered primary amines leading to the formation of pyridinium salt. This chemical
property makes them especially selective toward the amine group of the lysine side chain, even in the
presence of other nucleophiles such as thiol group. The scheme of reaction is presented in Figure 12.
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Figure 12. Reaction of peptide with 2,4,6-trisubtituted pyrylium salt (R*-alkyl or aryl).
It is worth noting that derivatization by pyrylium salt does not require the application of an active
ester, e.g., succinimidyl group like in the case of other commonly used derivatizing agents. Thus, there
is no risk of a side reaction with the sulfhydryl group of cysteine or the imidazole group of histidine.
However, either desalting or lyophilization of the tryptically digested sample is required due to the
side reaction with ammonium ions originating from ammonium bicarbonate buffer. Therefore, the use
of triethylammonium bicarbonate should be considered. The study on detection limits revealed the
possibility of detection of 2,4,6-triphenylpyridinium modified peptide at an attomole level in multiple
reaction monitoring mode (Figure 13). The MS/MS fragmentation spectra formed upon collisional
activation are characterized mainly by y type ions series, due to the presence of permanent charge at
C-terminus. Thus, the sequencing is facilitated as well as becomes more predictable.
Figure 13. ESI-MS-MRM chromatogram obtained for H-Gly-Leu-OH derivatized with
2,4,6-triphenylpyrylium salt and registered for 1 attomole [66].
The great advantage of pyrylium salts’ application has been their commercial availability as
well as cost-effectiveness. Furthermore, the compounds can be easily synthesized with a good
yield by a one-pot cyclization of two equivalents of benzalacetophenone and one equivalent of
benzaldehyde [67–69]. This fact prompted Waliczek and co-workers to prepare isotopically labeled
2,4,6-triphenylpyrylium (tetra-2,3,5,6-13C4) and then apply it to the formation of isobaric peptides
(2-plex) [70]. This novel approach (Figure 14) exploited the combination of 16O/18O labeling, commonly
used in proteomics and formation of a pyridinium-based ionization enhancer [71,72].
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Figure 14. Scheme presenting the formation of a pyridinium-based duplex (the blue circle indicates the
13C labeling) [70].
The enzymatic tryptic digestion and simultaneous 18O2-labeling has become a useful strategy
in comparative proteomics and allows for quantitative comparison of two samples during a single
LC-MS run. This technique has been featured by easy adaptation to clinical samples, cost-effectiveness,
and simplicity of performance. Despite many advantages, there are drawbacks, including peaks
overlapping and back-exchange [73]. The first one occurs particularly in multiple charged peptides
due to decrease of m/z difference between the labeled and unlabeled peptide. This may overcome
the problem of partial overlapping of the natural isotope peaks of unlabeled and labeled compounds.
The scheme of this approach is presented in Figure 14. The two samples are subjected to enzymatic
16O/18O exchange (trypsin) of the carboxyl group oxygen atoms in the C-terminal lysine residue, while
the second one remains unlabeled. The mass difference between these two forms is 4 Da. Then, the
18O2-labeled first sample is derivatized by 2,4,6-triphenylpyrylium salt, while the unlabeled sample is
treated with 2,4,6-triphenylpyrylium salts containing four 13C atoms. Finally, the obtained samples
are pooled and analyzed by LC-MRM MS. The previous study revealed the presence of an abundant
protonated pyridinium cation in the fragmentation spectrum, thereby playing a role of the balancing
group (m/z 308.14 and 312.15) in this method. Thus, a comparison of these two signal allows relative
quantitation. It should be noted here that the 18O labeling approach possesses some limitations
because of incomplete 16O/18O exchange in case of certain tryptic peptides. Therefore, in rare cases,
the proposed method may not be efficient enough and their exclusion from further analysis should be
considered. Moreover, this method enables the simultaneous analysis of only two samples and at the
current stage there is no possibility to expand it to e.g., 4-plex or 8-plex. However, it is worth noting
that a combination of 16O/18O labeling with derivatization by pyridinium salt solves some problems
regarding this approach. First of all, the relative quantitation of peptides relies on comparison of singly
charged and is shifted by 4 Da reporter ions, formed as a result of fragmentation of isobaric peptides.
Thus, no risk of peak overlapping occurs. Secondly, the pyridinium modified peptides are no longer
recognized by trypsin, which in turn prevents the back-exchange. Thirdly, the presence of ionization
tag in peptides increases ionization efficiency and allows the sensitive analysis of tryptic digests.
Summarizing the presented data, there is still a need for multiplexing of samples, thereby enabling
the simultaneous analysis of many samples. However, due to the frequently occurring decrease in
sensitivity with increased multiplexity, there is also a great need for application of ionization tags.
Thus, a design of the modern isobaric tags should in our opinion involve the ionization enhancer, thus
improving the sensitivity of analysis.
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11. Conclusions
The presented manuscript provides an overview of the current role of isobaric markers in
MS-based proteomics. In recent years, state-of-the-art applications in this field have expanded
enormously, proving its validity and utility. Currently, the application of labeling strategies dominates
in the field of quantitative proteomic and post-translational modifications’ profiling. Due to its success,
chemical isobaric labeling methods play a crucial role in proteomics and, supported by recent advances
in mass spectrometric instrumentation and bioinformatics tools, may help solve several problems
related to the early diagnosis, prognosis, and monitoring of some diseases. It can be concluded that
there is not one perfect and universal method for protein quantification; however, several usable
methods have been developed. Additionally, the continuous development of mass spectrometers
and new multiplex labeling techniques may significantly improve quantitative proteomic analysis.
Although the possibilities of wide use of isobaric tracers in quantitative studies of proteins are beyond
doubt, their application in screening medical tests is limited due to the high costs of isobaric reagents
and too small increase in the sensitivity of measurements. Therefore, new methods of inexpensive
labeling of peptide biomarkers are being intensively sought, which will include not only an isobaric
labeling function, but also ionization markers, thus significantly reducing the amount of biological
material needed for quantitative analysis. It can be expected that in the future the new isobaric markers
will be developed with elevated usable features, including the lowest possible price for production
of a set of isobaric reagents; high stability of the reagent allowing its long-term storage at room
temperature; high reactivity and specificity in reacting with a specific chemical group of biomarkers;
ability to smoothly release certain reporter ions from the labeled biomarker during CID, which will
provide reliable quantitative results; high multiplexicity of markers, which will ensure the possibility
of employing of a large variety and complex distribution of heavy atoms in the reporter and balancing
groups; and high sensitivity of the analysis, by using stable ionization markers in the ionizing marker
reporter group, such as cyclic quaternary ammonium salts.
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Abstract: The discovery of the anticancer activity of cisplatin and its clinical application has opened
a new field for studying metal-coordinated anticancer drugs. Metal-based anticancer drugs, such as
cisplatin, can be transported to cells after entering into the human body and form metal–DNA or
metal–protein adducts. Then, responding proteins will recognize adducts and form stable complexes.
The proteins that were binding with metal-based anticancer drugs were relevant to their mechanism
of action. Herein, investigation of the recognition between metal-based anticancer drugs and its
binding partners will further our understanding about the pharmacology of cytotoxic anticancer
drugs and help optimize the structure of anticancer drugs. The “soft” ionization mass spectrometric
methods have many advantages such as high sensitivity and low sample consumption, which are
suitable for the analyses of complex biological samples. Thus, MS has become a powerful tool for
the identification of proteins binding or responding to metal-based anticancer drugs. In this review,
we focused on the mass spectrometry-based quantitative strategy for the identification of proteins
specifically responding or binding to metal-based anticancer drugs, ultimately elucidating their
mechanism of action.
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1. Introduction to Metal-Based Anticancer Drugs
As early as the 1960s, Rosenerg first discovered that platinum complexes have an inhibitory effect
on tumor cell growth, and used platinum complexes to treat tumors [1]. In the past 30 years, cisplatin,
carboplatin, nedaplatin, oxaliplatin, and lobaplatin (Figure 1) have been successfully developed and
used for the clinical treatment of cancer. In particular, cisplatin, oxaliplatin, and carboplatin are
used worldwide as anticancer drugs. To date, all of the clinically used platinum drugs contain a
single PtII center with two exchangeable ligands in cis geometry. The interaction of these drugs
with cellular biomolecules such as sulfur-containing glutathione and metallothionein can deactivate
them before reaching their pharmacological target, DNA [2,3]. After platinum drugs enter into the
body, the intracellular Cl− concentration is low, and the drug is easily hydrolyzed to form an active
molecule. The active hydrolysate has a positive charge, and is electrostatically attracted by DNA,
which is a negatively charged genetic material located in the nucleus [4]. Binding to DNA forms DNA
intra-strand cross-linking, inter-strand cross-linking, and DNA protein cross-linking. The formation of
DNA cross-linking affects DNA strand synthesis, replication, and ultimately leads to cell death [5–9].
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Figure 1. Platinum chemotherapeutic drugs: cisplatin, carboplatin, oxaliplatin, and BBR3464.
The study of the mechanism of classical platinum drugs has helped chemists develop new
platinum drugs. Polynuclear platinum complexes (PPCs) are a new class of platinum anticancer
complexes, which are structurally different from cisplatin, and exhibit a different mode of DNA
binding, such as the phosphate clamp DNA binding mode of substitution-inert PPCs [10]. Especially,
conformational changes induced by long-range inter-strand and intra-strand cross-links are distinctly
different from those induced by mononuclear platinum complexes [11]. The prototype of this class,
BBR3464 [{trans-PtCl(NH3)2}2{μ-trans-Pt(NH3)2(H2N(CH2)6NH2)}]4+ (Figure 1), is the only platinum
compound without two exchangeable ligands in cis, and has reached Phase II clinical trials [12].
It is cytotoxic in cisplatin-resistant cell lines, and shows high efficacy in p53 mutant tumor cells [13].
BBR3464 can be deactivated in human plasma [14,15].
In addition to PPCs, there are also other trans-platinum complexes. Early studies have suggested
that transplatin is inactive, but recent studies have found that some trans-platinum complexes have
good in vitro and in vivo anti-tumor activity. The anti-tumor mechanism of this complex is still unclear.
Generally, although DNA has long been believed to be the major target of platinum anticancer drugs,
several proteins/enzymes have recently been proposed to be involved in the action of platinum
complexes [16].
The discovery of the anticancer activity of cisplatin and its clinical application has triggered the
study of metal-coordinated anticancer drugs; however, the serious side effects and intrinsic or acquired
drug resistance of cisplatin largely limited its further clinical application. This has led medicinal
chemists to explore other metal-based anticancer candidates, for example Ti, Os, and Ir complexes, to
circumvent the problems associated with cisplatin administration [17–20]. A number of non-platinum
complexes have entered clinical trials. Ruthenium compounds are regarded as promising alternatives
to anticancer platinum drugs based on several advantages, for example, ruthenium compounds
have lower toxicity and less drug resistance [21,22]. The most important developments comprise
the clinically tested RuIII compounds indazolium trans-[tetrachloridobis(1H-indazole)ruthenate(III)]
(KP1019), imidazolium trans-[tetrachlorido(DMSO)(1H-imidazole)ruthenate(III)] (NAMI-A), and RuII
compounds RAPTA (Figure 2). The structure of KP1019 was slightly modified due to solubility reasons,
and was renamed as NKP-1339 (also IT-139). NKP-1339 is currently in clinical trials, and obtained
orphan status from the Food and Drug Administration (FDA) in 2017. While the clinical trial for
NAMI-A has been abandoned. RuIII has a wide range of coordination numbers and geometries,
as well as accessible redox states, which offer the medicinal chemists a wide spectrum of reactivities
that can be exploited. RAPTA complexes are a promising class of organometallic RuII compounds that
inhibit processes related to metastasis in vitro and exhibit pronounced antimetastatic activity in vivo,
but only low antiproliferative activity [23,24]. Moreover, it has been shown that RAPTA compounds
preferentially bind to proteins, even in the presence of DNA [25,26].
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Figure 2. Chemical structure of ruthenium anticancer drugs: RuIII compounds indazolium trans-
[tetrachloridobis(1H-indazole)ruthenate(III)] (KP1019), imidazolium trans-[tetrachlorido(DMSO)(1H-
imidazole)ruthenate(III)] (NAMI-A), RAPTA-T.
Except platinum and ruthenium, arsenic and gold complexes are also used as anticancer
agents. AsIII and AsV are the main oxidation states of arsenic. The cytotoxic activity of arsenic
compounds in the trivalent state is strongly associated with the enhanced production of reactive
oxygen species (ROS) [27,28]. The biological activity of pentavalent arsenic is mainly based on
substitution for phosphate (e.g., in ATP) [29]. Amongst the various forms of arsenicals, the greatest
clinical success has been the one of arsenic trioxide (ATO; As2O3, Trisenox®) (Figure 3) in the treatment
of hematological cancers, especially acute promyelocytic leukemia (APL) [30,31]. Arsenic trioxide
forms inorganic As(OH)3 in an aqueous environment, and this form can be transported intracellularly
via aquaglyceroporin channels due to its similarity to glycerol [32]. In addition to arsenic trioxide, other
organic and inorganic arsenic agents are undergoing clinical trials for hematological malignancies,
such as S-dimethylarsino-glutathione (Figure 3) [33].
 
 
Arsenic trioxide S-dimethylarsino-glutathione (Darinaparsin, ZIO-101) 
Figure 3. Chemical structure of arsenic anticancer drugs.
In the early days, gold compounds were mainly used for the treatment of rheumatoid arthritis
(RA). Auranofin (Ridaura) was approved by the FDA for the treatment of RA in 1985 (Figure 4) [34].
Au compounds can be considered as prodrugs, and require activation (achieved by ligand exchange
reactions) before they can develop their full pharmacological potential [29]. Several Au compounds
are found to resolve the resistance of platinum compounds confirming different mechanisms of
action [35]. It seems that the main targets of Au compounds are proteins rather than DNA, since
scientists found the selenoprotein thioredoxin reductase plays a crucial role in the biological actions of
gold compounds and acts as a major and general receptor for gold compounds, which can interact
with specific thiol-containing and seleno-containing peptide moieties [36,37].
In addition to the above-mentioned metal drugs, many other metal complexes can be potentially
used for the treatment of cancer, such as vanadium (V), rhodium (Rh), zinc (Zn), and cobalt (Co) [26].
Generally, metal-based anticancer drugs have high affinity for sulfur-containing biomolecules, such as
proteins with Cys and Met residue. Thus, protein may play an important role in the mechanisms
of those drugs such as drug resistance, toxicity, and metabolism. A comprehensive investigation of
the interaction between metal-based anticancer drugs and their binding proteins or cell will further
our understanding about the pharmacology of cytotoxic anticancer drugs from a molecular level.
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Mass spectrometry-based quantitative strategy has been widely used for the identification of proteins
specifically responding or binding to metal-based anticancer drugs.
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Figure 4. Chemical structure of gold anticancer drugs.
2. Quantitative Proteomics: General Remarks
Proteomics is the large-scale study of proteins, with a particular emphasis on their structures and
functions. Proteins form a crucial part of the living organisms, as they are the main components
of the metabolic and signaling pathways of cells while playing very important structural roles.
Mass spectrometry is widely used in proteomic research because of its various advantages, including
high sensitivity, high throughput, and good compatibility. It is even more powerful when combined
with other separation techniques such as capillary electrophoresis (CE) and liquid chromatography
(LC). Among the mass spectrometric ion source, ESI and MALDI are the most commonly used.
Briefly, ESI generates multiply charged ions for biomolecules, while MALDI yields mostly singly
charged pseudomolecular ions of analytes. ESI-MS can be easily hyphenated with separation
techniques, whereas MALDI-TOF-MS cannot be directly combined to chromatographic methods;
thus, MALDI-TOF-MS is usually accompanied with two-dimensional (2D) gel electrophoresis in
proteomics, while ESI-MS is often coupled with nano-LC in proteomics to achieve higher sensitivity.
Consequently, both ion sources are utilized for proteomic research.
Most of the mass spectrometers that are available offer one or more fragmentation methods
that are used to provide information about the structure and composition of the ion of interest.
Collision-induced dissociation (CID) is the most frequently employed fragmentation technique in
current MS-based proteomics. In CID, selected peptides are subjected to collisions with inert gas
molecules such as helium and nitrogen [38]. HCD is another fragmentation method, which is available
for the LTQ Orbitrap [39]. In HCD, ions are fragmented in a collision cell rather than an ion trap,
and then transferred back through the C-trap for analysis in the Orbitrap [40]. Besides CID and
HCD, electron-based approaches such as electron capture dissociation (ECD) and electron transfer
dissociation (ETD) are also used in MS-based proteomics as fragmentation techniques. The mechanism
of electron-driven fragmentation techniques is fundamentally different from CID [41].
There are two general strategies applied in proteomic, which are called “bottom–up” and
“top–down”. Top–down describes the fragmentation of intact proteins without enzyme digestion.
This approach is limited to small and pure proteins, while bottom–up involves enzymatic digestion of
the analytes prior to fragmentation, and requires more sample preparation before data acquisition.
A variety of chromatographic separation and enrichment methods could be used to achieve better
peptide coverage and more identification. Owing to the introduction of enzymatic digestion, this
strategy is well suited for investigating lager proteins and protein mixtures. For the quantitative
proteomics research of biological systems, the “bottom–up” approach is more widely used.
Current methods for protein quantitation can be classified into two main categories: stable isotope
labeling and label-free quantitation. Stable isotope labeling can introduce isotopically labeled forms
into target components for relative quantification. The light labeled and heavy labeled proteins
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are mixed proportionally before LC/MS analysis, and the peak area ratio of ion pairs generated by
isotopically labeled analytes is used to quantify the components in the sample [42]. The workflow is
shown in Figure 5. ICAT, TMT, iTRAQ, and SILAC belong to this category, and they are commonly
used in quantitative proteomics research. A comparison of those methods is shown in Table 1.




Metal Drugs Investigated by
Each Method
ICAT Procedure is easy.
Only two samples can be labeled,
which is only applicable to proteins
containing cysteine.
Cisplatin [43,44]
TMT Quantification on multiplesets of protein samples. Expensive Cisplatin [45]
iTRAQ Quantification on multiplesets of protein samples. Expensive Cisplatin [44]
SILAC Applicable to cultured cell.
It cannot be applied to samples such as
tissues and body fluids. Expensive,
time-consuming, and complicated.
Cisplatin [46]
Gold (III) porphyrins [35]
LFQP Straightforward andcost-effective.
It requires more rigorous analytical







It resolves thousands of






Gold (III) NHC complexes [53]
 
Figure 5. The workflow of stable isotope labeling-based quantitative proteomics. This figure is adapted
from reference [44].
The ICAT reagent mainly consists of three parts: the first part is the affinity tag composed of
biotin, which is used to separate ICAT-labeled peptide. The second part is the linker, and it is used
to introduce the stable isotope. The third part is the reactive group that specifically binds to the thiol
group of a cysteine residue in a peptide. The ICAT reagent exists in two forms—light (contains no
deuterium) and heavy (contains eight deuterium atoms) form—and the mass difference among them is
exactly eight Da (Figure 6). After the isotopic label is introduced into the peptide, the response intensity
of two labeled forms for the same peptide is compared by MS. ICAT can analyze most proteins in
cells, tissues, body fluids, etc., with good compatibility, but it should be noted that this method is only
applicable to proteins containing cysteine [43,54–56].
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Figure 6. Structure and reaction mechanism of the ICAT reagent. This figure is adapted from
reference [57].
In order to solve the shortcomings of the ICAT reagent, Thompson et al. synthesized TMT (tandem
mass tags) reagent. The chemical structure of the commercial TMT agent is shown in Figure 7. It consists
of a mass reporter region, a cleavable linker region, a mass normalization region, and a reactive
group. The reactive group can specifically bind to the −NH2 group of the peptide. When utilized
for the relative quantification of multiple sets of protein samples, it enables the isotopically-labeled
forms of target molecules to have identical chromatographic behavior and primary MS characteristic.
The different label forms of target peptides are dissociated in the cleavable linker region and form
different reporter ions for mass spectrometry (MS/MS) detection. Therefore, the relative content of
target protein in different samples can be determined after comparing the intensity of reported ions.
Figure 7. The chemical structure of two-plex tandem mass tag (TMT) reagents. This figure is adapted
from reference [58].
iTRAQ is based on the same labeling strategy as TMT. The reagent consists of three parts (Figure 8),
and the four available tags have identical overall mass. For four-plex iTRAQ reagents, the reporter
group (green, N-methylpiperazine) mass is 114, 115, 116, and 117, respectively. The balance group
(blue, carbonyl group) has a mass of 31 Da, 30 Da, 29 Da, and 28 Da accordingly. The reactive group
(red, NHS ester) selectively reacts with the amino group of the peptide (the N-terminus and amino
groups of the side chain). After LC-MS analysis, proteins are quantified by the relative intensity of the
reporter group in MS/MS spectra. The iTRAQ technique has been widely used for the quantitative
study of proteins due to its high accuracy and precision. What’s more, it is able to simultaneously and
quantitatively analyze up to eight samples [59,60]. However, iTRAQ reagents are expensive, and can
significantly increase the cost of research.
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Figure 8. Chemical structure of the iTRAQ™ reagent. This figure is adapted from reference [61].
The stable isotope labeling methods mentioned above are all in vitro methods, and the typical
example of the in vivo method for the relative quantitation of proteins is the stable isotope labeling by
amino acids in cell culture (SILAC) [62]. The basic principle of this technique (Figure 9) is to add light
and heavy isotopically-labeled essential amino acids (usually lysine and arginine) to the cell culture
medium. After five to six doubling cycles, the amino acids of the newly synthesized protein in the cell
are almost completely labeled with stable isotopes. Therefore, the accurate quantification of proteins
can be achieved based on the peak intensity or area ratio of the two isotopically labeled peptides in
the mixed sample. SILAC technology is able to mix samples at the protein level, which can effectively
avoid the quantitative error caused by subsequent enzymatic digestion. It has high labeling efficiency
and high quantitative accuracy. However, the presence of isotope-labeled arginine metabolism and the
proline formation lead to low labeling efficiency and decreased quantification accuracy [63]. At the
same time, this technique is only applicable to the cultured cell, and cannot be applied to samples
such as tissues and body fluids, which are commonly used in medical research.
Figure 9. Overview of stable isotope labeling by amino acids in cell culture (SILAC) protocol.
The SILAC experiment consists of two distinct phases: an adaptation (a) and an experimental (b)
phase. This figure is adapted from reference [64].
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Label-free quantitative proteomics (LFQP) is based on spectral counting and peak intensity for
comparative analysis of the abundance of proteins. It provides a straightforward option for the
large-scale analysis of biological samples. In contrast to label-based methods, LFQP mainly quantifies
the number of identified peptides and the area of primary mass spectral peak by calculating the
peptide fragment matching [65,66]. LFQP is cost-effective, and does not require expensive isotope
reagents. In addition, LFQP is not time-consuming compared with some label-based methods that
require tedious labeling steps [67,68]. Due to the aforementioned reasons and the increase of analytical
capabilities of LC-MS/MS instrumentation in terms of resolution, accuracy, and sensitivity, LFQP has
gained more acceptance in biomedical research. The characteristic peptides of each protein can be
used for quantification [69], which can effectively improve the accuracy of non-labeled quantification.
However, the label-free approach requires more rigorous analytical measurements and statistical
validation compared with isotope-coded measurements.
As we can see, both labeling and label-free approaches have their own advantages and limitations
(Table 1). More and more methods are developed for quantitative proteomic analysis in recent years.
Those are the foundation for studying the mechanism of metal-based anticancer drugs.
3. Application of Quantitative Proteomics for Elucidation of the Mechanism of Metal-Based
Anticancer Drugs
3.1. Proteomic Analysis of Cellular Responses to Metal-Based Anticancer Drugs
It’s very important to monitor, in real time, the proteomic responses of cells to cytotoxic
metallodrugs, as such responses might provide valuable information on the mechanism of action of
the drug itself, and highlight which metabolic or signaling pathways of the cell are primarily affected
and/or activated. If the damage is too intense to be repaired, specific biochemical pathways will be
triggered, ultimately leading to cell apoptosis [70]. A number of studies utilizing this kind of strategy
have appeared in recent literatures.
Cho et al. exploited the proteomic method based on a label-free quantitation strategy to
study the cisplatin-induced hepatotoxicity [71]. Results showed that 76 proteins were up-regulated,
and 19 proteins were down-regulated. The up-regulated proteins in the cisplatin-treated group
include FBP1 (fructose 1,6-bisphosphatase 1), FASN (fatty acid synthase), CAT (catalase), PRDX1
(peroxiredoxin-1), HSPD1 (60-kDa heat shock protein), MDH2 (malate dehydrogenase 2), and ARG1
(arginase 1). Down-regulated proteins in the cisplatin-treated group include TPM1 (tropomyosin 1),
TPM3 (tropomyosin 3), and CTSB (cathepsin B), which were further confirmed by Western blot analysis.
Subsequent pathways analysis revealed that drug metabolism, fatty acid metabolism, glycolysis/TCA
cycle, urea cycle, and inflammation metabolism were involved in cisplatin-induced hepatotoxicity.
Cytotoxic gold-based complexes have different modes of action from cisplatin. It was found that
auranofin and Auoxo6 are more active than cisplatin against both the cisplatin-sensitive A2780/S
and resistant A2780/R cell lines. Guidi et al. reported the use of 2-DE and MS analysis to find the
molecular mechanisms through which auranofin and Auoxo6 caused their biological effects [52].
2-DE combined with MALDI-TOF analyses showed that 10 proteins were down-regulated, and one
protein was up-regulated in A2780/R cells treated with auranofin versus controls. For Auoxo6,
12 proteins were down-regulated and four proteins were up-regulated. After investigation of the
altered proteins, they proposed that auranofin mostly acts by altering the amount of proteasome
proteins, while Auoxo6 mainly modifies proteins related to mRNA splicing, trafficking, and stability.
Interestingly, thioredoxin-like protein 1, which is involved in oxidative stress defense, was greatly
reduced after treatment with both gold compounds.
The characteristics of high anticancer efficiency of cisplatin and the clinical inactivity of its trans
isomer (transplatin) have been considered a paradigm for the classical structure-activity relationships
of platinum drugs. However, some new analogues of transplatin exhibit activity in cisplatin-resistant
tumor cells, but the mechanism behind this activity is unknown. An MS-based proteomic strategy
combined with functionalized gold nanoparticles as affinity probes was developed to study the
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cellular proteins responding to damaged DNA by cisplatin and trans-PtTz (Figure 10) [72]. To exclude
nonspecific binding proteins to the platinated DNA, the negative probe with native double-stranded
DNA on gold nanoparticles was utilized as a control. As a result, the well-known protein HMGB1
was identified as a binding partner of platinated DNA by cisplatin, and the nuclear protein positive
cofactor PC4 was found to bind specifically with cross-linked DNA by trans-PtTz, which will shed
light on the mechanism of this active transplatinum complex.
Figure 10. Overview of the MS-based proteomic strategy to study the cellular proteins responding to
damaged DNA by platinum drugs. This figure is adapted from reference [72].
Palladium (Pd)-based compounds have gained the interest of many researchers, as they
exhibit similar coordination chemistry and better solubility compared with platinum drugs [73].
[Pd(sac)(terpy)](sac)·4H2O (sac = saccharinate, and terpy = 2,2′:6′,2”-terpyridine), a palladium-based
compound, was reported to be more potential than cisplatin in breast cancer cells. To figure out
the mechanism of action, Adiguzel et al. performed nanoLC-MS/MS analysis to investigate the
global proteomic changes after treatment of this Pd(II) complex [48]. Eventually, 681 proteins were
identified, among which 335 protein groups were quantified through the label-free quantitative
method. Furthermore, 30 differentially expressed proteins were identified between drug-treated cells
and untreated cells. These proteins were involved in the regulation of apoptosis, proliferation, protein
degradation, and DNA repair, etc. Ingenuity pathway analysis revealed that the involved pathway
appeared as the protein ubiquitination; therefore, apoptosis is the mechanism of cell death in response
to Pd(II) treatment, as a significant increase in ubiquitination was identified. Finally, they proposed
that the mode for the cytotoxic action of the Pd(II) complex was that cells initially attempt to repair
Pd(II)-induced damage, yet prolonged damage or exposure of higher doses lead to protein degradation
and apoptosis in cancer cells.
3.2. Analysis of the Molecular Basis of Platinum Resistance through Comparative Proteomic Analysis of Pt
Sensitive versus Pt-Resistant Cell Lines
There are lots of studies about the molecular basis of platinum drugs resistance. Indeed, acquired
resistance is often the reason for treatment failure, and therefore attracts great interest. Understanding
the molecular mechanism of resistance might help to circumvent it. Thus, a conspicuous number of
proteomic studies were specifically devoted to this issue.
A quantitative proteomic screening was performed to identify the proteins that are differentially
expressed in drug-resistant cell lines through which the mechanisms involved in cisplatin resistance
may be found out [46]. The SILAC approach with nano-LC-MS was employed in this experiment. As a
result, a total of 856 proteins, among which 374 proteins were differentially expressed between the
cisplatin-resistant cell (HeLa/CDDP) and sensitive cells (HeLa) were identified. The expression of
a few key proteins, including CD44, DDB-1, DJ-1, and XRCC5, were confirmed by Western blotting,
which was highly consistent with the proteomic analysis. A further protein interaction network based
on the differentially expressed proteins was constructed, and finally, the biological pathways, including
157
Molecules 2019, 24, 581
carbohydrates, energy-producing, regulation of apoptosis, and protein folding were involved in the
drug resistance.
A number of studies have found that mitochondria was correlated with the cisplatin resistance.
Mitochondrial DNA and membrane proteins were reported as preferential targets of cisplatin. It was
also shown by several groups that mitochondria impairment appeared to play an important role in the
platinum resistance of ovarian cancer cells. Using 2D DIGE integrated with MALDI-TOF-MS, Dai et al.
investigated the mitochondrial proteins difference between platinum-sensitive human ovarian
cancer cell lines (SKOV3 and A2780) with that of four platinum-resistant sublines (SKOV3/CDDP,
SKOV3/CBP, A2780/CDDP, and A2780/CBP) [51]. Through a 2D DIGE experiment, 236 spots were
identified, among which 128 spots were down-regulated in platinum-resistant cells, and 108 spots
were up-regulated in these resistant cells. Eleven spots that had more than threefold changes in
platinum-resistant cells compared with platinum-sensitive cell lines were analyzed and verified by
MALDI-TOF-MS. Five of the proteins, ETF, PRDX3, PHB, ATP-a, and ALDH, were identified. ATP-a,
PHB, and PRDX3 have been validated as mitochondrial proteins of ovarian cancer cells, and they were
further confirmed through immunoblotting. The expressions of ATP-a, PHB, and PRDX3 were further
validated in the clinical ovarian cancer sections; as a result, a significant difference existed in PHB
expression between the sensitive group and the resistant group, demonstrating that PHB might be a
correlative candidate protein for platinum resistance in the mitochondria of ovarian cancer cells.
Using the ICAT approach, Stewart et al. profiled the nuclear, cytosolic, and microsomal fractions
of IGOV-1 (cisplatin-sensitive) and IGOV-1/CP (cisplatin-resistant) ovarian cancer cell lines [43].
A total of 1117 proteins were identified and quantified, among which 121 proteins were expressed
differentially in cisplatin-resistant cell lines compared with the sensitive ones. Sixty-three proteins
were overexpressed in cisplatin-sensitive cells, and 58 proteins had low expression in these cells.
Among the 63 overexpressed proteins, several proteins were overexpressed at least fivefold in
resistant cells, including cell recognition molecule CASPR3 (13.3-fold), S100 protein family members
(8.7-fold), junction adhesion molecule Claudin 4 (7.2-fold), and CDC42-binding protein kinase (5.4-fold).
Other proteins exhibited low expression for at least fivefold in resistant cells, including hepatocyte
growth factor inhibitor 1B (13.3-fold) and programmed cell death 6-interacting protein (12.7-fold).
They also compared the expression of mRNA with that of protein in a subset of 92 highly differentially
expressed proteins, and the expression level of 37 proteins are in the same direction with that of
mRNA, and 55 are discordant, possibly reflecting the post-transcriptional control of protein expression.
By Gene Ontology (GO) analysis, many processes, including RNA splicing, processing, and DNA
replication were increased in cisplatin-resistant cells. The increased activities of these biological
processes may lead to faster repairs of cisplatin-induced DNA damages, thus resulting in a resistant
phenotype. They also found that three pathways (glycolysis, the interleukin signaling pathway, and the
PI 3-kinase pathway) were significantly up-regulated in cisplatin-sensitive cells, which were involved
in cell apoptosis.
Cisplatin-based chemotherapy is currently used for bladder cancer (BC), but it lacks efficiency
on patients who have acquired or developed resistance. In order to reveal the molecular mechanisms
underlying this resistance, Jung et al. carried out a multidimensional proteomic analysis on
cisplatin-sensitive (T24S) and resistant (T24R) T24 human BC cell lines [45]. It was reported that
the aberrant expression or mutations of the EGFR family are related to the carcinogenesis of bladder
cancer (BC); therefore, the temporal changes in protein abundance and phosphorylation in T24S and
T24R cells after EGF stimulation were also investigated. Sixplex TMT reagents were used to label
peptide samples. Consequently, the global proteome profiles in both T24R and T24S cells changed
slightly. Whereas, phosphoproteome in T24S cells changed more than T24R cells, which revealed
that T24S cells were impacted more greatly than T24R cells by EGF stimulation. The analysis of
altered proteins revealed associations of cisplatin resistance with DNA damage, repair, and cell
cycle regulation, which is consistent with previous reports [74]. Several key regulators linked to
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cisplatin resistance were confirmed. These results are promising, but need more clinical specimens for
phosphorproteomic analysis.
Neuroblastoma is a challenging childhood malignancy with a very high percentage of
patients relapsing after the acquisition of drug resistance. In order to investigate the molecular
pathways involved in the drug resistance of neuroblastoma, Piskareva et al. characterized three
cisplatin-sensitive/resistant cell line pairs using the label-free quantitative method [47]. As a result,
46/72, 68/43, and 34/63 proteins were found to be up-regulated and down-regulated for the three cell
line pairs, respectively. Differentially-expressed proteins for each individual cell line pair were used to
analyze the molecular and cellular functions that were involved through ingenuity pathway analysis.
Known mutual interactions among differentially expressed proteins for each cell line pair were used
to construct protein networks. Consequently, four proteins were in common across these networks,
including betatubulin (TUBB), beta-actin (ACTB), vimentin (VIM), and 78 kDa glucose-regulated
protein (HSPA5). Pathways analysis suggested that the epithelial-to-mesenchymal transition is a
feature during the development of drug resistance in neuroblastoma.
3.3. Mass Spectrometry-Based Quantitative Proteomics for Identification of Target Proteins for Metal-Based
Anticancer Drugs
Target identification utilizing photoaffinity groups together with clickable moieties recently
emerged as a useful strategy to identify macromolecular binding partners for small organic molecules,
but it was seldom used for the target identification of anticancer metal complexes. Fung et al. developed
a chemical probe for the target identification of [AuIII(CˆNˆC)(NHC)]OTf by introducing a small
photoaffinity diazirine group and a clickable alkyne moiety on NHC [53]. HeLa cells were treated
with the probe, and then irradiated followed by a click reaction; eventually, six photoaffinity-labeled
proteins were identified by gel electrophoresis accompanied by MALDI-TOF-MS, and these proteins
were also found in the protein samples from NCI-H460 and HCT116 cells treated with the same probe.
The six proteins were identified as mitochondrial heat shock protein 60 (HSP60), vimentin (VIM),
nucleoside diphosphate kinase A (NDKA), nucleophosmin (NPM), nuclease-sensitive element binding
protein (Y box binding protein, YB-1), and peroxiredoxin1 (PRDX1) by MALDI-TOF-MS/MS analysis.
Except for YB-1, other proteins were verified by HPLC-LTQ-Orbitrap MS analysis with high confidence.
Besides, gold(III) meso-tetraphenylporphyrin is notable for its high stability in biological environments
and potent in vitro and in vivo anticancer activities. Extensive chemical biology approaches, including
photoaffinity labeling, click chemistry, chemical proteomics, and the SILAC technique were used to find
the protein target of gold(III) porphyrins [35]. Compelling evidence revealed that heat-shock protein
60 (Hsp60), a mitochondrial chaperone and potential anticancer target, is a direct target of gold(III)
porphyrins in vitro and in cells. Structure-activity studies with a series of non-porphyrin gold(III)
complexes and other metalloporphyrins revealed that Hsp60 inhibition is specifically dependent on
both the gold(III) ion and the porphyrin ligand.
Organometallic anticancer agents often require ligand exchange for their anticancer activity,
which is generally believed to possess low selectivity for potential cellular targets. However, Meier et al.
found an unexpected target selectivity of a ruthenium(arene) pyridinecarbothioamide (plecstatin)
(Figure 11). They utilized a label-free quantitative method to seek out the potential target of plecstatin.
To address nonspecific interactions, a competition experiment was conducted by pretreatment with
drug [49]. As a result, roughly 400 proteins were identified, among which only outer dense fiber
protein 2 (ODF2, 210-fold) and plectin (PLEC, 160-fold) were considered as potential targets with
high enrichment factors. The latter one is a scaffold protein and cytolinker with pronounced effects
on the organization of non-mitotic microtubules, which was considered as an unexpected target
for plecstatin. Moreover, non-mitotic microtubules are an underappreciated drug target, and their
disturbance by plectin-targeting agents affects the motility of cancer cells, which may develop a
promising anticancer strategy.
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Figure 11. Potential protein targets of ruthenium(arene) pyridinecarbothioamides (plecstatins) were
obtained by integrated target-response profiling. (A) Chemical structures. (B) Schematic representation
of the integrated target-response profiling workflow. (C) Selected chromatograms and mass spectra
of a plectin-specific tryptic peptide. (D) Plot of the target profiling experiment. PLEC: plectin; ODF2:
outer dense fiber protein 2. This figure is adapted from reference [49].
RAPTA compounds have attracted researchers’ attention, as their modes of action are substantially
different from commonly used platinum-based chemotherapeutics. In this case, drug pull-down
combined with affinity chromatography, mass spectrometry-based proteomics, and bioinformatics
were utilized to figure out the target proteins of antimetastatic agent RAPTA in ovarian cancer
lysate [50]. A competitive experiment using an acetylated RAPTA analogue was carried out to
remove the non-specific binding proteins. Pull-down experiments without competitive experiments
resulted in the identification of a total of 184 proteins. After comparing data with the competitive
experiment, the number of high-affinity proteins decreased to 29, which can be classified into four types:
extracellular proteins, cell cycle-regulating proteins, histone-related proteins, and ribosomal proteins.
Among the 29 proteins, 15 proteins were found to be cancer-related. What’s more, the identified
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proteins, including the cytokines midkine, pleiotrophin, fibroblast growth factor-binding protein 3,
guanine nucleotide-binding protein-like 3, and FAM32A were consistent with the hypothesis that the
antiproliferative activity of RAPTA compounds is due to the induction of a G2/M arrest and histone
proteins [75].
4. Conclusion Remarks
In recent years, metal-based anticancer drugs have played an important role in the clinical
chemotherapy of cancer, especially platinum-based anticancer drugs represented by cisplatin.
The adverse effects and acquired resistance of platinum-based anticancer drugs triggered researchers to
exploit novel anticancer metallodrugs and figure out the underlying mechanism of anticancer activity
and drug resistance.
Initial studies identified DNA as the primary target of platinum-based drugs, but current research
has revealed that metal-based drugs can also bind with proteins, which was correlated with their
activity, drug resistance, toxicity, and metabolism. Proteomics is the large-scale study of proteins,
and mass spectrometry has been widely used in proteomic research because of its high sensitivity, high
throughput, and good compatibility. Current methods for protein quantitation include stable isotope
labeling and label-free quantitation, which have been widely used for the studies of target proteins and
cellular response proteins for metal-based anticancer drugs. The altered expression of proteins found by
quantitative proteomics revealed that several metabolic and signaling pathways, for example protein
ubiquitination, were involved in the mechanism of metal drugs. Cellular protein targets identified
through quantitative proteomics pinpointed the molecular pharmacology of metal-based anticancer
drugs, such as Hsp60 for gold (III) porphyrins. Therefore, mass spectrometry-based quantitative
proteomics becomes a powerful tool to elucidate the mechanism of action for metal-based anticancer
drugs, which will facilitate the design of more efficient anticancer drugs.
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TMT tandem mass tags
SILAC stable isotope labeling by amino acids in cell culture
LFQP label-free quantitative proteomics
2-DE two-dimensional (2D) gel electrophoresis
HMGB1 high mobility group box 1 protein
PC4 positive cofactor 4
DDB-1 DNA damage-binding protein 1
DJ-1 Protein/nucleic acid deglycase DJ-1
XRCC5 X-ray repair cross-complementing protein 5
2-D DIGE Two-dimensional fluorescence difference gel electrophoresis
ALDH aldehyde dehydrogenase
ETF electron transfer flavoprotein
PHB prohibitin
PRDX3 peroxiredoxin III
EGFR epidermal growth factor receptor
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Abstract: Trypsin is the protease of choice for protein sample digestion in proteomics. The most
typical active forms are the single-chain β-trypsin and the two-chain α-trypsin, which is produced by
a limited autolysis of β-trypsin. An additional intra-chain split leads to pseudotrypsin (ψ-trypsin)
with three chains interconnected by disulfide bonds, which can be isolated from the autolyzate
by ion-exchange chromatography. Based on experimental data with artificial substrates, peptides,
and protein standards, ψ-trypsin shows altered kinetic properties, thermodynamic stability and
cleavage site preference (and partly also cleavage specificity) compared to the above-mentioned
proteoforms. In our laboratory, we have analyzed the performance of bovine ψ-trypsin in the
digestion of protein samples with a different complexity. It cleaves predominantly at the characteristic
trypsin cleavage sites. However, in a comparison with common tryptic digestion, non-specific
cleavages occur more frequently (mostly after the aromatic residues of Tyr and Phe) and more
missed cleavages are generated. Because of the preferential cleavages after the basic residues and
more developed side specificity, which is not expected to occur for the major trypsin forms (but
may appear anyway because of their autolysis), ψ-trypsin produces valuable information, which is
complementary in part to data based on a strictly specific trypsin digestion and thus can be unnoticed
following common proteomics protocols.
Keywords: autolysis; chain; cleavage; digestion; peptide; proteoform; pseudotrypsin; specificity; trypsin
1. Cleavage Specificity of Trypsin
Trypsin, a serine protease, is commonly used as an important enzymatic reagent in biochemistry
and biology. It is almost indispensable especially for the digestion of protein samples to peptides in
bottom-up proteomics [1]. Apart from this application, trypsin is a tool in working with cell cultures.
During trypsinization, surface adhesion proteins are degraded, which allows adherent cells to be
detached from each other and the walls of plastic containers or plates in which they are being cultured.
In industry, interestingly, trypsin is applied to hydrolyze allergenic proteins for the production of
hypoallergenic milk [2]. In proteomics, sample digests are typically analyzed for protein identification
by nanoflow liquid chromatography coupled to tandem mass spectrometry (nLC-MS/MS). MS-based
data on peptides are searched against amino acid sequence databases, which benefits from the relative
stringent cleavage specificity of trypsin as the search algorithms incorporate the cleavage rule as
a filtering criterion. According to a study with complex samples from 2004, the enzyme cleaves peptide
bonds in proteins at pH 8.3 exclusively at the carboxyl end of arginine and lysine residues [3]. This is
in agreement with the canonical trypsin cleavage rule postulated a long time ago [4] even though it
was built on results obtained at that time only with a limited amount of substrates [5]. Thus, it has
long been accepted that trypsin does not cleave before proline and its activity is suppressed either
if a cysteine appears next to Arg/Lys or the basic residue is N- or C-terminally adjacent to an acidic
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residue. This old rule was questioned when a large data set of 14.5 million MS/MS spectra of peptides
from Shewanella oneidensis was processed to statistically evaluate the cleavage sites [5]. Interestingly,
numerous cleavages before proline were found. Their number was even higher than that referring to
the cleavages before cysteine.
An average length of tryptic peptides is 14 amino acids. This number has been deduced from
an in silico digestion of human proteins in the UniProt database [1]. Because of this reasonable size as
well as the presence of a positive charge at the C-terminal Arg or Lys, which enhances the ionization
process in the positive ionization mode, tryptic peptides are highly amenable to mass spectrometric
measurements. In fact, there are at least two defined positive charges in tryptic peptides (at both N-
and C-termini), which is favorable for a good fragmentation in MS/MS analyses [1,2].
2. Nonspecific and Missed Cleavage Sites
In addition to the cleavages after Arg or Lys, proteomics studies have often reported the
formation of semitryptic and nonspecific peptides during the digestion process involving trypsin [1,6].
The semitryptic cleavage assumes that one of the cleavage sites is tryptic, but the other site may be
at any residue. A minor chymotrypsin or chymotrypsin-like activity yields nonspecific cleavages
C-terminal to phenylalanine, tyrosine, tryptophan, or leucine residues [7]. This can result either from
the presence of a chymotrypsin contamination, which is variable in trypsin preparations supplied by
different vendors [1], or pseudotrypsin (ψ-trypsin), a product of trypsin autolysis, which possesses such
an activity in addition to the characteristic trypsin properties [8]. The presence of nonspecific peptides
in tryptic digests (excluding C-terminal peptides) is also elucidated by a secondary non-enzymatic
cleavage between Asp and Pro residues yielding peptides with an N-terminal proline. This is because
of the lability of the respective bond, which is easily hydrolyzed in solution as well as broken in the
gas phase [3].
When the protein substrate is not cleaved to a completion, missed cleavages occur, which make the
assignment of experimental data to amino acid sequence databases less specific and straightforward.
Missed cleavage sites were investigated for example by matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry (MALDI-TOF MS) using human cell line or Mycobacterium proteins
separated by two-dimensional gel electrophoresis and digested in-gel by a porcine trypsin [9].
The analysis showed that about 90 % of the detected peptides with missed cleavage sites could be
attributed to the following sequence motifs: (1) Arg or Lys with a neighboring proline at the C-terminal
side, (2) two successive basic residues (Arg-Arg, Arg-Lys, Lys-Arg, Lys-Lys), and (3) Arg or Lys with
an aspartic acid or glutamic acid residue at either N-terminal or C-terminal side. When processing
peptide MS- and MS/MS-based data by database searches (during which theoretical peptide sequences
are generated according to the selected input cleavage rules), the user may, among others, adjust
a maximum number of missed cleavage sites. Usually, a setting of 0, 1, or 2 missed cleavages for
peptides is recommended. The presence of missed cleavages in tryptic peptides represents a challenge
in quantitative MS-based proteomics, which uses peptides as surrogates for their parent proteins [10].
Under optimal conditions, peptides should be stoichiometric with the parent protein to enable accurate
quantitation. However, if a protein is digested into multiple overlapping peptides, the specific signal is
attenuated and in consequence the quantification becomes underestimated.
There are also side reactions of trypsin known, for example its transpeptidase activity, which
yields the addition of a single amino acid (Arg or Lys) to peptides in the reaction mixture. There are also
dipeptides added or two longer peptides are combined together. The additions have been described
for both N- and C-termini of peptides [7]. However, the incidence of the modified peptides is much
lower compared to their unmodified counterparts.
3. Trypsin Forms
Wilhelm Kühne, who discovered trypsin and coined its name in 1876, noticed that the enzyme was
produced as an inactive zymogen (trypsinogen) in pancreatic cells [11]. In the 1930s, Moses Kunitz and
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John H. Northrop elaborated procedures to isolate both trypsinogen and trypsin in crystalline forms,
which largely contributed to the development of enzymology [12]. Trypsinogen is stable at acidic
pH (2–4). In a neutral or alkaline solution, it is activated by a limited proteolysis catalyzed by either
duodenal enteropeptidase (enterokinase) or trypsin itself [4]. Thus, in the latter case, an autocatalytic
process occurs. The complete amino acid sequence of bovine trypsinogen was deduced from peptide
sequencing experiments by several independent groups in the 1960s [13,14] with later corrections at
ambiguous positions (some Asn/Asp and Gln/Glu were not distinguished in early studies because
of limitations of the sequencing methods used at that time). In addition to the dominant cationic
trypsinogen, a minor anionic trypsinogen is produced in bovine pancreas [15]. The UniProt accession
numbers are P00760 (TRY1_BOVIN) and Q29463 (TRY2_BOVIN), respectively; the corresponding
mature trypsin sequences share 72% identity.
The cationic trypsinogen sequence spans the length of 229 amino acids (Figure 1). Altogether,
there are six disulfide bonds in the molecule connecting the following cysteine residues: 13 and 143, 31
and 47, 115 and 216, 122 and 189, 154 and 168 plus 179 and 203 [14]. By the removal of the N-terminal
hexapeptide VDDDDK, the single chain β-trypsin is formed as the predominant product of trypsinogen
activation. Trypsin autolysis with a cleavage between Lys-131 and Ser-132 (numbered according
to the trypsinogen convention) produces α-trypsin, which has two chains connected by disulfide
bonds) [4]. A further cleavage at the bond Lys-176−Asp-177 yields ψ-trypsin with three discrete
chains [16]. Another known active trypsin forms include for example the two chain δ-trypsin [17–19]
and γ-trypsin [20] with chain splits at the bonds Arg-105−Val-106 and Lys-155−Ser-156, respectively.
On the contrary, a cleavage between Lys-49 and Ser-50 has been shown to inactivate the enzyme [18].
More degraded autolysis products are considered inactive [4]. Bovine trypsin is characterized by
a molar absorption coefficient ε280 of 40,000 mol·L−1·cm−1 [21] resulting from the presence of 4 Trp,
10 Tyr, and 12 Cys residues (oxidized to disulfides in the protein) in the sequence. A certain degree
of variability in these numbers can be found for trypsin enzymes from different mammalian or other
sources of origin [4]. All mentioned variants are often called “trypsin isoforms” in the literature
but this is not satisfactory. According to the International Union of Pure and Applied Chemistry
(IUPAC), the term isoform refers only to genetic differences and not to a variation at the protein
level. Hence, the real isoforms are e.g., the cationic and anionic trypsin. To solve this terminological
confusion, the term “proteoform” has recently been introduced, which covers all molecular forms
encoded by a single gene, including changes due to genetic variations, alternatively spliced transcripts
and posttranslational modifications [22].
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                               10        20        30        40        50 
                      ....|...β|....|....|....|....|....|....|....|..*.| 
Cationic trypsinogen  V--DDDDKIVGGYTCGANTVPYQVSLNSGYHFCGGSLINSQWVVSAAHCY  
Anionic trypsinogen   FPSDDDDKIVGGYTCAENSVPYQVSLNAGYHFCGGSLINDQWVVSAAHCY  
   
                               60        70        80        90       100 
                      i...|....#.#..#.#..#....|....|....|....|.*..|....| 
Cationic trypsinogen  KSGIQVRLGEDNINVVEGNEQFISASKSIVHPSYNSNTLNNDIMLIKLKS  
Anionic trypsinogen   QYHIQVRLGEYNIDVLEGGEQFIDASKIIRHPKYSSWTLDNDILLIKLST  
  
                              110       120       130       140       150 
                      ....|.δ..|....|....|....|....|..α.|....|....|....| 
Cationic trypsinogen  AASLNSRVASISLPTSCASAGTQCLISGWGNTKSSGTSYPDVLKCLKAPI  
Anionic trypsinogen   PAVINARVSTLLLPSACASAGTECLISGWGNTLSSGVNYPDLLQCLVAPL  
    
                              160       170       180       190       200 
                      ....|.γ..|....|....|....|..ψ.|....*....|....|....| 
Cationic trypsinogen  LSDSSCKSAYPGQITSNMFCAGYLEGGKDSCQGDSGGPVVCSGKLQGIVS  
Anionic trypsinogen   LSHADCEASYPGQITNNMICAGFLEGGKDSCQGDSGGPVACNGQLQGIVS  
      
                              210       220       230   
                      ....|....|....|....|....|....|.. 
Cationic trypsinogen  WGSGCAQKNKPGVYTKVCNYVSWIKQTIASN-  
Anionic trypsinogen   WGYGCAQKGKPGVYTKVCNYVDWIQETIAANS  
 
Figure 1. An alignment of the cationic and anionic bovine trypsinogen sequences. Italic letters
and a thin underlining at the beginning of the sequences highlight the activation peptides, which
are cleaved off during the trypsinogen conversion to mature trypsin. In the ruler line, asterisks
(*) indicate active-site residues (the charge relay system, also catalytic triad) and hash (#) symbols
mark calcium-binding residues. Greek alphabet letters indicate the cleavage sites in the active
single-chain β-trypsin (223 residues), which yield the other trypsin proteoforms (α, γ, δ, and ψ)
upon autolysis. The small-case letter ‘i’ denotes the cleavage site leading to an inactive trypsin
variant. All above mentioned cleavage sites are additionally highlighted by a symbol of scissors.
Thick red, blue, and green lines indicate individual ψ-trypsin chains. The alignment was made using
BioEdit 7.2.5 with trypsinogen sequences obtained from the UniProt database. The accession numbers
are P00760 (TRY1_BOVIN, cationic) and Q29463 (TRY2_BOVIN, anionic). The numbering refers to
anionic trypsinogen. For cationic trypsinogen, it is shifted towards the canonical numbering by two
units up because of the alignment.
4. Pseudotrypsin Purification from the Autolyzate
In the original report from 1969, ψ-trypsin was purified from an autolyzate of bovine trypsin using
isocratic ion-exchange chromatography [16]. The autodigestion proceeded at pH 8.0 and 25 ◦C in the
presence of calcium ions for up to 6.5 h. Then Na-p-tosyl-L-lysine-chloromethyl ketone (TLCK), which is
an irreversible trypsin inhibitor, was added at pH 7.0 to abolish any detectable activity. After a removal
of low-molecular weight compounds from the protein by gel permeation chromatography (1 mM HCl
as a mobile phase) and the subsequent lyophilization, the TLCK-treated autolyzate was separated on
an Sulfoethyl (SE)-Sephadex C-50 column (1 × 48 cm) in 100 mM Tris-HCl, pH 7.1, containing 20 mM
CaCl2. This procedure had previously been developed for a reliable resolving α- and β-trypsin [23].
In this arrangement, ψ-trypsin was eluted prior to the elution of α- and finally β-trypsin. It was found
not to contain an alkylation resulting from the TLCK treatment, which was elucidated by its decreased
activity towards trypsin substrates [16]. In a similar way, ψ-trypsin was purified on SE-Sephadex C-50
in several other studies. Some differences appeared in the column length, e.g., 1.5 × 150 cm [24], or the
authors optimized the composition of the mobile phase by varying sample loading, pH, flow rate and
concentration of NaCl [25].
In our laboratory, we used a HEMA-BIO 1000 SB column (0.75 × 25 cm) in a medium-pressure
protein liquid chromatography to separate trypsin autolyzate components [8]. The flow rate was
adjusted to 2 mL·min−1 and the whole time window to resolve isocratically ψ-, α-, and β-trypsin (in
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the given order of elution times) at pH 7.1 was 45 min long. We have recently replaced the HEMA-BIO
1000 SB column by a Uno S12 column (15 × 68 mm), which allowed reducing the separation time,
at the expense of resolution, but still yielded a pure ψ-trypsin (Figure 2). In this case, however, the use
of a gradient elution was necessary—the buffer B contained 1 M NaCl (Perutka et al., unpublished
results). In the 1970s, a French group, which studied kinetic properties of ψ-trypsin at that time,
developed a convenient purification method based on affinity chromatography [26,27]. The yield
was 15–20 % of the initial fully active trypsin. To prepare the affinity column, a trypsin inhibitor
from egg-white chicken ovomucoid was attached to aminoethyl-cellulose using glutaraldehyde as
a coupling reagent. The equilibration buffer for separation runs was 0.1 M Tris-HCl, containing 50 mM
CaCl2, pH 7.1. ψ-Trypsin appeared already in the flow-through fraction (just after the void volume).
Thus, it was necessary to include a size-exclusion chromatographic step prior to the affinity separation
in order to remove low-molecular-weight contaminants such as peptides. In contrast, the proteoforms
α and β remained bound and could be eluted (as an unresolved mixture) by applying an acidic elution
buffer of pH 2.3 [27]. This low affinity of ψ-trypsin is in agreement with results on the formation
of its complex with pancreatic trypsin inhibitor, where the corresponding dissociation constant was
increased by five orders of magnitude compared to that for a mixture of α- and β-trypsin [28].
Figure 2. Ion-exchange chromatography of trypsin autolyzate. The depicted separation was performed
on a Uno S12 column (15 × 68 mm; Bio-Rad, Hercules, CA, USA) using a linear gradient of NaCl
(0–1 M) in 100 mM Tris-HCl, pH 7.1, containing 10 mM CaCl2. The gray box indicates a time window,
in which the respective ψ-trypsin fraction was collected. The black line shows absorbance at 280 nm,
the red line refers to conductivity of the eluate.
5. Molecular Properties and Structure of Trypsin and Pseudotrypsin
Accurate experimental molecular mass values of bovine ψ-trypsin were first determined by
electrospray ionization (ESI)-MS [29,30]. For β-trypsin, α-trypsin, and ψ-trypsin, the following average
numbers (relative monoisotopic molecular masses) were obtained in the given order: 23296, 23310,
and 23325 [29] or 23294, 23312 and 23328 [30]. These numbers are in accordance with sequence-based
calculated values of 23293, 23311, and 23329, respectively [30], which reflect a relative mass difference
of 18 resulting from each consecutive autolytic cleavage. For ψ-trypsin, the most recent data are
23332 ± 4 (MALDI-MS) and 23330 ± 0.1 (ESI-MS) [8]. Thus, based on an accurate molecular mass
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determination, the purity of ψ-trypsin preparations can easily be evaluated, also to rule out the
presence of a chymotrypsin contamination coming from the original trypsin material.
Isoelectric points of proteins can be estimated from their amino acid sequences for example using
the software tool ProtParam (https://web.expasy.org/cgi-bin/protparam/). A theoretical pI value
of the cationic bovine trypsin (Uniprot accession number P00760, positions 24–246) is 8.69. Similarly,
for porcine trypsin (Uniprot accession number P00761, positions 9–231), the result is 8.26. Interestingly,
higher experimental values of 10.0/10.5 [31,32] were published for the bovine enzyme and 10.2/10.8 for
the porcine enzyme [33,34]. For ψ-trypsin, no experimental data on pI are available to our knowledge,
but similar values could be expected. The anionic bovine trypsin (Uniprot accession number Q29463,
positions 24–247) has a theoretical pI value of 4.90, which agrees well with an experimental result [35].
Chymotrypsin and trypsin were among first proteins with experimentally determined spatial
structures. The crystal structure of bovine chymotrypsin appeared already in 1967 [36] and was refined
later on [37]. At that time, a similarity in the three-dimensional folding of trypsin and chymotrypsin
could be assumed because of the amino acid sequence homology and matching positions of disulfide
bonds. The crystal structures of bovine β-trypsin and trypsinogen were solved in the 1970s [38–40].
Figure 3 shows a view of the trypsin structure (PDB accession code 1AQ7 [41]) visualized using
PyMol 1.3. Trypsin is a globular protein. Its overall fold comprises two six-stranded Greek-key
β-barrels [42]. The active site with the catalytic triad of amino acids is located between the two
barrels. His-57 and Asp-102 belong to the N-terminal barrel whereas Ser-195 originates from the
C-terminal barrel (this numbering is according to the chymotrypsinogen convention, see in Walsh
and Neurath) [13]. Helices represent only minor secondary structure components, for example at
the C-terminus. The enzyme contains a calcium ion, which is important for activity. Its coordination
chemistry involves several residues from the calcium-binding loop [38]. The calcium ion interacts with
the side-chain oxygens (in the trypsinogen numbering) of Glu-58, Glu-65 (this one via a coordinated
water molecule), and Glu-68 plus the carbonyl oxygens of Asn-60 and Val-63. No crystal structure of
ψ-trypsin has been solved up to now. As this proteoform contains two chain splits (between: 1. Lys-131
and Ser-132, 2. Lys 176 and Asp-177; according to the trypsinogen numbering), the whole molecule is
loosened somehow in comparison to that of β-trypsin. The bond Lys-176−Asp-177 is located close
to the anionic binding site (i.e., specificity site: Asp-177, which is the position 189 when expressed
in the chymotrypsinogen numbering). Upon the autolytic splitting, the binding site arrangement
is disconnected. In consequence, the affinity for polypeptide trypsin substrates is lowered and the
cleavage specificity broadened [8,24]. This structural alteration does not prevent from binding of
a pancreatic trypsin inhibitor; only the dissociation constant of the enzyme-inhibitor complex is
increased [24,28]. ψ-Trypsin still keeps a certain level of specificity, which is based on hydrophobic
interactions, as confirmed using synthetic ester substrates [27].
After trypsinogen activation, the new N-terminal residue (Ile-16, in chymotrypsinogen numbering)
inserts into a cleft, where it establishes an ion pair (via α-amino group) with Asp-194 next to the
catalytic serine. This results in a conformational rearrangement. The amino group of Gly-193 moves
into a position, which completes the oxyanion hole at the active site [2]. The hole is formed by the
trypsin amide hydrogens of Gly-193 and Ser-195 in favor of stabilization of the developing negative
charge on the carbonyl oxygen atom of the cleaved substrates.
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Figure 3. The crystal structure of bovine β-trypsin. This overall view was made in PyMOL 1.3
using a pdb formatted file (accession number 1AQ7 [41]) downloaded from the PDB database
(http://www.rcsb.org/pdb). Trypsin fold comprises two β-barrels. The active site with the catalytic
triad of amino acids is located between them (in the center of this figure) and highlighted in green.
Red color on the bottom left shows the calcium-binding residues. The KD bond, which is cleaved
to generate ψ-trypsin is expressed as an orange side chain (Lys-176) at a yellow backbone segment
(Asp-177). Blue-line side chains at other yellow segments indicate the presence of the basic residues,
where the β-trypsin polypeptide chain is cleaved to produce α-trypsin (Lys-131, above the calcium
site and not far away from Lys-176 in this projection), γ-trypsin (Lys-155, top right, in the helix),
and δ-trypsin (Arg-105, behind the calcium site). Finally, magenta color at the bottom indicates Lys-49,
which is disconnected from Ser-50 to yield the inactive autolytic form.
6. Pseudotrypsin Activity with Artificial Substrates (Enzyme Kinetics)
Compared to α-trypsin and β-trypsin, the overall structural change resulting from the additional
intrachain split in ψ-trypsin yields differences in the activity and specificity. This was evaluated already
in the 1960s and 1970s by measuring kinetic parameters for low-molecular-weight substrates (Table 1).
Smith and Shaw [16] recognized during the chromatographic purification that ψ-trypsin did not show
any measurable activity with Nα-benzoyl-D,L-arginine-4-nitroanilide (Bz-Arg-pNA) as a substrate
under experimental conditions optimized for α-trypsin (i.e., no amidase activity). Nevertheless, they
could demonstrate a hydrolytic activity of ψ-trypsin by detecting a stoichiometric incorporation of
[14C] diisopropyl fluorophosphate at the active site, which is typical for serine proteases or esterases
in general. However, the rate of 14C incorporation was very slow, which indicated a decreased
reactivity of ψ-trypsin compared to α-trypsin. Similarly, a slow conversion of the active site titrant
p-nitrophenyl-p′-guanidinobenzoate (NPGB) was observed. Comparative kinetic data measured with
several artificial ester substrates are shown in Table 1. For example, the affinity of ψ-trypsin for the
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cationic Nα-benzoyl-L-arginine ethyl ester (Bz-Arg-OEt) represented by the determined Michaelis
constant value is lower by three orders of magnitude than that of α-trypsin [16]. Such a big difference in
affinity was observed also for carboxybenzyl-L-lysine esters or Nα-p-tosyl-L-arginine methyl ester [27].
Not only the affinity, but also the activity (catalytic constant) is often largely different. A typical
chymotrypsin substrate Nα-acetyl-L-tyrosine ethyl ester (Ac-Tyr-OEt) is hydrolyzed by α-trypsin
almost 3000 times faster than by ψ-trypsin (Table 1). At the same time, the respective Km values are
comparable as the binding of this neutral substrate is not affected so much by the disconnection of
Asp-177 (the specificity site) in ψ-trypsin [16]. As a consequence of the reduced affinity and activity
towards cationic substrates, the efficiency constant values kcat/Km are decreased by many orders of
magnitude (up to 6) for ψ-trypsin [16,27].
Table 1. Kinetic data for bovine α-trypsin and ψ-trypsin with artificial substrates. This table is adapted
from Smith and Shaw [16] and completed by results with non-fractionated trypsin [43]. All experiments
were performed at pH 8.0 and 25 ◦C.
Enzyme Substrate a kcat (s−1) Km (mol·L−1) Ki (mol·L−1)
α-Trypsin Bz-Arg-OEt (0.05 M CaCl2) 24 2.5 × 10−6 -
ψ-Trypsin Bz-Arg-OEt (0.001 M CaCl2) 0.19 1.1 × 10−2 -
ψ-Trypsin Bz-Arg-OEt(0.05 M CaCl2, benzamidine)
- - 3.7 × 10−2
Trypsin (non-fractionated) Bz-Arg-OEt (0.025 M CaCl2) 14.6 4.3 × 10−6 -
α-Trypsin Ac-Tyr-OEt(0,05 M CaCl2, 10% 2-propanol)
57 6.2 × 10−2 -
ψ-Trypsin Ac-Tyr-OEt(0.001 M CaCl2, 10% 2-propanol)
0.02 3.7 × 10−2 -
Trypsin (non-fractionated) Ac-Tyr-OEt(0.05 M CaCl2, 5% dioxane)
14.5 4.2 × 10−2 -
Trypsin (non-fractionated) Bz-Arg-pNA (benzamidine) b - - 1.8 × 10−5
a Further information on the composition of the reaction mixture is provided in parentheses; b This reaction was
performed at pH 8.15 and 15 ◦C.
Benzamidine has been shown a potent competitive inhibitor of trypsin. It is approximately of
the same size as the side chain of lysine and arginine and contains both a positively charged group
and hydrophobic moiety in its structure. The Ki value of benzamidine for the reaction of trypsin
with Bz-Arg-pNA is 1.8 × 10−5 mol·L−1 [4]. In contrast, the binding of the inhibitor to ψ-trypsin is
characterized by an increased Ki value 3.7 × 10−2 mol·L−1, which is in agreement with the Km value
for the neutral (and thus non-specific) substrate Ac-Tyr-OEt (Table 1). The irreversible trypsin inhibitor
TLCK does not inactivate ψ-trypsin at all [16]. Further evidence of the reduced ψ-trypsin affinity to
positively charged ligands was observed with a basic pancreatic trypsin inhibitor. The second-order
rate constant of the association is decreased by a factor of 16 when ψ-trypsin is used instead of α- and
β-trypsin and the dissociation constant is increased by a factor of 1.5 × 105 from 6 × 10−14 mol·L−1
(a quasi-irreversible binding in the case of trypsin) to 9 × 10−9 mol·L−1. This value is similar to that
of chymotrypsin, which also associates with this inhibitor but lacks the trypsin specificity site [28].
When the disulfide bond Cys-179−Cys-203 in trypsin is selectively reduced and the emerged cysteines
subsequently carboxymethylated, the resulting enzyme derivative still binds the inhibitor efficiently.
Interestingly, the observed kinetic parameters of the association and dissociation correspond to those
determined for ψ-trypsin [28].
The reaction mechanism of trypsin is illustrated in Scheme 1 (based on that in [27]) Acylation and
deacylation rate constants (k2 and k3, respectively) were measured with the active site titrant NPGB and
pure bovine α-, β-, and ψ-trypsin preparations [27]. Whereas the acylation rate was found to be 1000
slower for ψ-trypsin than for the other proteoforms at optimum pH, the deacylation rates were rather
comparable. A similar difference in the acylation rate was observed with p-acetoxyphenylguanidine
p-toluenesulfonate. This compound belongs to “inverse substrates” as it contains the specific cationic
center within the leaving group instead of the acyl moiety [44]. Measurements with different
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carboxybenzyl-L-lysine esters (cationic i.e., specific trypsin substrates) indicated that acylation is
largely the rate-limiting step for ψ-trypsin contrary to deacetylation as it appears in the case of
α-/β-trypsin [27,45]. For neutral (nonspecific) substrates, acylation is rate limiting also for the major
proteoforms. The kcat values for ψ-trypsin were found sensitive to the substrate leaving group in
contrast to those observed for α-trypsin, which shows that the catalysis by this form is not completely
nonspecific and hydrophobic binding subsites are preserved.
Scheme 1. The reaction mechanism of trypsin. A protein substrate (S) with the indicated N- and
C-termini and the cleavage site is cleaved by trypsin (T) into two large peptides or polypeptides
P1 and P2. TS stands for a Michaelis trypsin-substrate complex, TS’ represent an acyl-enzyme
intermediate. The reaction rate constants are as follows: k1—enzyme-substrate association rate
constant; k−1—enzyme-substrate dissociation rate constant; k2—enzyme-substrate acylation rate
constant; k3—enzyme-substrate deacylation rate constant; kcat = k2k3/(k2 + k3). This scheme has
been adapted from the reference [27].
7. Cleavage Specificity towards Peptides and Proteins
Both major forms of trypsin (α and β) prefer Arg-X sites to Lys-X sites during the hydrolysis of
synthetic as well as polypeptide substrates at an optimal pH of 8–9. The preference ratio is even more
pronounced at higher pH values (>pH 10) because the ε-amino group of lysine is largely discharged
under these conditions and becomes less attractive [4]. The cleavage specificity of ψ-trypsin towards
peptide bonds was first analyzed with two peptide substrates: a mixture of bovine and porcine
glucagon and a heptapeptide fragment of the B chain of insulin with a sequence of GFFYTPK [24].
The heptapeptide was selected because of the content of aromatic residues to evaluate whether
ψ-trypsin shows a preference similar to that of chymotrypsin. The glucagon sequence contains three
canonical trypsin cleavage sites (Lys-12, Arg-17, and Arg-18). In a parallel work, the same group
demonstrated that pure α- and β-trypsin preparations did not show any effect on the insulin-derived
heptapeptide and carboxy sites of aromatic amino acid residues in glucagon [46]. Conversely to the
effect of α-chymotrypsin used as a 1% model contamination in a commercial trypsin preparation
(control digest), no effect of ψ-trypsin on the heptapeptide was observed. The digestion of glucagon
was performed in 0.1 ammonium carbonate containing 20 mM CaCl2 at pH 8.0 and ψ-trypsin generated
the same fragments as it had been observed in the parallel study with α- and β-trypsin. However,
the yield of these fragments was lower than those produced by the major forms, indicating its decreased
affinity to polypeptides. However, ψ-trypsin showed an additional ability to cleave bonds adjacent to
the aromatic amino acids Phe and Trp [24].
Dyčka et al. [8] performed overnight in-gel digestions of six standard proteins with monomer
molecular masses of 12–95 kDa (cytochrome c, lysozyme, myoglobin, glucose oxidase, serum
albumin, and glycogen phosphorylase) using ψ-trypsin, non-fractionated trypsin (treated by
N-p-tosyl-L-phenylalanine chloromethyl ketone—TPCK—to inactivate a possible chymotrypsin
contamination) and chymotrypsin to obtain a more complex view of the cleavage specificity.
The numbers of sequence-matched peptides with the respective sequence coverage values from
nLC-MALDI-MS/MS were similar for ψ-trypsin and trypsin. A majority of the registered ψ-trypsin
cleavage sites (77 %) were produced by its action upon the C-termini of Arg and Lys residues (in the
case of trypsin, it was 86 %). Additional cleavages appeared particularly after Phe and Tyr residues,
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which confirmed the previous data obtained with glucagon [24]. Interestingly, ψ-trypsin provided
1.5-fold higher number of peptides containing missed cleavage (Arg and Lys) sites, which probably
results from the lower substrate binding ability of this proteoform [8].
8. The Use of Pseudotrypsin for Protein Identification in Proteomics
At the present time, ψ-trypsin is not commonly used in biochemistry and proteomics as it is
not commercially available and its purification takes a few days with a low yield of pure protein
at the end. From 200 mg of bovine trypsin as a starting material [8], only milligrams of the final
product could be obtained. The applicability of ψ-trypsin has a potential in protein identification
experiments involving ESI- or MALDI-MS/MS as it generates more peptides with missed cleavage
sites than native trypsin and also nonspecific peptides terminated mainly by Phe and Tyr residues
(resembling partially the chymotrypsin mode of action). In consequence, higher sequence coverage
values and increased number of matched peptides can be achieved. Interestingly, pseudotrypsin has
been hypothesized to cause the cleavage of a Cys–Gly bond in NDRG1 protein [47]. Another possibility
of application resides in studying posttranslational modifications. Such a modification may under
a common routine interfere with trypsin digestion, for example when a phosphorylation occurs close to
an arginine or lysine, and would then require selecting of another protease [48]. On the other hand, for
its broader cleavage specificity, ψ-trypsin is not recommendable for mass spectrometry-based protein
quantification experiments [49] because of the possible distribution of the same predicted canonical
cleavage site in more peptides (multiple cleavage products due to missed cleavages or additional
cleavage sites).
A comparative in-gel digestion of a gel fraction of rat urine proteins resulted in 22 identifications
after the use of ψ-trypsin. The same number was reached with a commercial non-fractionated trypsin,
but only 17 were identified in both cases. Hence a simple combination of the two digestions provided
about 20 % more identification [8]. The total number of the matched peptides was 233 and 199,
respectively. The numbers of the cleaved Arg and Lys sites were comparable (around 130); in the
case of Phe and Tyr site cleavages, two times more peptides were produced by ψ-trypsin. Recently,
this proteoform was applied to analyze nuclear proteins after a DNase treatment of barley nuclei
and sodium dodecyl sulfate polyacrylamide gel electrophoresis of the released protein material
(Perutka et al., unpublished results). Peptides from the digests were analyzed by MALDI and ESI
MS/MS and the results compared with parallel tryptic digestions. The identified nonspecific peptides
in the ψ-tryptic digests represented 15–20 % of the total peptide number (compared to 7 % for
a standard trypsin). In agreement with previous reports [8,24], peptides with C-terminal Tyr and Phe
residues (and also Leu) were found in a significant percentage representation but were only minor to
those resulting from the characteristic trypsin cleavage after the basic Arg and Lys residues (Figure 4).
The higher number of Arg-ending over Lys-ending peptides in the MALDI-TOF/TOF MS/MS results
(but not in the ESI-based results; not shown) probably reflected the fact that Arg-peptides provide
more intense signals in MALDI-TOF MS [50], and thus they are preferably selected for the subsequent
data-dependent fragmentation. Database searches allowed identifying novel proteins which had
not previously been recognized based on standard tryptic peptides and deposited in the database
UNcleProt [51]. They accounted for around 10 % of all identifications. The digestion performance
of ψ-trypsin was compared relatively to that of a commercial trypsin using MALDI-TOF MS-based
quantification of bovine serum albumin peptides (Perutka et al., unpublished results). Tryptic digestion
was performed in a buffer made of H218O [52]. During proteolysis, labeled standards were generated
by incorporating 18O isotope into the carbonyl group of the nascent peptides. The ψ-tryptic digest was
made in a buffered H216O and then mixed equivolumetrically with the labeled standards. The ratios
of non-labeled versus labeled peptides were calculated from the areas of isotopically resolved peaks
in MALDI-TOF MS spectra. As a result, the observed overall overnight digestion performance of
ψ-trypsin was found lower by around 20 %.
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Figure 4. C-terminal amino acids (P1 cleavage site) of peptides in ψ-tryptic and tryptic digests.
This table summarizes results obtained after in-gel digestions of barley nuclear proteins. The percentage
values were averaged from data for almost 40 distinct protein fraction samples. MALDI TOF/TOF
MS/MS allowed to identify 1199 and 1238 peptides, respectively. PEAKS Studio 8 software
(Bioinformatics Solutions, Waterloo, ON, Canada) was used to process the MGF-formatted files by
searching against a Hordeum vulgare protein sequence database downloaded from the National Center
for Biotechnology Information, USA, at 1% peptide false discovery rate (Perutka, Z. et al.; unpublished
results). Peptide sequences containing C-termini of the identified proteins were not included in
the calculation.
9. Concluding Remarks
Early studies identified ψ-trypsin as a proteoform resulting from trypsin autolysis. Amino acid
analyses of its polypeptide chains revealed the existence of an additional split between Lys-176 and
Asp-177 compared to the primary structure of α-trypsin. The enzyme can be obtained from a trypsin
autolyzate by ion exchange chromatography. Purification protocols that are available utilize one of
the characteristic features of ψ-trypsin: in contrast to α- or β-trypsin, it is not modified by the trypsin
inactivator TLCK and shows a minimum retention on cation exchangers such as Sulfoethyl-Sephadex.
Enzyme kinetics studies with synthetic amino acid esters demonstrated a largely decreased
affinity and activity towards cationic substrates. This has been elucidated by the presence of the
characteristic chain split, which disconnects the specificity site (Asp-177) from the active site (Ser-183,
His-46, Asp-90; all indicated according to the trypsinogen numbering convention). The reaction
mechanism of ψ-trypsin with specific substrates differs from that of α- or β-trypsin in the rate limiting
step. No crystal structure of ψ-trypsin has been solved yet, but the anticipated existence of the modified
(‘neutral’) active site and the ability to hydrolyze tyrosine-derived ester substrates lead to cleavages
characteristic of chymotrypsin. So far, only a few studies have focused on the digestion of peptides and
proteins by ψ-trypsin. These studies have confirmed its preferential action on Arg and Lys residues but
also at Phe and Tyr residues (which is typical for chymotrypsin) as minor cleavage sites. The produced
peptides contain frequent missed cleavages because of the absent specificity and reduced affinity
towards the cationic sites. However, overnight digestions of protein samples provide enough peptides
for identification experiments involving nLC-MALDI or nLC-ESI MS/MS. Subsequently, combining
data from tryptic and ψ-tryptic digestions has been shown to be advantageous in order to increase
the number of matched peptides and sequence coverage values. Furthermore, peptides with missed
cleavage sites could be beneficial for studying posttranslational modifications of proteins.
ψ-Trypsin should not be used as an equivalent substitute of trypsin or chymotrypsin and, in fact,
there is no need to do it. However, as it makes preferential cleavages after basic Arg and Lys residues
and has a more developed side specificity for aromatic and Leu residues, which is not expected to
occur for pure major trypsin forms α and β (but may appear anyway because of their autolysis),
it produces valuable complementary information. The unavailability of any commercial material
represents a big obstacle for the application of ψ-trypsin in common proteomics research. On the other
hand, a single-step affinity chromatographic method has already been introduced [27], which could
make the preparation of the enzyme easier (after a revision and transformation with the use of modern
chromatographic materials).
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Abbreviations
Ac-Tyr-OEt Nα-acetyl-L-tyrosine ethyl ester
Bz-Arg-OEt Nα-benzoyl-L-arginine ethyl ester
Bz-Arg-pNA Nα-benzoyl-D,L-arginine-4-nitroanilide
ESI electrospray ionization
IUPAC International Union of Pure and Applied Chemistry
MALDI matrix-assisted laser desorption/ionization
MS mass spectrometry
MS/MS tandem mass spectrometry
NPGB p-nitrophenyl-p′-guanidinobenzoate
nLC nanoflow liquid chromatography




TPCK N-p-tosyl-L-phenylalanine chloromethyl ketone
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